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SUMMARY 
The work presented in this thesis is concerned with the characterisation of human 
plasma transferrins showing abnormal electrophoretic mobilities on polyacrylamide 
gels. The work is divided into three studies: (i) a study of transferrin variants detected by 
nondenaturing polyacrylamide gel electrophoresis; (ii) a study of the plasma 
concentrations of individuals showing transferrin phenotypes associated with the three 
most common Tf C alleles, Tf Cl, Tf C2 and Tf C3; and (iii) a study of a reported 
nondegenerate nucleotide difference in the sequence of the cloned human transferrin 
gene. 
In the first study, six transferrin variants (3 Tf Br,,.,,, s and 3 Tf D. 5) showing 
abnormal electrophoretic mobilities on nondenaturing polyacrylamide gels, and the two 
Tf C variants, Tf Cl and Tf C2 which occur at polymorphic levels (> 1%) in human 
populations, were isolated and purified from human plasma. Transferrins were purified 
by a combination of DEAE Sephacel anion-exchange chromatography, SP. Sephadex 
cation-exchange chromatography and G-200 gel-filtration chromatography. A series of 
comparative studies were then carried out on the isolated transferrins to determine 
whether the six transferrin variants detected in this thesis and the Tf C2 variant, showed 
similar characteristics to the wild-type Tf Cl. Transferrins were studied for sialic acid 
content of the two glycan chains, and for molecular weights and isoelectric points of the 
iron-free (apo) and iron-saturated (holo) transferrin forms. Metal-binding properties 
were examined by studying the binding of Fe", Cu", Al" and Ga"'. Iron-binding was 
studied at physiological and endosomal pH (7.5 and 5.5 respectively) using FENTA as 
the iron donor. Binding of Cue*, Al"' and Ga'* were examined at physiological pH using 
3 
CUNTA, ALNTA and GANTA respectively. The ability of transferrins to retain bound 
iron was examined by studying pH-induced iron release over a pH range of 6.0-4.0. 
Conformational stabilities were determined by studying the iron-binding abilities of 
apotransferrins following exposure to urea or thermal denaturation, and by studying iron 
loss from holo transferrins following exposure to urea or thermal denaturation. Other 
than expected differences in isoelectric points, and slightly faster rates of iron loss from 
variant holo transferrins titrated at physiological pH, all variant transferrins were found 
to show similar characteristics to Tf Cl, with identical molecular weights and sialic acid 
content, similar metal-binding properties, and similar stabilities to urea or thermal 
denaturation. The results indicate that the structure and function of the variant 
transferrins are not adversely affected by their differences in primary structure. 
The second study examined the relationship between plasma transferrin concentration 
and transferrin phenotypes representing five of the six most common Tf C phenotypes 
(i. e. Tf Cl, Tf C2, Tf C2-1, Tf C3-1 and Tf C3-2), to determine whether plasma 
concentrations were dependent on transferrin phenotype as suggested in literature. 
Transferrin phenotypes of 931 unrelated individuals were determined by electrophoresis 
of plasma on polyacrylamide isoelectric focusing gels. Plasma transferrin concentrations 
were determined by single radial immunodiffusion using rabbit anti-human transferrin 
IgG. A significant difference was found between the plasma concentrations of the five 
transferrin phenotypes (p < 0.01) indicating that transferrin concentration was dependent 
on phenotype. The results suggest that the two Tf C alleles, Tf C2 and Tf C3 are 
associated with low plasma concentrations. 
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The third study was initiated to investigate a report in literature that a nondegenerate 
nucleotide difference of adenine for guanine at base 1086 in exon 8 of the human 
transferrin gene, may indicate the presence of a hitherto unrecognised transferrin variant 
with Asn rather than a wild-type Asp at position 310 of the amino acid sequence. The 
nucleotide sequence of exon 8 from 220 unrelated individuals showing transferrin 
phenotypes associated with the three most common Tf C alleles, Tf Cl, Tf C2 and Tf 
C3, and from 5 individuals showing abnormal transferrin phenotypes in the first study, 
were amplified by polymerase chain reaction. Amplified products were digested with 
the restriction endonuclease, Fok I which has a single recognition site in exon 8 
containing the proposed wild-type guanine at base 1086, or with Bsm I which also 
shows a single recognition site containing the proposed adenine nucleotide. The study 
failed to detect the presence of the proposed transferrin variant, confirming that the 
wild-type guanine was present in all 225 individuals. 
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CHAPTER ONE 
1. GENERAL INTRODUCTION 
Plasma (serum) transferrin is the iron transport protein responsible for transporting iron 
between sites of iron absorption, utilisation and storage. It is a member of a wider family 
of monomeric iron-binding glycoproteins found amongst the cells and physiological 
fluids of all vertebrates, that are capable of reversibly binding ferric (Fe 3+) ion in the 
presence of synergistic carbonate (C032") ion (Harris & Aisen, 1989; Baker & Lindley, 
1992; Baker, 1994). Since the initial detection of a plasma transferrin variant by 
Smithies (1957), in excess of 36 variants showing differential electrophoretic mobilities 
to the wild-type transferrin have been detected by nondenaturing polyacrylamide 
electrophoresis (PAGE) and polyacrylamide isoelectric focusing (PAIEF) (Farhud et al., 
1988). With the exception of 8 variant alleles that show polymorphic frequencies (> 1%) 
in at least one major population, most variant alleles are rare and show restricted ethnic 
or geographical distributions. Detected variants raise the question of a selective role for 
the variant allele. Of the transferrin variants studied to date, two variant alleles namely 
Tf C2 and Tf C3, have consistently been shown to have a selective disadvantage, and 
have been associated with reproductive disorders (Weitkamp & Schacter, 1985; Saha et 
al., 1990) and other disorders such as Alzheimer's disease (van Rensburg et al., 1993). 
Conversely, a selective advantage has recently been reported for the Tf C3 allele in 
smoking-associated lung cancer (Sikstrom et al., 1996). Variant transferrins studied to 
date show the same iron-binding properties as the wild-type transferrin, the exception 
being two variants, Tf DEVus (Evans et al., 1982) and Tf BsH,, W (Welch & Langmead, 
1990) which show a lability of the C-lobe binding site iron. The amino acid substitution 
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for the two variant alleles have been determined as arginine for glycine at position 394 
for Tf DEvANs (Evans et al., 1988b) and aspartic acid for isoleucine at position 378 or 381 
for Tf BSH,, W (Welch & Langmead, 1990). Elucidation of the amino acid substitution in 
Tf DEv Ns was not only instrumental in determining the reasons for the observed lability 
of the C-terminal binding site, but also contributed to the growing knowledge about the 
significance of amino acids in the transferrin molecule (Evans et al., 1994). The research 
in this thesis primarily involves the isolation, purification and study of the iron-binding 
properties of abnormal transferrins. Findings of abnormal iron-binding properties may 
then lead to further research and subsequent information about the structural or 
functional importance of amino acids in transferrin. 
1.1. THE TRANSFERRIN FAMILY 
Plasma fransferrin belongs to a group of closely related proteins called transferrins 
(siderophilins) that are typically monomeric glycoproteins with a single polypeptide 
chain of 670-700 amino acids and a molecular weight (Mw, ) of about 80,000 (For a 
review see: Aisen & Listowsky, 1980; Brock, 1989; Baker & Lindley, 1992; Baker, 
1994). Transferrins of different size have however been reported for the urochordate, 
Pyura stolonifera (MW - 40,000) and the crab, Cancer magister (MH, - 150,000) (Martin 
et al., 1984; Huebers et al., 1982). Most of the transferrins show a characteristic ability 
to bind, very tightly but reversibly, two Fe3+ ions in the presence of CO32' ions, although 
melanotransferrin (see below) and the transferrin from the sphinx moth, Manduca sexta 
appear to only have one functional iron-binding site (Bartfield & Law, 1990; Baker et 
al., 1992). Apart from their iron-binding capacities, the transferrins are also 
characterised by a 2-fold internal homology with about 40% of the amino acids in the C- 
and N-terminal halves of the protein being identical (MacGillivray et al., 1982; Metz- 
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Boutigue, 1984; Baker et al., 1987). Plasma transferrin was first isolated by Schade & 
Caroline (1946), and its ability to bind iron in the presence of bicarbonate subsequently 
determined by Schade et al., (1949). The bound iron was determined to be in the Fe 3+ 
state from crystallisation of the protein (Koechlin, 1952). Since its discovery, the protein 
has been variously known as siderophilin, ß metal binding globulin, serotransferrin and 
transferrin. The current accepted nomenclature is transferrin, with respect to its iron- 
transport function, the name plasma transferrin indicating the source of the protein. The 
protein is primarily found in serum and in extracellular fluids such as cerebrospinal 
fluid, milk, semen and amniotic fluid of all vertebrates studied to date (Aisen & 
Listowsky, 1980; Williams, 1985; de Jong et al., 1990). Other primary members of the 
group are: (a) lactoferrin (previously called lactotransferrin) which is distributed in 
mammalian extracellular secretions such as milk, tears, pancreatic juice and saliva, and 
is also found in leucocytes; (b) ovotransferrin (previously known as conalbumin 
L! which is found in bird and reptile oviduct secretions, and egg whites; and 
© melanotransferrin (also known as p97) which is a membrane bound protein present at 
low levels on the surface of normal cells, but expressed at high levels in melanoma cells 
(Brown et al., 1982; Williams, 1985; de Jong et al., 1990). 
1.2. TRANSFERRIN FUNCTION 
Transferrin is synthesised primarily by the liver hepatocyte cells (Morgan, 1983). 
However, several extrahepatic cells also show transferrin synthesis. Significant levels of 
the transferrin mRNA have been reported in the adult rat brain, with lower levels in 
other tissues such as the testis, stomach, muscle and heart (Alfred et al., 1987). Other 
reported sites of transferrin synthesis include mammary epithelial cells (Lee et al., 
1987), the T4+ helper-inducer subset of T lymphocytes (Lum et al., 1987) and 
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macrophages (Stecher & Thorbecke, 1967). The initial translation product is a 
polypeptide chain nineteen residues longer than the final molecule. The extra residues 
represent a leader sequence which needs to be excised by proteolytic enzymes before 
secretion may occur (Thibodeau et al., 1978; Schreiber et al., 1979). The distribution of 
transferrin synthesis in a variety of extrahepatic tissues have lead to a number of 
proposed, functions for the protein including antioxidant, antimicrobial and growth 
factor activities. The ability of transferrin and the two other transferrins, lactoferrin and 
ovotransferrin to tightly bind iron mean that they are capable of acting as antioxidants, 
preventing the generation of toxic free radicals. Despite the presence of the enzymes 
superoxide dismutase which scavenges the superoxide free radical, 02', and glutathione 
peroxidase and catalase which remove hydrogen peroxide (H202), both 02 and H202 
can be detected during normal metabolism in many biological systems (Karnovsky & 
Badwey, 1983; Babior, 1984). Free cellular iron is capable of catalysing the 
decomposition of H202 with subsequent formation of the extremely reactive hydroxyl 
radical (OH) via the Haber-Weiss reaction shown below (Halliwell & Gutteridge, 1984 
& 1985): 
Oi + H202 ---------------> 02 + OR + OH' (1) 
Fe salt catalyst 
The above reaction is the sum of several interlinked reactions involving both Fe 3+ and 
Fe 2+ ions, where traces of Fe3+ ions can react with H202 or 02 to produce Fe2+ ions 
which in turn can react with both H202 and OH to form more Fe 3+ ions, thus continuing 
the cycle of free radical formation. Binding of free iron by transferrin therefore prevents 
generation of the OH which is capable of reacting with most molecules in living cells, 
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resulting in destructive effects such as lipid peroxidation of plasma membranes and 
DNA damage (Halliwell & Gutteridge, 1984 & 1985; Wiseman & Halliwell, 1996). 
A second proposed function of transferrin, lactoferrin and ovotransferrin is that they 
have antimicrobial activities based on their ability to sequester iron, thereby depriving 
bacterial 'systems of the iron they require for growth. However many gram-negative 
bacteria such as Escherichia cola can override transferrin-imposed iron deprivation 
through the action of high-affinity uptake mechanisms incorporating high-affinity iron 
chelators called siderophores, and their outer-membrane receptors (Crosa, 1989; 
Williams et al., 1990). Siderophores are capable of obtaining iron from transferrins over 
a period of time, prior to internalization via the siderophore receptors. Other human 
pathogenic bacteria such as Neisseria gonorrhoeae and Neisseria meningitidis, have 
outer membrane protein receptors capable of recognising, binding and internalizing 
iron-containing transferrin or lactoferrin (Micklesen & Sparling, 1981). Transferrin and 
lactoferrin are -- 
thought to also have a direct bactericidal effect on gram- 
negative bacteria. This effect has been particular ly characterised in the case of 
lactoferrin with the identification of a bactericidal peptide fragment of lactoferrin named 
lactoferricin (Bellamy et al., 1992; Yamauchi et al., 1993). Transferrin, lactoferrin and 
lactoferricin are believed to exert their direct bactericidal effect by damaging the outer 
membrane of gram-negative bacteria, thereby increasing the permeability of the outer 
membrane to antibacterial drugs (Ellison et al., 1988; Ellison et al., 1990). The direct 
effects are believed to be modulated by Cat+, Mg 2+ and Fei+, as addition of the three 
block lipopolysaccharide release by transferrin, lactoferrin and lactoferricin, whilst Ca2+ 
also decreases the lactoferrin-induced increased susceptiblity of Escherichfa coli to the 
antimicrobial drug rifampicin (Ellison et al., 1990; Yamauchi et al., 1993). Transferrin 
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has also recently been suggested to have an anti-imflammatory role. Activation of 
leukocyte phagocytosis via Fc gamma receptors is by two macromolecular activators of 
phagocytosis from platelets (MAPP) called s-MAPP and 1-MAPP with a M,, of 
150,000 and 300,000 respectively (Sakamoto et al., 1987). Both s-MAPP and 1-MAPP 
have precursors called pre-s-MAPP and pre-l-MAPP respectively, which are taken into 
platelets, converted into MAPP, and then released (Yokoya et al., 1992; Sakamoto et al., 
1996). Sakamoto et al., (1997) have suggested that both s-MAPP and 1-MAPP, and 
their precursors are formed from dimer and tetramer transferrin respectively. The 
observation was deduced from results including homogeneity between s-MAPP and 
transferrin, immunoreactivity of MAPP and pre-MAPP with anti transferrin monoclonal 
antibodies, and the fact that MAPP function was dependent on iron. Furthermore, 
platelets incubated with dimer and tetramer transferrin were capable of producing 
MAPP function. 
In addition to the above functions, several studies have suggested that transferrin also 
shows growth factor activity. Amouric et al., (1984) for example found that transferrin 
is more efficient than lactoferrin in stimulating the growth of the human colon 
adenocarcinoma cell line, HT 29. Similarily, Yeoman et al., (1996) have also reported 
an enhanced growth of the poorly differentiated human colon tumor cell line, HCT116, 
when ex6genous transferrin and insulin are added to the culture medium. Other studies 
have found that lactoferrin has more potent growth stimulating activity than transferrin 
(Nichols et al., 1987). The latter for both transferrin and lactoferrin have been shown to 
depend on the iron-containing status of the proteins. Oguchi et al., (1995) found that 
whereas the iron-saturated (holo) forms of both proteins enhanced proliferation of the 
human intestine cell line, Caco-2, the unsaturated forms were found to repress 
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proliferation. As with other polypeptide growth factors like insulin, an obligatory step in 
growth stimulation by transferrin involves the binding of the protein to transferrin 
receptors, which can be found on the surface of proliferative normal cells (Trowbridge 
& Omary, 1981). One of the early growth factor-induced events seen in mouse tumor 
and rabbit alveolar macrophages (Buys et al., 1984) and in human fibroblasts (Wiley & 
Kaplan, 1984) was a rearrangement of transferrin receptors resulting in increased 
numbers of transferrin receptors at the cell surface at a cost to the intracellular 
transferrin receptor pool. It was suggested by Sun et al., (1987) that the increased 
occurrence of transferrin receptors at the cell surface stimulated the reduction of 
transferrin-bound iron by the plasma membrane redox system, NADH: Ferricyanide 
oxidoreductase. This was thought to result in a transient alkalinization of the cytoplasm, 
a condition also associated with the mitogenic action of growth factors. It therefore 
appears that transferrin aids cellular proliferation by not only supplying iron for crucial 
iron-containing enzymes such as ribonucleotide reductase, but by also contributing to 
the various biochemical changes which lead to mitogenesis (de Jong et al., 1990). 
The main function of transferrin however remains that of iron transport where it serves 
as a means of maintaining Fe3+ in a soluble and nontoxic form during transport between 
absorption, utilisation and storage sites. The presence of the protein is critical as Fe 3+ the 
predominant iron state at physiological pH, ionic composition and oxygen tension, is 
readily hydrolysed and polymerized to form insoluble aggregates of iron at 
concentrations greater than 10-17M (Aisen & Listowsky, 1980). Futhermore, Fe 3+ bound 
to transferrin is prevented from catalysing the decomposition of H202 to form toxic OR 
as described above. 
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1.3. IRON ABSORPTION AND REGULATION 
Iron is known to be distributed within the human body in a number of different 
compartments. An adult human of 70kg has about 4g of iron, about 2.5g of which is 
found in erythrocytes, lg in the liver, 300mg in myoglobin and respiratory enzymes, 
4mg in the plasma and the rest contained in intracellular iron body stores (Conrad & 
Umbreit, 1993). It has been estimated that the daily turnover of iron between 
erythrocytes and intracellular iron stores through the reticuloendothelial system and 
erythropoiesis, is about 20mg/day, whilst daily absorption and loss is about 1-2mg/day 
(de Jong et al., 1990; Conrad & Umbreit, 1993). Intracellular iron can be incorporated in 
iron-containing enzymes such as ribonucleotide reductase, aconitase and other iron- 
sulphur containing proteins, and into hemoproteins like cytochromes, haemoglobin and 
myoglobin (Kühn & Hentze, 1992). The distribution of iron among the various iron- 
requiring tissues is accomplished by plasma transferrin in the manners described below. 
Iron absorbed from the diet may be present in the form of non-haem (inorganic) iron 
which includes a range of Fe3+ and Fe2+ complexes, or present as haem iron comprising 
haemoglobin and myoglobin. Haem iron is more efficiently absorbed than non-haem 
iron presumably because it is unavailable to chelating agents, whilst Fe" is more 
readily absorbed than Fe3+ because of its higher solubility at physiological pH. The 
processes by which dietary iron is absorbed and translocated through the intestinal 
epithelial cells (enterocytes) are poorly understood. Absorption of non-haem iron, 
predominantly as Fei+, by the duodenal mucosa cells is believed to involve the reduction 
of Fe 3+ to Fe 2+ prior to absorption. Solubilization of Fe 3+ is achieved by the acidic pH 
environment of the stomach before reduction to Fe 2+ by vitamin C. The latter which is 
more soluble than Fe 3+ at the alkaline pH of the intestinal duodenum is maintained in its 
soluble form by binding to mucin (Conrad et al., 1991). Mucin-bound iron is then 
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delivered to integrin on the absorptive surface of the mucosal cells for uptake into the 
cells (Conrad et al., 1993). Cytoplasmic mobilferrin is then believed to accept the iron 
from integrin, and to act as a shuttle protein for iron delivery to the basolateral 
membrane for subsequent entry into the circulation (Conrad et al., 1990; Conrad et al., 
1992; Conrad & Umbreit, 1993). The mechanism for the absorption of haem iron is also 
believed to involve a carrier-mediated process, although the nature of the mechanism 
remains unclear. Although it has been shown that Fe2+ can be transported across the 
brush border of enterocytes by a low-affinity transferrin-independent mechanism 
(Simpson & Peters, 1985), it is not known whether haem can be transported by the same 
process. The internalised haem moiety is however believed to be broken down by haem 
oxygenase releasing iron which enters the same cytoplasmic pool as iron from non-haem 
sources. Iron required by the body is transferred into the circulation where it is bound by 
plasma transferrin. Despite general consensus that absorbed iron is in the Fe 
2+ state, 
crystallisation studies have found that transferrin-bound iron is in the Fe 
3+ state. The 
delivery of iron to the circulation is presumed to be by a carrier-mediated process. The 
nature of the process is however not known although it has been suggested that integrin 
may also play a role (Conrad & Umbreit, 1993). Iron not required by the body is stored 
in the intracellular storage protein ferritin, and subsequently lost when the cell is shed at 
the end of its life span. Ferritin is a single chain protein composed of a protein shell 
(apoferritin) enclosing a core of iron in the form of ferric hydroxy-phosphate (Aisen & 
Listowsky, 1980; Worwood, 1989). The protein shell is made up of 24 subunits of two 
types, H and L, which is arranged in the form of a hollow sphere with 6 channels about 
0.5nm wide, through which iron atoms can pass and enter the interior. Iron enters 
ferritin as Fe 2+ which is then oxidised to Fei+. Conversely, iron released from ferritin is 
reduced to Fe 2+ before release, although the nature of iron mobilisation from ferritin also 
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remains to be clarified. As humans have a limited capacity to excrete iron, body iron is 
controlled at the absorption stage in the proximal small intestine. Increased absorption is 
found in situations where body iron stores are low and tissue iron requirements are high, 
and when the rate of erythropoiesis is high. Conversely, absorption is depressed when 
body iron stores are high and can match tissue requirements for iron. The mechanisms 
by which enterocytes sense body iron requirements however remain unclear. Several 
studies suggest that iron absorption and subsequent transport into the circulation is 
restricted to the mature cells (enterocytes) of the mid to upper villus, whilst the 
immature cells of the intestinal crypt accept signals relating to the status of body iron. 
The mechanism does not appear to be dependent on transferrin as there is a lack of 
transferrin mRNA in enterocytes (Parmley et al., 1985; Pietrangelo et al., 1992). 
Pietrangelo et al., (1992) and Mckie et al., (1996) however found differences in the 
distribution of transferrin receptor mRNA in intestinal tissue, where the level of 
transferrin receptor mRNA was higher in the ileum than in the duodenum in iron 
overload situations. Conversely, iron deficiency resulted in a twofold increase in 
transferrin receptor mRNA levels in both the ileum and duodenum. The former situation 
of decreased duodenum transferrin receptors therefore reduces the uptake of iron by 
transferrin from mucosal cells, whilst the latter situation favours the increased uptake of 
iron. Early studies by Conrad & Crosby (1963) found that the basolateral membranes of 
intestinal crypt cells were capable of taking up iron from the body. Anderson et al., 
(1990b) and Nunez et al., (1996) have since both confirmed that transferrin receptors are 
present on basolateral membranes. The latter study also found that the majority of iron 
taken up by Caco-2 intestinal epithelial cells was by basolateral endocytosis of 
transferrin-iron. In the mechanism subsequently proposed by Anderson (1996) for the 
control of iron absorption, circulating transferrin is believed to be one of the ways in 
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which the intestinal crypt cells are provided with information about the body iron status. 
The model proposes that low body iron causes an increase in the level of transferrin 
receptors on the basolateral membrane of the crypt cells. This results in increased 
endocytosis of holo transferrin and subsequent iron release, before the apo transferrin- 
transferrin receptor complex is recycled to the cell surface. The increased iron 
concentration of the crypt cells is believed to act as a signal for the expression of genes 
important for iron absorption. However the crypt cells are unable to absorb iron until 
they migrate up the villus and differentiate into mature absorptive enterocytes over a 2-3 
day period. The converse is thought to happen in situations of iron overload. 
1.4. TRANSFERRIN-DEPENDENT IRON UPTAKE BY MAMMALIAN CELLS 
Transferrin-bound iron may be taken up by mammalian cells in a number of ways. The 
most characterised mechanism is that of receptor-mediated endocytosis (RME), 
although a number of cells also take up iron by a transmembrane reductase system (for a 
review see Qian & Tang, 1995). The majority of studies on the first mechanism of RME 
have been carried out in reticulocytes, although the mechanism can be found in most 
cells. The following is therefore a description of the findings for these cells in particular. 
A diagrammatic representation of the process is shown in Figure 1.1. 
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Figure 1.1. Diagrammatic representation of transferrin receptor-mediated endocytosis. 
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The above symbols denote the following: a-0 = transferrin; = transferrin receptor; 0= carrier; .= 
ATP; "= AMP; v= ATP-Fe; v= AMP-Fe; t= iron (From Qian & Tang, 1995). 
An integral part of the process is the transferrin receptor, a dimeric transmembrane 
glycoprotein (MH 180,000) composed of two subunits (M,,, 90,000) linked by a 
disulphide bridge. Each subunit is orientated in the membrane with a cytoplasmic N- 
terminus and an extracellular C-terminus (Schneider et al., 1982). The extracellular form 
of each subunit has a transferrin-binding site, and three asparagine-linked complex and 
high mannose oligosaccharide chains believed to be essential for the correct transport of 
the receptor to the cell surface (Williams & Enns, 1993). A 2.3kb mRNA encodes the 
760 residue polypeptide which shows little homology with transferrin. However like 
transferrin, the 31kb gene for the receptor is also found in the chromosome 3q2 region, 
at 3q26 (McCleland et al., 1984; Rabin et al., 1985). RME iron uptake is initiated by the 
binding of iron-containing transferrin to the transferrin receptor on the cell membrane 
(step 1, Fig. 1.1. ). At physiological pH (7.4) and. temperature (37°C) the transferrin 
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receptor has a higher affinity for iron-containing transferrin than for apo transferrin (Ka 
1.1 x 108M 1 and 4.6 x 106M'1 respectively), therefore only iron-containing transferrin 
molecules are bound by the receptor (Young et al., 1984b). The transferrin-transferrin 
receptor complexes are clustered together and internalised via clathrin-coated pits (step 
2) which then lose their clathrin coat and fuse to become vesicles called endosomes 
(Harding et al., 1983; lacopetta & Morgan, 1983; Crichton & Charloteaux-Wauters, 
1987). The intravesicular pH is then lowered to about pH 5.6 (step 3) by the action of an 
ATP-dependent proton pump (Yamashiro et al., 1983) suggested to be that of the 
reticulocyte endosome H+-ATPase (Li et al., 1995). At the low intravesicular pH, the 
binding of iron to transferrin is weakened and this facilitates the dissociation of iron 
(step 4) from the protein (Paterson et al., 1984). It was recently suggested by Bali & 
Asien, (1991) that an additional mechanism was involved in the release of transferrin- 
bound iron in endosomes. The observation was made on the basis that although the 
entire cycle of RME is believed to take about 3min (Iacopetta & Morgan, 1983), 
spontaneous release of iron from holo transferrin at pH 5.5 takes hours to complete 
since the transferrin C-terminal lobe is acid-stable and can retain iron in the absence of 
chelating agents down to about pH 4.8 (Princiotto & Zapolski, 1975; Baldwin et al., 
1982; Foley & Bates, 1988). Bali & Aisen, (1991) suggested that the transferrin receptor 
itself facilitated iron release from holo transferrin at pH 5.6, as iron release from the C- 
lobe monoferric transferrin-transferrin receptor complex was greater (-70%) than from 
the free monoferric form. They proposed that a conformational change in the transferrin 
receptor induced a secondary conformational change in the bound transferrin, 
particularly in the C-lobe. This was then thought to lead to opening of the iron-binding 
cleft facilitating iron release and allowing complete dissociation of transferrin-bound 
iron in the endosome. Some studies have shown that iron release 
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and/or mobilisation of released iron in isolated rabbit reticulocyte endosomes require the 
presence of a reductant (Nunez et al., 1990; Watkins et al., 1992). Although it is 
therefore generally thought that the released iron is first reduced from Fe 3+ to Fe2+ in the 
endosome and then translocated across the endosomal membrane into the cytosol, the 
processes following iron release have not yet to been clearly defined. The involvement 
of an iron reduction step is also the basis for another transferrin-dependent iron-uptake 
mechanism, the transmembrane-reductase system. Studies by Sun et al., (1987b) and 
Thorstensen & Romslo (1988) implicated the involvement of the plasma membrane 
redox system, NADH: Ferricyanide oxidoreductase in rat liver hepatocytes. They 
proposed a reductive mechanism where binding of holo transferrin to the transferrin 
receptor occurs in close proximity to the plasma membrane redox system. Concert 
proton and electron fluxes then destabilise the transferrin-iron bond and reduce the iron 
which is subsequently trapped by appropriate plasma membrane Fe 
2+ ligands. These are 
internalised and the reduced iron taken up by mechanisms in effect in the RME model. 
The iron-free transferrin on the plasma surface is meanwhile displaced from the 
transferrin receptor by iron-containing transferrin and the cycle repeated. This reductive 
mechanism of iron uptake from transferrin was however challenged by Thorstensen & 
Aisen (1990) who failed to find an association between the transmembrane-reductase 
system and iron release from transferrin in isolated rat liver plasma membrane. 
Regardless of the mechanism of iron entry in cells, released intravesicular iron has to be 
transported through the vesicular membrane into the cytosol for incorporation into 
intracellular compounds such as ferritin or haem. The general consensus is that 
translocation is via a carrier-mediated uptake mechanism (step 5) although once more 
the nature of the process is not fully defined. Studies by Egyed (1988) and Morgan 
(1988) suggested a high affinity carrier-mediated mechanism for the transport of Fee+, or 
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Fee' and Fe 3+ into rabbit reticulocytes. It was suggested that this Fe 2+ transport 
mechanism was modulated by Na+ as increased intracellular Na+ facilitated Fe 2+ uptake 
by rabbit reticulocytes and vice versa (Egyed, 1991). Although this Na+ / Fe 2+ transport 
system was primarily suggested as a transferrin-independent mechanism for iron entry 
into reticulocytes (sec. 1.4.1. ), it was also proposed to be a possible mechanism for the 
translocation of transferrin-iron following release from the protein in endosomes. It has 
recently been suggested that a 17.5kDa subunit (the proton pore complex) of the 
vacuolar H+-ATPase may be involved in the translocation of iron from the endosome to 
the cytosol (Li et al., 1995). Studies on isolated rabbit reticulocyte endosomes suggested 
that there were two groups on the H+-ATPase. One group of iron-binding sites was 
suggested to be responsible for endosomal acidification as mentioned earlier, whilst the 
second group on the proton pore complex was thought to be involved in the processes 
leading to iron translocation. As with the mechanisms of translocation of iron from the 
endosome into the cytosol, the mechanisms for the incorporation of the translocated iron 
into intracellular compounds is not clearly defined. A variety of low Mr compounds 
including adenosine triphosphate (ATP) are thought to act as ligands capable of 
chelating cytoplasmic iron and transferring it to intracellular storage and/or utilisation 
sites. Two different iron receptors for example have been shown to exist on 
mitochondrial membranes, one for ATP-Fe and the other for adenosine monophosphate 
(AMP)-Fe (Weaver & Pollack, 1990; Pollack, 1992). Utilisation of iron bound to the 
former receptor was found to be less efficient than from iron bound to the latter 
receptor. It was therefore suggested that the ATP-Fe receptor bound intracellular ATP- 
Fe which was then hydrolysed to AMP-Fe. The latter then binds to the AMP-Fe receptor 
which would deliver the iron for haem synthesis (step 6). In addition to facilitating iron 
dissociation from transferrin, the low intravesicular pH of the endosome also serves to 
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enhance the binding of the iron-free (apo) transferrin to the transferrin receptor. This is 
believed to be an additional means of deflecting the endocytosed transferrin from 
lysosomal degradation. The apo transferrin-transferrin receptor complex is then sorted 
into exocytic vesicles and recycled possibly via the Golgi to the cell membrane (step 7) 
where subsequent exposure to the neutral extracellular pH causes the apo transferrin to 
be rapidly displaced from the transferrin receptor by iron-containing transferrin. 
(Dautry-Varsat et al., 1983; Klausner et al., 1983). This cycle may be repeated about 300 
times before degradation of the transferrin receptor (Omary & Trowbridge, 1981), and 
about 100-200 times before degradation of transferrin (Katz, 1961). 
1.4.1. TRANSFERRIN-INDEPENDENT IRON UPTAKE BY MAMMALIAN 
CELLS 
Although most cells take up iron via the transferrin-dependent RME mechanism, iron 
uptake has also been suggested to occur via transferrin-independent mechanisms. 
Studies have shown that non-transferrin-bound iron can be transported into reticulocytes 
by a carrier-mediated mechanism that can be divided into two components, one 
saturable with a Km of approximately 0.2µM, and another non-saturable that increases 
linearly with increasing iron concentration (Egyed, 1988; Morgan, 1988; Qian & 
Morgan, 1990). The process appeared to be dependent on cellular ATP concentration, 
and was modulated by Na+ as increased intracellular Na+ facilitated Fe 2+ uptake and 
vice versa (Egyed, 1991; Qian & Morgan, 1991). The saturable component of the 
transport process was found to disappear when reticulocytes matured into erythrocytes, 
and was therefore suggested to be reticulocyte-specific (Morgan, 1988; Egyed, 1991). 
This was confirmed by Hodgson et al., (1995) who found that a high-affinity saturable 
mechanism limited to reticulocytes could take up transferrin-free Fee+, whilst mature 
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erythrocytes retained some capacity to take up transferrin-free Fe 2+ via the low- 
affinity non-saturable mechanism. Recent studies by Stonell et al., (1996) suggested 
that the Naa -associated transport mechanism was that of the Na+ /Mg2+ exchanger 
(antiport) as iron uptake was inhibited by both extracellular Na+ and Mgt+, and 
stimulated by intracellular Mgt+. Although the high-affinity saturable mechanism is 
thought to be a mechanism of iron uptake as well as the mechanism for the 
translocation of released endosomal iron, the function of the low-affinity non-saturable 
process remains unclear (Qian & Morgan, 1992; Quail & Morgan, 1994). Like 
reticulocytes, intestinal mucosal cells and hepatocytes are known to also take up 
transferrin-free iron via a carrier-mediated mechanism. Studies by Muir et al., (1984) 
and Simpson & Peters (1985) have shown that Fe 2+ can be transported into purified 
mouse intestinal brush-border membrane vesicle by a saturable mechanism of two 
components. One component showed rapid high-affinity, (Kd < 1µM) low capacity 
binding that was presumed to occur to the outside of the vesicle, whilst the other 
more predominant component showed low-affinity, low capacity binding with an initial 
rate which showed a hyperbolic dependence on the medium Fe 2+ (Km 35-90µM) 
(Simpson & Peters, 1985). The high-affinity process was also found to be insensitive to 
NaCl, whilst the low-affinity process was NaCl- KCl- and pH-sensitive. It was 
subsequently proposed that the low-affinity process was responsible for iron 
transport across the brush-border membrane prior to intravesicular binding. A similar 
carrier-mediated transport mechanism has also been proposed for hepatocytes 
(Grohlich et al., 1979; Morgan & Baker, 1986). The two processes implicated for 
intestinal mucosal cells and liver hepatocytes however appear to be distinct from those 
operating in reticulocytes and erythrocytes. Whereas the high-affinity process in 
reticulocytes is inhibited by extracellular NaCl (Hodgson et al., 1995; Stonell et al., 
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1996), the corresponding component in intestinal mucosal cells appears to be insensitive 
to NaC1 (Simpson & Peters, 1985). Furthermore, although the low-affinity process of 
the intestinal mucosal cells like the erythrocyte equivalent is inhibited by extracellular 
NaCl, the former is also sensitive to extracellular KC1 unlike that of erythrocytes. It 
therefore appears that the nature of the carrier-mediated transport mechanisms for 
transferrin-free iron in cells may depend on the cell type. More recently, an alternative 
mechanism for transferrin-free iron uptake has been suggested by Richardson & Ponka 
(1995). Studies on the human melanoma cell line SK-MEL-28, found that ferric 
ammonium citrate (FAC) was capable of inducing iron uptake. The process was 
determined to be independent of the transferrin receptor and hence the RME mechanism 
as well the transmembrane-reductase mechanism. The proposed mechanism was thought 
to be stimulated by the production of hydroxyl free radicals (OH-) which can be 
produced from the superoxide radical (02) under physiological and pathophysiological 
conditions in vivo as a result of the iron-catalysed Haber-Weiss reaction (rtn. (1), sec. 
1.2. ). The OR then activates a membrane-bound iron transport system that is capable of 
binding and transporting iron in the form of low Mr compounds for internalisation 
within the cell (Richardson & Ponka, 1995). It was suggested that this FAC-activated 
iron uptake process was a protective mechanism against oxidant stress generated in the 
presence of low M, iron-complexes in pathophysiological states such as iron overload 
disease where the level of free cellular iron (i. e. potential catalytic iron) may be higher 
than normal. The mechanism was also present in a range of other cells including human 
fibroblasts, Chinese hamster ovary cells and Hela cells (Kaplan et al., 1991; Richardson 
& Ponka, 1995). The exact nature of the process however remains to be defined. 
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1.4.2. REGULATION OF IRON METABOLISM 
Iron is known to regulate the synthesis of three proteins involved in its own metabolism 
(for a review see Lash & Saleem, 1995 and Mascotti et al., 1995) . The three proteins 
are that of ferritin, the transferrin receptor and the enzyme erythrocyte 5-aminolevulinate 
synthase (erythroid delta-aminolevulinic acid synthase; eALAS) which catalyses the first 
step of the haem biosynthetic pathway that utilises about 80% of the ATP-bound 
(chelatable) intracellular iron (Kühn & Hentze, 1992; Ferreira & Gong, 1995). In 
situations of iron depletion, cells need to reduce the amount of stored iron, redirect the 
utilisation of intracellular chelatable iron to the synthesis of crucial iron-containing 
enzymes, and to increase iron uptake into cells. This is achieved by a fall in ferritin and 
eALAS synthesis and an increase in the synthesis of the transferrin receptor (Binder et 
al., 1994; Lash & Saleem, 1995). Conversely, iron overload sees a rise in ferritin and 
eALAS synthesis and a corresponding decrease in transferrin receptor synthesis 
resulting in increased iron storage and utilisation and a decrease of plasma iron uptake. 
Iron regulation of the three proteins primarily occurs at the translational level (Kühn & 
Hentze, 1992). The structural element within mRNA that allows iron to regulate the 
synthesis of the three proteins was identified as a cis - acting repression site within the 
5' untranslated region (UTR) or 3' UTR of the mRNA (Aziz & Munro, 1987). This cis - 
acting repression site called the iron responsive element (IRE) or iron regulator element, 
was found to be a stem-loop structure usually consisting of 27 bases (Kühn & Hentze, 
1992). A simplified model of the IRE is shown in Figure 1.2. 
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Figure 1.2. The consensus secondary structure of the functional iron responsive 
element found in ferritin mRNA. 
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In the sequence, M represents any nucleotide except guanine, and N-N' indicates two 
base-paired nucleotides within a stem structure. (From Mascotti et al., 1995) 
The six-base loop sequence (CAGUGM) where M can be C, U or A, and an unpaired C 
located on the 5' side of the IRE immediately preceding the 5bp stem (Fig. 1.2. ) of the 
IRE are phylogenetically conserved (Bhasker et al., 1993; Henderson et al., 1994). The 
ferritin IRE (Murray et al., 1987; Hentze et al., 1987) and eALAS IRE (Dandekar et al., 
1991; Cox et al., 1991) are both located in the 5' UTR of their mRNA, near the mRNA 
cap structure. Whereas ferritin and eALAS have only one copy of the IRE in the 5' 
UTR, transferrin receptor mRNA has five functional copies in the 3' UTR (Casey et al., 
1988; Leibold & Laudano, 1990). Binding of a trans - acting factor to the respective IRE 
in the 5' UTR of ferritin and eALAS represses mRNA translation, subsequently 
facilitating the regulatory conditions required in situations of iron depletion. This trans - 
acting factor has been identified and is primarily known as the iron regulatory protein 
(IRP). Other names for the factor include iron regulatory factor, iron responsive element 
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binding protein and ferritin repressor protein. IRP is a 98kDa, 889 amino acid protein 
translated from a 3.6kb mRNA (Yu et al., 1992). The rat liver IRP shares 95% and 
98% sequence homology with human and mouse IRP respectively, indicating a high 
level of conservation. In addition it shares a high degree of homology with iron-sulphur 
(Fe-S) cluster containing proteins such as aconitase (Hentze & Argos, 1991). A second 
IRP called IRP-2 was recently reported to be expressed in several tissues although the 
distribution in tissue and abundance of its mRNA was different to that of IRP (now 
called IRP-1) (Samaniego et al., 1994). The protein was found to share 61% sequence 
identity with IRP-1 and was also present in lower eukaryotes indicating a high degree of 
conservation (Guo et al., 1995). Although both IRP-1 and IRP-2 bind to IRE regions 
with equal affinity, each protein was found to recognise unique IRE-like sequences 
. indicating that they had different specificities for IRE's (Henderson et al., 1996). The 
two proteins also appear to differ in the way in which they mediate iron regulation. IRP- 
1 has been determined to be the apo (non-functional) form of cytoplasmic aconitase, 
existing as an IRE binding form with a (3Fe-4S) cluster that binds intracellular 
iron in iron overload situations (Kennedy et al., 1992; Haile et al., 1992; Beinert & 
Kennedy, 1993). This results in a conformational change (4Fe-4S) to give IRP-1 with 
aconitase activity (functional cytoplasmic aconitase). The latter has a low affinity for 
IRE so dissociates from the IRE allowing translation of ferritin and eALAS to resume, 
and transferrin receptor mRNA to be degraded (Kühn & Hentze, 1992; Harrison & 
Arosio, 1996). The converse situation occurs when cellular iron is low. Unlike 
IRP-1, it has been found that IRP-2 cannot acquire aconitase activity with subsequent 
dissociation from the IRE (Guo et al., 1994). Regulation appears to be related 
instead to cellular levels of the protein. IRP-2 levels have been found to be inversely 
regulated by iron levels (Samaniego et al., 1994), iron uptake resulting in the 
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degradation of the protein (Guo et at., 1995). It was proposed that degradation was 
linked to the proteasome as inhibitors that blocked the proteasome function also 
prevented the degradation of IRP-2. The mechanism of iron regulation in situations of 
iron overload by IRP-2 therefore apparently involves increased degradation of the 
protein, the end result being a lower concentration of IRP-2 binding to the IRE and 
subsequent initiation of ferritin and eALAS synthesis and degradation of transferrin 
receptor mRNA. 
Haem has also been suggested to play a role in iron regulation. Two mechanisms have 
been proposed, one indirect and one direct. The indirect process is believed to involve 
entry of haem into cells via a carrier-mediated protein such as hemopexin or 
haptoglobin. Transferrin may also be involved as it is capable of binding porphyrins 
such as haem, although the porphyrins can not displace bound iron (Stout, 1992). 
Internalised haem is believed to be degraded by haem oxygenase, releasing iron which 
can then stimulate the various iron regulatory processes outlined above. ' The second 
proposed mechanism involves the direct binding of haem to functional IRP (i. e. IRP 
bound to the IRE). Studies have suggested that hem can induce ferritin synthesis by 
binding to IRP and inducing dissociation of the latter from the IRE (Lin et al., 1990; Lin 
et al., 1991). Binding of haem is thought to result in the formation of several high 
molecular weight species (HMS) which are either a covalent complex of IRP molecules, 
or a complex of IRP and other unknown proteins (Goessling et al., 1992,1994). The 
IRP in the HMS is non-functional so dissociates from the IRE thereby inducing ferritin 
synthesis. HMS has a short half-life and is degraded within a few hours. However, a 
brief influx of haem means that undegraded HMS can revert back to form functional 
IRP which represses ferritin synthesis. 
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Other factors implicated in cellular iron regulation are cytokines, nitric oxide and 
erythropoietin. Interleukin-1 ß (IL-1p), tumour necrosis factor a and interferon y for 
example, all decrease transferrin-iron uptake into the human monocytic cell line U937 
(Fahmy & Young, 1993). Similarly, studies on mouse macrophages found that the two 
cytokines interleukin-4 and interleukin-13 regulated macrophage iron metabolism in at 
least two ways (Weiss et al., 1997a). One mechanism was via an IRP-independent 
modulation of transferrin receptor mRNA expression, whilst the second was by 
opposing nitric oxide-mediated IRP activation of ferritin mRNA translation. Rogers et 
al., (1994) have 'also reported a 5' IRE-distinct sequence of 20 nucleotides within the 
ferritin H-chain which showed a twofold enhancement of H-ferritin translation after 
treatment with IL-1 ß. It therefore appears that the selective effects of the various 
cytokines may be exhibited through different regions in the 5' UTR of the ferritin 
mRNA. Associated with cytokine regulation is the involvement of the inflammatory 
mediator, nitric oxide (NO). Studies have shown that NO can give dose-dependent 
upregulation of transferrin receptor expression in K562 erythroleukemia cells, as well as 
partly increasing ferritin mRNA levels (Oria et al., 1995). It has also been shown to 
increase the IRE-binding affinity of IRP-1 but not of IRP-2 in rat hepatoma cells, the 
increase in IRP-1 affinity coinciding with repression of ferritin synthesis (Phillips et al., 
1996). Albakri & Stuehr (1996) recently found that NO decreased haem availability, 
which may explain why rat hepatoma cells stimulated by cytokines and 
lipopolysaccharide to produce NO showed decreased mitochondrial and IRP-1 aconitase 
activities (Phillips et al., (1996). The indirect role of NO in iron regulation during 
inflammation therefore appears to involve the prevention of haem binding to IRP-1, 
thereby affecting the direct haem regulatory mechanism mentioned above. 
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Erythropoietin which primarily induces erythroid progenitor cell proliferation and 
differentiation, has also been found to enhance the IRE-binding affinity of IRP-1 in 
human (K562) and murine erythroleukemic cells (Weiss et al., 1997b). As with the 
mechanisms described above, erythropoietin activation of IRP-1 was found to be 
associated with a marked increase in transferrin receptor mRNA levels, enhanced cell 
surface expression of transferrin receptor, and an increased uptake of iron into cells. The 
mechanism was however not observed in human myelomonocytic cells indicating that 
erythropoietin-stimulated translational induction of transferrin receptor expression was 
specific to erythroid cells. The regulation of cellular iron metabolism is therefore a 
complex series of events linking a number of proteins, where binding of an IRP to an 
IRE in the 5' UTR or 3' UTR of the mRNA respectively, inhibits or enhances 
translation. 
1.5. PRIMARY STRUCTURE OF HUMAN PLASMA TRANSFERRIN 
Plasma transferrin is a single polypeptide chain of 679 amino acids and two asparagine 
(N)-linked complex glycan chains, with an overall M,  of 79,570 (MacGillivray et al., 
1983). The protein has 19 disulphide bridges, 11 in the COOH-terminal and 8 in the 
N112-terminal. The high level of sequence homology (40%) between the NH2- and 
COOH-terminal halves of the chain lead to the suggestion that the protein was 
composed of two iron-binding domains (MacGillivray et al., 1982; MacGillivray et al., 
1983). The two domains suggested were the N domain of residues 1-336, and the C 
domain of residues 337-679 (Fig. 1.3. ). Following subsequent protein crystallisation 
studies which showed that the two domains were further subdivided into two halves 
(sec. 1.8.1. ), the current nomenclature for the two halves are, N. and C-lobes. Similar 
internal sequence homology has also been reported for hen ovotransferrin (37% ) 
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Figure 1.3. The complete amino acid sequence of human plasma transferrin. 
1 20 40 
V PD KTV R AVS EEA KC QSFR D HMKSVI PSDGPSVA VKK ASYLD C 
337 360 
III E RL KC DEW SV SDV GKIE VSA ETTED C D EC KPV K ALS 
60 80 
RAIAANE ]AU VT LGV YLAP K AE FY 
380 11400 
AKIMNG MS LGV GKC V AE Y 
100 120 
GSKED PQTF YY VA VKK DS GFQ MN QLR GK K SCHI GLG 
420 440 
MKSDDD CEDT PEAG YF AVA VKK SASDL TW DNL GK K SCHI AVG 
140 160 
RSG MI I LLYCDL PEPRKPLEKAVANF FS GCA CADGTDFP 
40 80 
RTG NI M LLYNKI NHCRFD EF SECA GSKKDS 
20 
Q LC QCP CG C STLNQ GSG FK LG GDV VK S 
5 20 
SM SGL EPNNKEG T FR VEK VK QV 
220 240. - 
F13 LANK ADRDQY ELL LR KP DEYKD C EVP T VV 
54 560 5 
TQ PGGKNPDPWAKMLNEKD ELL LGR QEY C RAP AW 
260 290 
AR SMGGKEDLIWEL NQAQEH F KDKSKEFQLF SSPH K DLL K 
60 620 
TR KEACVHKI RQQQHL FS NVTDCSGNFCL FRSE LL R 
300 320 336 
SAHGFLKVPPRMNAKM'Y LG YEYVTAIRNLREGTC PEAPI 
640 660 679 
DTVCLAKLHDRNTYEKY LG QEYVKAVGNLRKCSTSSLLEACTFRRP 
The upper line represents the N-lobe sequence, and the lower line the C-lobe sequence. Gaps have been 
placed to maximise sequence homology between human serum transferrin, chicken ovotransferrin and 
human lactoferrin sequences (latter two sequences not shown). Boxed areas represent homologous 
residues in the N- and C-lobe. (From MacGillivray et at., 1983). 
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(Williams, 1982), human lactoferrin (37% - Metz-Boutigue et al., 1984) and 
melanotransferrin (46% - Rose et al., 1986). In addition, comparisons of the sequences 
for the above transferrins have revealed significant homology between human plasma 
transferrin and hen ovotransferrin (51%), human lactoferrin (59%) and 
melanotransferrin (39%). Present-day vertebrate transferrins are therefore thought to 
have evolved from the duplication and fusion of an ancestral gene specifying a single- 
domain 40kDa protein (MacGillivray et al., 1983; Williams, 1982; Baldwin, 1993). The 
gene duplication event is believed to have occurred before the divergence of the 
mammalian and insect line (Bartfield & Law, 1990; Baldwin, 1993) as a means of 
perhaps preventing the loss of transferrin and hence iron through glomerular filtration 
(de Jong et al., 1990). The duplication theory is also supported by the pattern of 
disulphide bridges in transferrins. Comparisons of the primary structures for various 
transferrins have shown that there are six disulphide bridges (1-6, Williams 1982 
nomenclature) that are conserved in both lobes of all transferrins (Williams, 1982; 
Bailey et al., 1988; Baldwin, 1993). With the exception of bridge 3 which spans more 
than 40 residues (Fig. 1.4. ), the conserved bridges have been found to be local in nature, 
and do not traverse the two halves (domains) of each lobe (Bailey et al., 1988; Baldwin, 
1993). Of the additional bridges found in rabbit plasma transferrin (the equivalent 
structure to human plasma transferrin), bridges 7-9 in the C-lobe are semiconserved and 
have no counterparts in the N-lobe. They are all long range, spanning about 200 residues 
and are presumed to have arisen after gene duplication (Bailey et al., 1988). The 
remaining 4 bridges, numbers 10 and 11 in the C-lobe, and numbers 12 and 13 in the N- 
lobe are restricted to each lobe. 
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Figure 1.4. The disulphide bridge pattern in rabbit serum transferrin. 
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In the above: solid lines denote conserved bridges 1-6; dashed lines denote semiconserved bridges 7-9; 
dashed-dotted lines denote bridges 10-12. (Taken from Bailey et al., 1988). 
1.5.1. STRUCTURE OF THE N-LINKED COMPLEX GLYCAN CHAIN 
Transferrin is a glycoprotein containing about 6% carbohydrate which consists of two 
N-linked complex oligosaccharide chains attached to asparagine residues 413 and 611 in 
the C-terminal lobe (Aisen & Listowsky, 1980; MacGillivray et al., 1983). Synthesis of 
the glycan chains is carried out in the rough endoplasmic reticulum and the Golgi 
system while the protein is en route to its final destination (for a review of glycosylation 
see Opdenakker et al., 1993). The enzyme-catalysed process in which oligosaccharides 
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are covalently linked to asparagine residues in the sequon Asn-X-Thr (where X is any 
amino acid other than proline or aspartic acid), depends on a number of factors. These 
involve sequential, and sometimes mutually exclusive interactions between highly 
specific glycosylating enzymes and the protein, which are affected by the protein 
structure, and the internal and external environment, and developmental stage of the cell 
(de Jong & van Eijk, 1989; de Jong et al., 1990; Opdenakker et al., 1993). Despite the 
complexity of the glycosylation process, structural variation of the two N-linked glycan 
chains is limited in human transferrin. The glycans are invariably of the complex type, 
differing only in the degree of branching and terminal sialic acid content. A total of nine 
structural carbohydrate forms can be found in human plasma since each glycan chain 
may be bi-, tri- or tetra-antennary, with each branch ending with a possible sialic acid 
residue (Spik et al., 1985; de Jong & van Eijk, 1989; de Jong et al., 1990). The most 
predominant plasma form however appears to be a biantennary structure with each 
branch ending with one sialic acid residue (tetrasialotransferrin) (Fig. 1.5. ). The two 
glycan moieties of transferrin are known to show structural variations with nine possible 
isoforms ranging from a transferrin with no terminal sialic acid residues 
(asialotransferrin) to one with eight sialic acid residues (octasialotransferrin) (Spik et al., 
1985; de Jong & van Eijk, 1989; de Jong et al., 1990). The number and distribution of 
glycan chains also vary in the transferrin family, with for example one chain in the C- 
lobe of rabbit serum transferrin (Evans et al., 1988a; Bailey et al., 1988) and two in the 
C-lobe of human serum transferrin (MacGillivray et al., 1982,1983). Glycosylation is 
believed to affect protein structure and function through intramolecular interactions like 
secretion and receptor recognition, and contributes to protein stability and conformation 
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Figure 1.5. Structure of the predominant glycan structure of human plasma transferrin. 
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The above symbols denote the following: Asn = asparagine; GLcNAc = N-acetyl glucosamine; MAN = 
mannose; GAL = galactose; S. A. = sialic acid; a or (3 with numbers = glycosidic linkages; the boxed area 
= core structure common to all N-linked oligosaccharides. 
by protecting the protein against intracellular and extracellular degradation (Opdenakker 
et al., 1991). The functional role of the glycan chains in transferrins however still remain 
to be fully established. Although it was suggested that the glycan moiety signals 
transferrin clearance from the circulation (Regoeczi et al., 1974), this has been refuted 
by Imber & Pizzo (1983). More recent studies by van Berkel et al., (1995) have also 
reported that human kidney-derived cells cultured in the presence of tunicamycin (an 
inhibitor of N-linked glycosylation) are still capable of secreting intact unglycosylated 
recombinant human lactoferrin. Previous studies by Legrand et al., (1990) indicated that 
glycosylation affected the stability of the iron-binding site, as deglycosylation of tryptic 
NU domain and N-lobe fragments of human and bovine lactoferrin either abolished or 
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reduced the iron-binding capacity. van Berkel et al., (1996) however found that 
deglycosylation of human lactoferrin did not affect iron-binding, or the ability of the 
protein to bind to bacterial lipopolysaccharide or human lysozyme, indicating that the 
glycan moiety was not relevant to the anti-microbial and anti-inflammatory activities of 
the protein. Mason et al., (1993) also found that unglycosylated recombinant human 
transferrin in which the two Asn glycan residues (413 and 611) were mutated to Asp, 
bound to HeLa S3 cells with the same affinity as a recombinant glycosylated transferrin 
and 3 other commercial transferrin samples. Similar findings were also reported by 
Kawakami & Lönnerdal (1991) and Alcantara et al., (1992) for the binding of human 
lactoferrin to human intestinal and bacterial receptors respectively. The. studies of van 
Berkel et al., (1995) also found that unglycosylated human lactoferrin was more 
susceptible to tryptic proteolysis, suggesting that a major function of glycosylation in 
transferrins is to protect against proteolysis. 
1.6. HUMAN PLASMA TRANSFERKIN GENE 
The transferrin mRNA has a 2324bp nucleotide sequence encoding the 679 residue 
protein sequence, and the 19 residue leader sequence required for protein secretion 
(Yang et al., 1984). Other than a few amide assignments, the translated sequence was 
found to agree very closely with the amino acid sequence determined by MacGillivray et 
al., (1983). Chromosomal mapping from Eco RI digestion of human-mouse somatic cell 
hybrid DNA revealed that the transferrin gene was located on human chromosome 3, 
within the 3g21-25 region (Yang et al., 1984). The complete transferrin gene reported by 
Schaeffer et al., (1987) is about 33,500bp in length, organised into 17 exons (ranging 
from 33-206bp) and 16 introns (ranging from 675-5000bp) as shown in Figure 1.6. 
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Figure 1.6. The distribution of exons and introns in the human transferrin gene. 
ABCDEFGHIJKLMNOP 
123456789 10 11 12 13 14 15 16 17 
1 Kb 
In the above, introns are to scale, but exons are not. Letters denote introns and numbers exons (Adapted 
from Schaeffer et al., 1987). 
In an earlier study by Park et al., (1985), partial characterisation of the transferrin gene 
(24kb sequence encoding - 70% of the protein) revealed that exons 3,4,5 and 6 were 
homologous in size (- 90%) and sequence (- 50%) to exons 10,12,13 and 14. It was 
proposed that the present day human transferrin gene resulted from a duplication event 
involving unequal crossing-over from recombination between sequences located in 
introns 1-2 and 9-10 of an ancestral 10-exon gene (Fig. 1.7A). This formed an 
intermediate 18-exon gene (Fig. 1.7B) which lost an exon 4 in the 5' moiety during 
evolution. Independent evolution in the duplicated gene then lead to present-day 
transferrin of unequal intron and homologous exon sizes (Fig. 1.7C) (Park et al., 1985). 
The observations of Park et al., (1985) are supported by the complete genomic 
sequences of human plasma transferrin (Schaeffer et al., 1987) and chicken 
ovotransferrin (Jeltsch et al., 1987). Both show strong internal homology between exons 
(i. e. exon pairs 2/9,3/10,4/12,5/13,6/14,7/15 and 8/16), ranging from about 40% to 
about 60% identity. In addition, both genes have 17 exons and 16 introns, with a 
significant degree of homology between the sizes of the respective exons in the two 
genes (Jeltsch & Chambon, 1982; Schaeffer et al., 1987; Jeltsch et al., 1987). 
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Figure 1.7. The proposed model for the origin of present-day human transferrin. 
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The upper numbers in C correspond to the numbers in A&B, whilst the lower numbers correspond to 
present-day exons. Thick bars denote exons sequenced by Park et al., 1985 (From Park et al., 1985). 
With respect to the proposed gene duplication model described above (Fig. 1.7), Jeltsch 
et al., (1987) proposed that the evolution of present-day transferrins proceeded by 
insertion or deletion of whole codons as size differences between homologous exons 
" 
were in multiples of 3bp. 
1.6.1. LIVER-SPECIFIC TRANSCRIPTION OF THE HUMAN TRANSFERRIN 
GENE 
The transferrin gene is transcribed at high levels in liver hepatocytes and at lower levels 
in other cells such as the Sertoli cells of the testis (Alfred et al., 1987). The liver-specific 
expression of the gene is controlled by the binding of trans-acting nuclear factors to a 5' 
regulatory region of the gene composed of a combination of positive and negative cis- 
acting elements that act in concert with each other (Adrian et al., 1986; Brunel et al., 
1988; Schaeffer et al., 1989; Mendelzon et al., 1990). There are four functionally 
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different regions in the 5' regulatory DNA sequences: (1) a proximal cell type-specific 
promoter located between positions -125 and -45bp; (2) a distal promoter region from 
-620 to -125bp; (3) a distal negative-acting region between -1.0 and -0.6Kbp; and (4) an 
enhancer located between -4.0 and -3.3Kbp (Schaeffer et al., 1989). The proximal 
promoter sequence located between -125 and -45bp is composed of five separate 
elements called proximal region (PR) I, PRII, central region (CR), and distal region 
(DR) I and DRII (Brunel et al., 1988) according to their relative positions to the cap site 
(Fig. 1.8. ). The PRI and PRII regions are essential for liver-specific transcription as 
mutations in either region either abolish or reduce transferrin transcription in hepatoma 
cells, even in the presence of other regulatory sites (Schaeffer et al., 1993). Early studies 
reported the binding of liver-specific factors called transferrin liver factor I (LFI) and 
CCAAT/enhancer-binding proteins (C/EBP) to the PRI and PRII sites respectively 
(Brunel et al., 1988). It was subsequently reported by Schaeffer et al., (1993) that LFI 
was a complex composed of at least three different liver PRI-binding proteins. The 
major and minor species were found to correspond to hepatocyte nuclear factor-4 (HNF- 
4) and chicken-ovoalbumin-upstream-promoter transcription factor (COUP-TF) 
respectively. Liver-specific transcription was therefore suggested to be directed by the 
binding of HNF-4 and COUP-TF at the PRI site, and C/EBP at the PRII site. 
Transcription was thought to depend on the balance of HNF-4 and COUP-TF, since 
equimolar amounts of the latter abolished HNF-4-induced activation in human Hep 3B 
cells (Schaeffer et al., 1993). The antagonistic interactions between the two were 
thought to result from the formation of HNF-4-COUP-TF heterodimers which prevent 
the binding of either to the respective PR site. 
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Figure 1.8. Regulatory cis-acting elements in the 5' human transferrin gene promoter. 
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(From Schaeffer et al., 1989) 
An antagonistic effect of COUP-TF was also reported by Suire et al., (1996). Previous 
studies by Suire et al., (1995) had found that follicle stimulating hormone (FSH) was 
capable of stimulating transferrin gene expression in rat Sertoli cells. FSH stimulates 
gene transcription by activating the cyclic AMP (cAMP) pathway leading to activation 
of protein kinase A, which phosphorylates the cAMP-responsive-element-binding 
" 
protein (CREB). The latter in turn binds to the PRII site of the transferrin gene, thereby 
promoting transcription (Suire et al., 1996). The only PRI-binding factor identified by 
Suire et al., (1996) was COUP-TF, which prevented transcription in rat Sertoli cells 
when overexpressed. The inhibition by COUP-TF appeared to be a specific event as 
overexpressed HNF-4 (not present in Sertoli cells) did not affect transcription. The 
authors suggested that the limiting transcriptional ability of overexpressed COUP-TF 
was due to an inability of CREB binding to PRII. Transcriptional suppression of the 
transferrin gene has also been reported to be mediated by a group of compounds 
including aryloxyalkanoic fibrate drugs, and native and substituted long chain fatty 
acids, known collectively as hypolipidemic drugs/peroxisome proliferators (HD/PP) 
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(Hertz et al., 1996). HD/PP normally activates transcription through the formation of 
high affinity heterodimers composed of peroxisome proliferators-activated receptors 
(PPAR) and retinoic acid X receptors (RXR). The PPAR-RXR dimers then bind to 
sequence-specific PPAR-activated response elements (PPRE) in the gene promoter, 
activating transcription. Hertz et al., (1996) however found that liver transferrin 
transcription was reduced in rats treated with HD/PP. Studies on human Hep G2 cells 
found that HD/PP repression was associated with the activity of HNF-4 which binds to 
the PRI in the liver. The postulated that the suppression of transcription was the result of 
nonproductive binding of PPAR/RXR to and subsequent displacement of HNF-4 from 
the PRI site. They also proposed that as HNF-4 expression is regulated by HNF-4 itself, 
HD/PP-induced transcription suppression may also involve PPAR/RXR displacing 
HNF-4 from the enhancer in the HNF-4 gene. This hypothesis was supported by the 
observation that liver nuclear extracts from treated animals showed significant 
reductions in HNF-4 levels. 
Unlike the well characterised promoter regions of the human transferrin gene which are 
believed to be specific for cell-type expression, the distal and central regions remain to 
be fully characterised. The distal region is believed to contain positive and negative cis- 
acting elements which regulate the promoter activity. DRI, DRII and CR are believed to 
be positive-acting transcription factors, whilst A and B (Fig. 1.8. ) are negative-acting 
elements (Schaeffer et al., 1989). The transferrin enhancer located between -4.0 and - 
3.3Kbp has been shown to be composed of 5 enhansons organised into two distinct 
structural and functional domains, A and B (Fig. 1.9. ) (Boissier et al., 1991). 
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Figure 1.9. Organisation of the human transferrin gene enhancer. 
-3600 bp -3300 bp 
Ia Ib II III IV 
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la = Domain A; Ib, II, III and IV = Domain B; Factors interacting with individual enhansons are shown 
under each box.; The numbers above the enhansons indicate the position of the enhancer relative to the 
" cap site of human transferrin (Adapted from Auge-Gouillou et at., 1993). 
Domain A, believed to mediate enhancer activity, has an octanucleotide sequence 
TGTTTGCT, which was found to bind two liver-specific nuclear factors called 
enhancer-binding protein (EBP)-45 and EBP-40 (Petropoulos et at., 1991). Domain B 
was found to be capable of binding several liver nuclear proteins, although binding of 
one protein required the presence of all the others. Unlike Domain A, it had no enhancer 
activity but was capable of blocking the activity of a distal negative region located 
downstream between -1000 and -620bp, which in turn is believed to modulate enhancer 
activity (Schaeffer et al., 1989). Full enhancer activity is therefore thought to require the 
synergistic action of the two enhancer domains, A and B (Petropoulos et al., 1991). It 
was recently reported by Auge-Gouillou et al., (1993) that the liver nuclear factor EBP- 
40 which binds to enhanson la of Domain A is actually HNF-3a, and that the proteins 
interacting with enhansons lb and IV of Domain B are part of the nuclear-factor (NF)1 
family. The proteins binding to enhansons II and III were thought to be AP-4 and an 
unidentified protein EIII, respectively (Fig. 1.9. ). Whilst NFI and HNF-3a were found to 
bind independently to enhancers lb and Ia respectively, EIII binding to enhanson III 
appeared to depend on the binding of AP-4 with enhanson II. It was therefore proposed 
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that the binding of NFI to enhanson IV may occur through the formation of a multimeric 
complex between AP-4, EM and NFI (Auge-Gouillou et al., 1993). 
1.7. SECONDARY AND TERTIARY STRUCTURES OF HUMAN PLASMA 
TRANSFERRIN 
The high level of sequence homology between plasma transferrin, lactoferrin and 
ovotransferrin (Williams, 1982; Baldwin, 1993) means they show similar three- 
dimensional structures. Current knowledge of the secondary and tertiary structure of 
human plasma transferrin has subsequently been derived from a number of 
crystallographic studies. These include studies on whole human lactoferrin (Anderson et 
al., 1987; Anderson et al., 1989; Baker et al., 1996), rabbit serum transferrin (Bailey et 
al., 1988) and hen ovotransferrin (Kurokawa et al., 1995). In addition, various 
transferrin fragments including the N-terminal half-molecules of hen ovotransferrin 
(Dewan et al., 1993), human lactoferrin (Day et al., 1993; Faber et al., 1996) and rabbit 
serum transferrin (Sarra et al., 1990), as well as a quarter-molecule fragment of duck 
ovotransferrin (Lindley et al., 1993) have also been crystallised. 
1.7.1. FOLDING STRUCTURE OF TRANSFERKIN 
Plasma transferrin, lactoferrin and ovotransferrin are folded into homologous lobes, N 
and C, each comprising two dissimilar domains, I and II, with the iron-binding site 
located deep within the inter-domain clefts (Fig. 1.10. ) 
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Figure 1.10. Domain organisation of transferrin. 
The above symbols denote the following: "= iron-binding site; solid line connecting peptide = lactoferrin; 
dash line connecting peptide = plasma transferrin. 
The relative orientation of the two lobes also vary among transferrins, requiring for 
example a rotation of 167° and a translation of 23A before the two rabbit serum 
transferrin lobes can be superimposed (Bailey et al., 1988). The differences in lobe 
orientation between human lactoferrin and rabbit serum transferrin (15°) and hen 
ovotransferrin (15.7°), is greater than the differences between rabbit serum transferrin 
and ovotransferrin (6.8°) (Kurokawa et al., 1995). The differences are believed to arise 
through disruption of helix formation by the presence of two Pro residues in the 
bridging peptides, and two additional disulphide bridges at either end of the bridging 
peptides of serum transferrin and ovotransferrin. The crystal structures for the three 
transferrins have revealed that the two lobes have similar supersecondary structures 
based on a central ß-sheet of five or six strands (Fig. 1.11. ) with helices packed on 
either side (Bailey et al., 1988; Anderson et al., 1989; Kurokawa et al., 1995). 
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Figure 1.11. Schematic representation of the folding pattern for the two lobes of human 
lactoferrin. 
In the above figure, the N-lobe is on the left and the C-lobe on the right. Helices are shown as cylinders, 
and ß-sheets as arrows (From Anderson et al., 1989). 
The overall level of secondary structure is about 24% right-handed ß-sheet and about 
4% a-helix. Apart from an additional antiparallel strand in the domain I ß-sheet (strand 
j), the topology of ß-sheet in each lobe is the same with strands directed towards the 
interdomain binding cleft (Fig. 1.11. ). Likewise the a-helices in both lobes run 
antiparallel to the ß-sheets so that their positively charged N-termini are directed 
towards the binding cleft. The residues comprising domain I of each lobe have been 
found to correspond to different regions of the polypeptide chain. The first ninety or so 
residues comprising three parallel ß-strands (a-c) and three helices (1-3) form part of 
domain LA fourth parallel ß-strand composed of two strands (d & e) then runs behind 
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the iron-binding site to begin the folding of domain II, which is made up of about 160 
residues with five ß-strands (g-i) and six helices (4-8a). An extended ß-strand composed 
of two strands (i and j; the backbone strands) then crosses back behind the iron site to 
complete the folding of domain I. Finally the chain runs back across the domain 
interface to finish with helix 11 packed against domain II (Anderson et al., 1989; Baker, 
1994). 
1.7.2. TRANSFERKIN BINDING SITES 
The iron-binding sites of plasma transferrin are located at equivalent positions at the 
interface between the two domains of each lobe. They are about 42A apart with the iron 
atoms deeply buried at about 10A below the protein surface (Anderson et al., 1987; 
Baker et al., 1987; Anderson et al., 1989). 
1.7.2.1. STRUCTURE OF IRON BINDING SITES 
The immediate co-ordination sphere for both iron atoms are the same with the 
surrounding protein providing four ligands as shown in Figure 1.12. (Baker et al., 1987; 
Jhoti et al., 1988; Legrand et al., 1988; Anderson et al., 1989; Sarra et al., 1990; Lindley 
et al., 1993; Baker, 1994). The equivalent transferrin protein ligands are the carboxylate 
oxygen of Asp63 (C-lobe, 392), the phenolate oxygen's of Tyr95 (426) and Tyr188 
(517) and the imidazole nitrogen of His249 (585). The four protein ligands of 30' and 
1N therefore provide an overall 3' charge to balance the 3+ charge of the iron atom in 
each lobe. A noticeable feature of the iron-binding sites is that the four ligating residues 
are widely spaced along the polypeptide chain and belong to distinct parts of the protein 
structure. 
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Figure 1.12. The iron and anion binding sites in human lact6ferrin. 
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The above numbering is for the N-lobe, but the same arrangement is, found for the C-lobe. The residue 
numbers for human lactoferrin (U) and transferrin (Tf) are shown in the inset (From Baker, 1994). 
Asp63 (392) are provided by domain I, Tyr188 (517) by domain II, and the remaining 
two residues Tyr95 (426) and His249 (585) by the two backbone ß-strands that cross at 
the back of the iron sites between the two domains (Fig. 1.12. ). The four protein ligands 
are octahedrally arranged around the iron atom with Asp63 (392) and Tyr95 (426) 
situated trans to each other, whilst the two remaining ligands occupy cis positions. The 
synergistic carbonate anion required for the binding of iron provides ligands for the 
remaining two cis-octahedral positions surrounding the iron atom. Two oxygens of the 
carbonate anion are bound to iron, and form two hydrogen bonds with the NH of a 
conserved Argl2l (lactoferrin) and A1a123. The third oxygen also forms hydrogen 
bonds with G1y124 and Thr117 (Anderson et al., 1989). The anion is thought to 
neutralise the positive charge (-1.6+) at the anion-binding site, and to complete the iron 
coordination by providing the two remaining ligands. The carbonate ion is believed to 
bind first in a series of events that culminate in the formation of an iron-transferrin- 
anion tenary complex (Anderson et al., 1990a). Opening of the N-lobe binding cleft was 
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thought to follow rotation of the NH domain by 53 ' as a result of pivoting of helices 11 
and 5, and flexing of the two backbone ß-strands (Fig. 1.11. ). The open binding cleft 
then exposes the basic sidechains of Argl2l, Arg210 and Lys301 (N-lobe), which 
attract the carbonate anion so that it binds to the NH domain at the N-terminal of helix 5 
(Fig. 1.13. ). The presence of four of the six iron ligands then facilitates binding of the 
iron atom. Rotation of the NH domain then allows the two remaining protein ligands 
(Asp60 and His253) to be in position to bind the iron, resulting in closure of the domain. 
Recent studies by Nadeau et al., (1996) using a synergistic anion equivalent, 
bromopyruvate, that acts as an affinity label for ovotransferrin by preferentially 
modifying lysine residues, found that His196, Cys197, Lys199 and Lys202 were 
modified by the anion in a proteolytic N-terminal half-molecule of ovotransferrin. As 
these residues are located on or at the termini of helix 8 which ends at the anion binding 
site (Fig. 1.12. ), it was suggested that the carbonate anion would be attracted by these 
residues and channelled along helix 8 to its binding site. 
68 
Figure 1.13. Conformational changes of the human lactoferrin N-lobe during iron- 
binding. 
(a) (b) 
The above letters denote the following conformations: (a) open, and (b) closed. Helices are shown as 
cylinders, and p-strands as hatched regions. The arrow denotes the approximate hinge position of the two 
backbone ß-strands (From Anderson et al., 1990a). 
1.7.2.2. SITE-DIRECTED MUTAGENESIS STUDIES: IMPORTANCE OF 
4. IRON-BINDING LIGANDS 
Funk et al., (1990) reported the first successful expression of recombinant human serum 
transferrin using baby hamster kidney cells. A 2.3kb cDNA encoding human transferrin 
was cloned into a M13mp18 plasmid before the introduction of two translational stop 
codons and a Hind III site by in vitro site-directed mutagenesis. The isolated DNA 
construct coding for the N-terminal half-transferrin (hTf/2N) was then cloned into the 
eukaryotic expression vector pNUT, and expressed in baby hamster kidney cells. The 
recombinant hTf/2N was then purified from the medium by successive chromatography 
steps. Since then several transferrins including human lactoferrin (Stowell et al., 1991), 
glycosylated and unglycosylated human transferrin (Mason et al., 1993), and 
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glycosylated and unglycosylated full-length or half-molecule human lactoferrin (van 
Berkel et al., 1995; van Berkel et al., 1996) have been expressed in mammalian systems. 
Other workers such as Hershberger et al., (1991), Ikeda et al., (1992), and Steinlein & 
Ikeda, (1993) have also successfully expressed human serum transferrin in Escherichia 
coli (E. coli). More recently, a N-terminal half-transferrin has been expressed in the 
methylotrophic yeast, Pichia pastoris (Steinlein et al., 1995) whilst the full-length 
transferrin has been expressed in a baculovirus system of High five insect cells (Ali et 
al., 1996). Although expression in E. coli is more favourable than in mammalian systems 
as large-scale cultures can be rapidly and inexpensively produced, the expressed 
transferrins are biologically inactive due largely to incorrect intramolecular disulphide 
bridge formation. Expression in yeasts, which can form intramolecular disulphides, and 
in insect host cells which possess many of the protein-processing and protein-folding 
mechanisms of mammalian systems, therefore provide simple and cost-effective 
methods of obtaining functional transferrin. In both examples given above, the 
recombinant half-molecule and full-length transferrins were found to be capable of 
binding iron in the presence of bicarbonate (Steinlein et al., 1995; Ali et al., 1996), 
whilst the latter was actively taken up by receptor-mediated endocytosis. 
Such expression systems have allowed the study of various ligands that are present at 
the iron-binding sites. Woodworth et al., (1991) found that reducing the positive charge 
at the iron-binding site through mutations of Lys206 to Gln, and His207 to Glu, resulted 
in a higher affinity for iron. Conversely, decreasing the negative charge by changing the 
conserved iron ligand, Asp63 to Ser, was found to reduce the affinity of the recombinant 
for iron. Zak et al., (1995) reported that replacing His207 in human transferrin with a 
more hydrophilic and negatively charged Glu, impeded iron release at pH 7.4, by 
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stabilising the closed conformation of the two domains. This was attributed to possible 
hydrogen-bonding between G1u207 and G1n92, a situation found in lactoferrin where 
salt bridging between G1u211 and Arg89 (equivalent to G1n92 in transferrin) stabilise 
the closed conformation which partly accounts for the slower release of iron from 
lactoferrin compared to transferrin. Conversely, mutation of the conserved Arg124 that 
is hydrogen-bonded to one of the carbonate oxygen's (Fig. 1.12. ) to either Ser or Lys, 
was found to increase iron release at pH 7.4. The latter was thought to be due to steric 
effects with respect to the smaller sidechain of Lys, and to the fact that the Ser sidechain 
is uncharged (Zak et al., 1995). Faber et al., (1996) also found that mutation of Arg12l. 
(Arg124 in human transferrin) to Ser or Glu in recombinant N-terminal half-molecules 
of human lactoferrin, resulted in decreased acid stability and more facile iron release. 
The carbonate anion in each mutant was found to be displaced 0.5A from its position in 
the wild-type protein, resulting in the anion becoming partially detached from the N- 
terminus of helix 5 in the anion binding site (Fig. 1.2. ). Like Zak et al., (1995) the 
disruption of the anion binding site in both mutants were attributed to the loss of 
favourable interactions (i. e. charge and hydrogen bonds) between the carbonate anion 
and the sidechains of Ser and Glu. In addition, it was thought that the more accessible 
carbonate could be easily protonated at low pH resulting in decreased electrostatic 
attraction to the bound iron (Zak et al., 1995; Faber et al., 1996). The importance of 
sidechains in the anion binding, site was also shown by Baker et al., (1996) in oxalate- 
substituted lactoferrin. The oxalate anion, which can act as a synergistic anion for 
transferrins, was found to bind to both lobes of lactoferrin in a bidentate manner similar 
to the smaller carbonate anion. However, binding of the larger oxalate anion forced the 
respective Arg sidechains in the two lobes to move in a different manner. Displacement 
of Arg121 in the N-lobe was found to be more restricted than for Arg465 in the C-lobe. 
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The differences were attributed to the fact that Arg465 could form hydrogen bonds with 
Tyr398 and Tyr526, both of which are beyond the immediate anion coordination sphere, 
whereas Argl2l was restrained by a hydrogen bond to Serl9l outside the coordination 
sphere. The authors subsequently proposed that anion binding was not only dependent 
on residues within its immediate anion binding pocket, but was also dependent on 
second shell residues beyond the latter. 
Recombinant studies also allowed the involvement of Asp63 to be studied in greater 
detail. Lin et al., (1993a) found that replacement of Asp63 with either Ser or Cys, 
reduced the iron-binding affinity of a N-terminal half-transferrin by about 5-6 orders of 
magnitude. Studies by Grossman et al., (1993) and Lindley et al., (1993) both implicated 
Asp63 in the conformational changes associated with the two lobes. Grossman et al., 
(1993) found that mutation of Asp63 to Ser or Cys in a N-terminal half-molecule of 
human transferrin resulted in incomplete closure of the iron-binding cleft. As Asp63 
(domain I) forms an interdomain hydrogen bond with Ser125 (domain II) in intact 
diferric duck ovotransferrin (Lindley et al., 1993) it was proposed that the respective 
Asp residues in both lobes were responsible for domain closure. Conversely, opening of 
the binding cleft is believed to involve the sidechains of two Lys residues. The crystal 
structure of human apolactoferrin showed that unlike the C-lobe, the binding cleft of the 
N-lobe was wide open (Anderson et al., 1990). However, solution low-angle scattering 
studies by Grossman et al., (1993) have shown that both lobes are open in solution. The 
crystal structure of the monoferric N-lobe of hen ovotransferrin showed that the 
sidechains of Lys209 (domain II) and Lys301 (domain I) were in contact with each other 
across the interdomain cleft, and were located between the central iron atom and the two 
backbone strands (Dewan et al., 1993). The close proximity of the two (2.3A) suggested 
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that either one or both Lys had a pKa value below the experimental pH (5.9) and were 
therefore not positively charged. However, it was proposed that at more acidic pH, such 
as in the acidified endosome, protonation of the residues would lead to opening of the 
binding cleft as a result of electrostatic repulsion forcing apart the two domains. The 
common arrangement of the Lys-Lys arrangements in the N-lobe of most other 
transferrins appear to support the mechanism. A triple arrangement of Lys534-Asp634- 
Arg632 in the C-lobe of human transferrin (Zuccola, 1993) and rabbit serum transferrin 
(Bailey et al., 1988) is thought to represent a second type of pH-sensitive triggering 
mechanism for domain opening in the C-lobe. The conserved Asp634 in domain II 
forms two hydrogen bonds that bridge the Lys534 (domain I) and Arg632 (domain II) 
residues. It was therefore suggested by Dewan et al., (1993) that neutralisation of 
Asp634 at pH values near its pKa (-4.5) would break or weaken the two hydrogen 
bonds, such that the opposing positive charges of Lys534 and Arg632 would result in 
opening of the C-lobe domains. A second possible cause of domain opening could 
simply be the loss of one of the interdomain interactions as a result of the neutralisation 
of Asp634. As Lys209 in human lactoferrin is changed to a Arg, lactoferrin does not 
have the pH-sensitive dilysine trigger mechanism present in its N-lobe. This was 
confirmed by Zak et al., (1995) who found that iron released from a recombinant N- 
terminal half-transferrin with Arg206 (equivalent to Arg209 in lactoferrin) occurred 
nearly an order of magnitude slower than from a normal recombinant N-terminal half- 
transferrin. It was therefore suggested by'Dewan et al., (1993) that at pH values below 
the pK, of G1u216 which forms an interdomain salt bridge with the second lysine, 
Lys301, the salt bridge would break, releasing Lys301 to interact with the positively 
charged Arg210, thereby opening the binding cleft. An alternative proposal was that 
protonating G1u216 would break the interdomain salt bridge thereby facilitating domain 
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opening. As with the three other iron ligands, mutagenesis of the neutral His at the iron- 
binding site decreases the stability of iron binding as a result of electronic and steric 
factors. N-terminal half-molecule recombinants of human lactoferrin in which His253 
(His249 in human transferrin) was changed to several potential iron ligand residues, all 
showed decreased iron stability at acidic pH and reduced , max in the range 420-436nm 
(wild-type 450nm) (Nicholson et al., 1996). Although the crystal structure of one of the 
recombinants, Met253, showed that the overall protein conformation was similar to the 
wild-type N-terminal lactoferrin, the Met sidechain was not coordinated to the iron, 
leaving the latter in a less stable five-coordinate geometry. 
1.8. IRON UPTAKE AND IRON RELEASE MECHANISMS OF 
TRANSFERRIN: DIFFERENCES BETWEEN IRON-BINDING SITES 
The binding of Fe 3+ in the presence of C03 2' by apotransferrin involves the loss of three 
protons per bound iron, with the iron-transferrin complex showing a salmon-pink colour 
with , max between 460-470nm 
(van Snick et al., 1973; Aisen & Listowsky, 1980). The 
absorbance at 460-470nm is due to a ligand charge-transfer phenolate (n) -* metal (di*) 
transition involving a Tyr residue at the iron-binding site (Harris & Aisen, 1989; Baker, 
1994). Iron binding can also be followed in the UV region at 245nm and 290nm because 
of perturbations of the n-rt* transitions of the aromatic ring of the ionised Tyr. The 
increase in , max at 460-470nm 
is however generally used to monitor iron binding, and 
provides a means of determining the amount of iron bound in titration studies. There are 
a number of small but significant differences between the two iron-binding sites, despite 
their similar locations and iron ligand arrangements. The iron binding and release 
properties of both sites for example are known to differ in response to pH (Princiotto & 
Zapolski, 1975; Harris, 1977; Aisen et al., 1978; Aisen & Listowsky, 1980; Baldwin et 
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al., 1982). The C-lobe binding site (also known as Fei-transferrin, Site A, Transferrin- 
Fe, Acid stable) exhibits a tendency to bind iron first at both acidic and neutral pH, and 
also retains iron at a lower pH than the N-lobe binding site (Fe,,, -transferrin, Site B, Fe- 
transferrin, acid-labile). In addition, the N-lobe site unlike the C-lobe site, does not bind 
iron below pH 5.7. The greater binding affinity of the C-lobe is reflected in a 20-fold 
difference in the apparent binding constants at pH 7.4 (Aisen et al., 1978). The 
respective binding constants are logKi = 20.6 and logK2 = 19.4. It is though that the 
differences in iron binding and release are due to the different mechanisms of domain 
opening in the two lobes (Dewan et al., 1993). As the Lys-Lys trigger of the N-lobe 
would operate around the pKa of Lys (-6.0), the N-lobe binding cleft would open at a 
higher pH (hence release iron) than the Lys-Asp-Arg trigger of the C-lobe which would 
operate around the lower pKa of Asp ('-4.5). The tighter binding and slower release of 
iron from the C-lobe may also be associated with reduced flexibility of the C-lobe, as 
the latter has an additional disulphide bridge (number 7) which crosses the iron-binding 
cleft and anchors both C-lobe domains (Bailey et al., 1988; Baker et al., 1994). There is 
no equivalent bridge in the N-lobe. 
In vitro and in vivo studies of iron binding usually use ferric chelates as iron donors to 
prevent hydrolysis and polymerisation of Fe 3+ at alkaline pH (Aisen & Listowsky, 
1980). Ferric nitrilotriacetate (FENTA) is often used because of the speed with which it 
delivers iron to transferrin. The two iron-binding sites however show different responses 
to FENTA and other chelates such as ferric citrate and ferrous ammonium sulphate 
(Fe(NH4)2SO4)" For example, the latter two give preferential iron loading at the N-lobe 
site between pH 7.4-8.5, whilst FENTA preferentially loads the C-lobe site at pH 6-8.5 
(Evans & Williams, 1978; Harris & Aisen, 1989). The proposed mechanism for iron 
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uptake and release by transferrin is shown in Figure 1.14. (Bates & Wernicke, 1971; 
Cowart et al., 1982,1986). In the proposed model, transferrin may bind iron by 
extracting the metal from the chelating ligand (FeL) either via a mixed protein-iron- 
ligand complex (FeLT) (pathways a& b), or by a direct pathway ©. It is generally 
believed that pathways (a) and (b) are followed with the C032- binding to apotransferrin 
before the formation of a transferrin-anion-metal-chelate complex. Loss of the chelate 
ligand, and conformational 
Figure 1.14. Proposed mechanism of iron uptake and release by transferrin. 
FeLT 
(a) (b) 
FeL +T FeT +L 
The above symbols denote the following: T= transferrin; L= chelating ligand; Fe = iron 
changes of the protein (sec. 1.7.2.1. ) then facilitate binding of the iron (Aisen & 
Listowsky, 1980; Cowart et al., 1982,1986; Anderson et al., 1990a; Nadeau et al., 
1996). Calorimetric binding studies by Lin et al., (1993) showed that the C-site, unlike 
the N-site, was capable of weakly binding bicarbonate in the absence of iron. It was 
therefore proposed that prebinding of bicarbonate to most C-sites of apotransferrin 
allows fast binding of added iron, whilst iron-binding to N-sites involve a fast process 
where the iron-chelate complex is weakly bound, followed by a slow process involving 
the insertion of bicarbonate and removal of chelate ligand. It has however been recently 
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suggested by Pakdaman & el Hage Chahine (1996) that iron uptake does not involve the 
formation of an intermediate FeL complex, but rather proceeds via pathway C. They 
proposed that iron uptake involves rapid extraction of iron by apotransferrin to form the 
C-site monoferric transferrin, which then deprotonates and undergoes a fast 
conformational change. The iron-loaded C-site then facilitates iron-uptake at the N-site 
through proton losses (- 2 or 3) and other slow conformational changes. 
Most kinetic studies of iron release involve the use of chelating agents such as 
pyrophosphate, EDTA and NTA, which sequester the iron released from transferrin 
under decreasing pH conditions. Iron release from transferrin occurs over a pH range of 
6.0-4.0, with loss occurring first from the acid-labile N-site (Princiotto & Zapolski, 
1975; Aisen & Listowsky, 1980; Baldwin et al., 1982). Iron loss from transferrin to iron 
chelators is believed to proceed via two pathways, one showing saturation kinetics and 
the other a dependence on the iron chelator. Harris et al., (1987) reported that iron 
release from the C-site to pyrophosphate involved rapid attack by the chelator to form a 
chelator-iron-transferrin-C03 2 complex (pathway (b), Fig. 1.14. ), followed by 
dissociation of the chelator-bound iron (pathway (a), Fig. 1.14. ). Unlike the saturation 
pathway described above, the second pathway showed a first-order dependence on the 
chelator concentration. In addition it also appeared to depend on the nature of -the 
chelator as nitrilotris for example favoured the saturation pathway at both sites whereas 
pyrophosphate favoured the first-order pathway at the C-site but not at the N-site. 
Subsequent studies proposed that the first-order pathway was modulated by binding of 
non-synergistic anions (e. g. perchlorate (C104) and chloride (Cl) ions) to a kinetically 
significant anion-binding (KISAB) site that was distinct from the synergistic anion- 
binding site (Harris & Bali, 1988; Egan et al., 1992,1993; Marques et al., 1995). The 
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mechanism explains the first-order dependence of the pathway, as anion occupancy of 
the KISAB site is thought to increase with increasing ionic strength, and also explains 
why Cl" ions in particular have been found to increase iron release from the C-site 
(Baldwin, 1980; Williams, 1982). In contrast to the latter studies, Zak et al., (1995) 
reported that Cl" ions inhibited iron release from recombinant N-lobe and proteolytic N- 
lobe transferrin fragments, and from the N-lobe binding site of transferrin. It was 
therefore suggested that iron binding and release were modulated by at least three 
classes of anion-binding sites. Binding of C032" to the synergistic anion-binding site 
promoted iron binding, whilst binding of non-synergistic anions to the KISAB site in the 
C-lobe and to a third site in the N-lobe modulated iron loss from the two sites. Earlier 
studies suggested that iron loss from the N-site was by the saturation pathway (Harris et 
al., 1987). el Hage Chahine & Pakdaman (1995) have more recently suggested an 
alternative mechanism where iron loss from the N-site in mildly acidic (>pH 4.5) and 
acidic (<pH 3.5) conditions is controlled by slow protonation of one of the amino acids 
at the iron-binding site. Structural modifications of the iron-binding site then leads to 
decarbonation and iron loss. The authors also reported that iron release from the C-site 
was slower than from the N-site, and proceeded via two pathways. The first pathway, 
the saturation pathway, occurred above pH 4 and was dependent on the nature of the 
chelator, whilst the second pathway involving acid-promoted decarbonation operated 
below pH 4. 
Iron release from transferrin is also known to be modulated by binding to the transferrin 
receptor. Bali & Aisen (1991) found that receptor-complexed N- and C-lobe monoferric 
transferrins had slower rates of iron release at pH 7.4 compared to the free monoferric 
forms. In contrast, iron release from the C-lobe monoferric-receptor complex at pH 5.6 
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was significantly higher (-70%) than from the free form, unlike iron loss from 
complexed and free N-lobe monoferric transferrins which were essentially the same. 
Turkewitz et al., (1988) previously reported that the 70kDa fragment of the extracellular 
transferrin-binding domain of the transferrin receptor, showed a conformational 
transition below pH 6. This conformational change was suggested to induce a secondary 
conformational change in the C-lobe of receptor-bound transferrin, leading to domain 
opening and subsequent iron loss (Bali & Aisen, 1991). The latter is supported by Egan 
et al., (1993) who found that iron release from free (i. e. due to anion-occupied KISAB 
site) and receptor-complexed C-lobe monoferric transferrin at pH 5.6 or 7.4, were 
independent of each other suggesting that the two binding sites were distinct from each 
other. Zak et al., (1994) have shown that the primary receptor recognition site of 
transferrin is in the C-lobe, as studies of iron donation to hepatoma-derived HuH-7 cells, 
or binding to transferrin receptors on HuH-7 or leukemic K562 cells was only possible 
with proteolytic iron-containing C-lobe fragments. Their results were similar to the 
findings of Williams & Moreton (1988) and Oratore et al., (1989) who suggested that 
binding of ovotransferrin to the transferrin receptor was independent of an association of 
the two lobes. Conversely, Brown-Mason & Woodworth (1984), and Mason et al., 
(1987,1996) reported that both lobes of ovotransferrin had to be present and associated 
before ovotransferrin was bound by the chick reticulocyte receptor. The disparity in 
results is thought to depend on the nature of the half-terminal fragments used. Mason et 
al., (1996) suggested that the recombinant fragments used in their study had greater 
thermal stability and were more homogeneous than the proteolytic fragments used in the 
other studies. The observations by Bali & Aisen (1991) that opening of the C-lobe 
binding cleft at endosomal pH was modulated by the transferrin receptor, has been 
questioned by Castellano et al., (1994). Solution X-ray scattering studies of 
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apotransferrin, monoferric and holotransferrin, and mono- and di-aluminium transferrin 
at pH 5.5 or 7.4, showed that conformational differences on metal binding or release, 
were smaller than differences caused by pH. It was therefore proposed that the open and 
closed conformations were independent of the transferrin receptor, but rather depended 
on the pH of the micro-environment. 
1.9. METAL-BINDING PROPERTIES OF PLASMA TRANSFERRIN 
As transferrin is only about 30% iron-saturated in plasma (Liebman & Aisen, 1979), 
there is a potential capacity for the protein to bind other metal ions that enter the body. 
A number of studies have shown that it is capable of binding most of the first transition 
series metals including chromium, manganese, zinc, nickel and copper (Cu2) (Aisen et 
al., 1969; Harris, 1977,1983,1986; Harris & Aisen, 1989). Other metals known to bind 
to transferrin include aluminium (A13) and gallium (Ga3) (Tomimatsu & Donovan, 
1976; Harris & Pecoraro, 1983), lanthanides like gadolinium (Gd3 4) and scandium 
(Sc3+) (Zak & Aisen, 1988; Li et al., 1996) and actinides such as thorium (Th4+) and 
plutonium (Pu4) (Harris et al., 1981; Taylor et al., 1987). Although most of the metals 
appear to have no physiological significance, their spectroscopic properties have been 
useful in studying transferrin structure and function. A few reports have suggested that 
plasma transferrin is the carrier protein for manganese (Davidsson et al., 1989), and that 
it is capable of effectively competing with plasma albumin for zinc (Harris, 1983) and 
aluminium (Fatemi et al., 1991; van Rensburg et al., 1995). Out of all the metals known 
to bind to transferrin, A13+, Ga3+ and in particular Cu2+ have been studied the most. Cu2+ 
binding gives a yellow coloured complex with a characteristic Tyr phenolate --* metal 
charge transfer band at 430nm. Solution X-ray analysis suggested that binding of Cu2+ 
to the two lobes of ovotransferrin resulted in a slight conformational change with either 
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one Tyr or the His at the iron-binding sites being displaced from the metal coordination 
sphere (Garratt et al., 1991). Smith et al., (1992) confirmed that Cu2+ binding was 
associated with a small movement of about 1. OA in the N-lobe and about 0.4A in the C- 
lobe, leaving the N-site Cu2+ in a five-coordinate, square planar geometry, and the C-site 
Cu2+ in a distorted six-coordinate octahedral arrangement. The binding constant of Cu2+ 
to the N-site was found to be 15 times less than that of the C-site (log K2 = 11.1 and log 
K1 = 12.3 respectively), indicating that as with Fei+, Cu2+ bound to the C-site first 
(Hirose et al., 1996). Cu2+ binding and release like Fei+, was also affected by anions 
with the binding constants showing a 10-fold decrease in the presence of potassium 
chloride (KC1) and sodium perchlorate (NaC1O4). Electron paramagnetic resonance 
(EPR) ' spectra of Cu2+ at the N-site in dicupric transferrin showed a dramatic change in 
the presence of anions, suggesting that the anions induced a conformational change in 
the coordination geometry of Cu2+ at the N-site. Like Cu24, A13+ and Ga3+ bind to both 
sites of human transferrin. Both give colourless complexes with , max around 240nm 
and 290nm due to perturbations of ionised Tyr and in particular ionised Trp at the 
metal-binding site (Tomimatsu & Donovan, 1976; Harris & Pecoraro, 1983; Tang et al., 
1995). Of the two metal ions, Ga 3+ is most similar in size to Fe 3+ (ionic radius 0.62A 
and 0.65A respectively), and is bound more strongly than A13+ (ionic radius 0.54A). The 
respective binding constants are log K1 = 18.1 and log K2 = 17.1 for Ga3+ (Harris & 
Pecoraro, 1983) and log K1 = 13.5 and log K2= 12.5 for A13+ (Harris & Sheldon, 1990). 
Ga3+ binding is also similar to Fe 3+ in that in the presence of a synergistic anion like 
oxalate, Ga3+ preferentially loads the C-site before binding to the N-site (Kubal et al., 
1993). Nuclear magnetic resonance (NMR) spectroscopy of binding to transferrin and a 
recombinant N-lobe transferrin fragment showed that Ga 3+ binding to the C-lobe lead to 
a change in the local structure associated with the N-acetylated sugar residues of the 
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glycan chains at either Asn413 or Asn611 in the C-lobe. This suggested that Ga3+ 
(metal) binding was communicated to the surface of the C-lobe, an event that could be 
important for receptor recognition and receptor-mediated metal release (Bali & Aisen, 
1991; Zak et al., 1994). Unlike Fe 3+ and Ga3+, A13+ in the presence of bicarbonate was 
found to enter the N-lobe first (Kubal et al., 1992). The binding constants reported 
above therefore correlate to the N- and C-site respectively. NMR spectroscopy showed 
that binding of A13+ was associated with a small conformational change in the N-lobe, 
possibly involving movement of two residues, Leu122 and I1e132, towards Trp128 
which is closely associated with the metal-binding site. Circular dichroism, UV-visible 
and fluorescence spectroscopy studies by Tang et al., (1995) found that although both 
lobes bound A13+, the latter could not displace Fei+. Furthermore, although the backbone 
structure of transferrin was not significantly altered on A13+ binding, there was a small 
decrease in the a-helix content. As with the study by Kubal et al., (1992), the 
conformational changes were thought to involve Trp residues (Trp460 in the C-lobe, 
and Trpl28 in the N-lobe) near the binding sites. Li et al., (1996) have recently 
suggested that the strength of metal binding to human serum transferrin is related to 
metal ion acidity rather than to metal size as previously believed. A comparison of log 
Ki for several metals such as Cue+, Sc3+, A13+ and Fe 3+ against their stability constants 
for hydroxide binding (Fig. 1.15. ), showed that the most readily hydrolysed (acidic) 
metal ions (e. g. Fe 3) were bound most strongly to transferrin. 
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Figure 1.15. Correlation of the strength of transferrin and hydroxide binding to metal 
ions. 
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1.10. HETEROGENEITY OF HUMAN PLASMA TRANSFERRIN IN 
POLYACRYLAMIDE GELS 
Electrophoretic heterogeneity of human plasma transferrin in polyacrylamide gels can be 
attributed to three main causes, namely: (i) differences in carbohydrate moiety as 
described earlier (sec. 1.6.1. ); (ii) differences in iron content; and (iii) variations in 
amino acid sequence. The following is a description of microheterogeneity as a result of 
0. 
the latter two factors. 
1.10.1. UREA POLYACRYLAMIDE GELS 
The electrophoretic behaviour of plasma transferrin in polyacrylamide gels is partly 
dependent on the iron content. The protein is about 30% saturated under physiological 
conditions (Liebman & Aisen, 1979) and has been shown to exist as four transferrin 
species with respect to iron content. These four species were initially determined by 
Makey & Seal, (1976) using 6M urea-PAGE on the basis that the net negative charge of 
the protein was increased by the loss of three protons per bound iron, and that binding of 
iron to transferrin protected the protein against denaturation by urea. The four detected 
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species were found to be: (i) apotransferrin, which was extensively denatured and so had 
the lowest anodal mobility; (ii) C-lobe monoferric transferrin; (iii) N-lobe monoferric 
transferrin; and (iv) holotransferrin, which had the greatest protection and highest net 
negative charge, and so had the highest anodal mobility. The difference in mobility of 
the two monoferric transferrins were attributed to the relative ease with which the iron- 
free (unprotected) lobe denatured in urea (Evans & Williams, 1980). As the C-lobe has 
three more disulphide bridges than the N-lobe (Bailey et al., 1988; Baldwin, 1993), the 
unprotected C-lobe (i. e. N-lobe monoferric transferrin) is more resistant to urea 
denaturation than the unprotected N-lobe (C-lobe monoferric transferrin). The 
distribution of iron in circulating transferrin appears to favour the N-site, although the 
C-site has a higher affinity for iron (log K2 = 19.4 and log Kl = 20.6 respectively) 
(Aisen et al., 1978). Williams & Moreton (1980) found that the average distribution of 
iron in 22 fresh plasma samples was 39% apotransferrin, 11% C-lobe monoferric, 23% 
N-lobe monoferric and 27% holotransferrin. The distribution was however found to be 
affected by storage with a significant increase in the N-site fraction after 4 days at 37 ' C, 
and a shift to the C-site after 6 days at -15 ' C. Recent studies have suggested that the 
distribution is related to the receptor recognition properties of the C-site (Bali & Aisen, 
1991; Egan et al., 1993; Pakdaman & el Hage Chahine, 1996). As the receptor-binding 
region is believed to in the C-lobe (Zak et al., 1994), it is suggested that binding of iron 
to the C-site facilitates transferrin-binding and subsequent cellular uptake by receptor- 
mediated endocytosis, leaving a preponderance of N-lobe monoferric transferrin in the 
circulation. This is supported by the fact that circulating apotransferrin and N-lobe 
monoferric transferrin have a lower affinity for the transferrin receptor (Ka = 4.6 x 106 
f1 and 2.8 x 107 W1 respectively) than holotransferrin (Ka = 1.1 x 108 M'1) (Young et 
al., 1984b). 
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1.10.2. NONDENATURING POLYACRYLAMIDE GELS 
Electrophoretic heterogeneity of plasma transferrin as a result of variations in the amino 
acid sequence was first revealed by Smithies (1957) who discovered two distinct 
transferrin bands in two American Negroid females. Since then at least 36 variant 
" transferrin alleles have been detected in most human populations by PAGE at alkaline 
pH (Fig. 1.16. ) (Farhud et al., 1988). The most common electrophoretic phenotype is 
that of a single transferrin band (the wild-type Tf C), which migrates towards the anode 
in the ß-globulin fraction behind albumin. Variant transferrins with a greater net 
negative charge than Tf C show faster anodal mobilities than Tf C and are known as Tf 
Bvs. Conversely, those with slower, less anodal mobilities are known as TF 
D,,,., s. The various transferrins are controlled by multiple alleles at a single 
transferrin locus, with resulting phenotypes arising from codominant inheritance of a 
transferrin allele from each parent (Smithies & Hillier, 1958; Kamboh & Ferrell, 1987). 
Apart from Tf C which reaches its highest frequencies in Caucasian populations (98- 
99.8%), only four other alleles occur at polymorphic frequencies greater than 1% in 
more than one population (Kamboh & Ferrell, 1987; Farhud et al., 1988). These are: (i) 
Tf D,, which is prevalent among American Negroes and Australian Aborigines; (ii) Tf 
Dm, a widespread allele in populations of South and Southeast Asia; (iii) Tf B2, which 
is the main variant allele in European populations; and (iv) Tf Bo.,, which is largely 
confined to Central and North American Indian tribes. The few variant transferrins 
characterised to date show that the electrophoretic differences are due to a substitutional 
change of a single amino acid, that can be explained by a single nucleotide change in the 
codons of the respective residues (Yang et al., 1984). 
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4. 
Figure 1.16. Relative electrophoretic mobilities of 36 inherited variant alleles of human 
transferrin. 
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Substitutional changes have been determined as: (i) Gly for Asp at position 277 in Tf D, 
(Wang & Sutton, 1965); (ii) Glu for Gly at position 300 in Tf B2 (Wang et al., 1966); 
(iii) Arg for His at position 300 in Tf Dcm (Wang et al., 1967); (iv) Arg for Gly at 
position at position 394 in Tf D,,. s (Evans et al., 1988b); and (v) Asp for Ile at position 
378 or 381 in Tf Bs,,., w (Welch & Langmead, 1990). Variant transferrins that have been 
purified in sufficient quantities to allow iron binding and release studies to be carried 
out, have been shown to exhibit similar properties to the wild-type Tf C (Kamboh & 
Ferrell, 1987). Two variants showing abnormal iron binding properties have been 
reported by Evans et al., (1982) and Welch & Langmead (1990). Evans et al., (1982) 
found that although the variant, Tf DEVANS was capable of binding two iron atoms, iron 
was lost from the C-site during electrophoresis in 6M urea-polyacrylamide gels, 
resulting in a N-lobe monoferric transferrin with an anodal mobility slightly less than 
normal N-lobe monoferric transferrin. The variant apoprotein also had a slower 
electrophoretic mobility than normal apotransferrin, with the C-lobe denaturing at a 
lower urea concentration, and showing a lower thermal stability. Spectroscopic analysis 
showed a blue shift in the visible spectrum of the holotransferrin with , max at 435nm 
" rather than at 470nm. This suggested that at least one of the iron atoms was liganded in 
an abnormal manner to the protein. In vitro receptor-binding studies showed that the 
variant bound to transferrin receptors with an association constant one magnitude lower 
than normal transferrin (6.25 ± 2.53 x 1071mo1"1 and 6.31 ± 1.82 x 1081mo1'1 
respectively). In addition, the variant donated less iron to lymphocytes (22.2 ± 8.3 
pg/106 cells/h vs. 48.1 ± 15.6 pg/106 cells/hr for normal transferrin). Further studies 
showed that although the variant was capable of binding iron at both metal-binding 
sites, it could only bind Zn2+ and A13+ at one site, which was presumed to be that of the 
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N-lobe (Evans et al., 1984). Iron release studies in the presence of NaC1O4, and EPR 
spectra of proteolytic N- and C- lobe fragments confirmed that the iron at the N-site was 
bound normally. Amino acid analysis of the variant indicated that Arg had replaced Gly 
at position 394 of the primary sequence with a guanine -+ adenine transition in the first 
nucleotide of the codon (Evans et al., 1988b). 
The increased lability of the C-lobe of Tf DE,,, 4,,, s has been attributed to altered domain 
closure. Jhoti et al., (1987) found that the blue shift spectra of a crystallised NII (N-lobe 
domain II) fragment of duck ovotransferrin was similar to the spectra of holo Tf DE,,,,,, s. 
As the duck ovotransferrin fragment lacks the Asp residue in domain I that is involved 
in iron binding (sec. 1.7.2.1. ) and domain closure in both lobes (sec. 1.7.2.2. ), Evans et 
al., (1994) suggested that the blue-shift in Tf DEVANs reflected an altercation of the 
normal role of Asp392. Solution X-ray scattering analysis of holo Tf DEVMS confirmed 
that the C-lobe was in the open state. Computer modelling suggested that this was the 
result of an inability of Asp392 to bind to iron in the normal manner, and to form the 
interdomain hydrogen bond with Ser125 that closes the iron-binding cleft (Sarra et 
al., 1990; Lindley et al., 1993). The reduced affinity for iron of the C-lobe of Tf DE, ANs 
therefore appears to be due to interactions between the variant Arg394 and Asp392. It 
was proposed that an Asp392 hydrogen bond formation to the backbone amide, and an 
ion pair formation to the guanidinium group of Arg394, draws the Asp392 residue away 
from the iron atom, thereby affecting iron binding and release. The variant detected by 
Welch & Langmead (1990), Tf BSHAW also showed a lability of the C-site iron with very 
little of the added iron binding to the C-site. Iron loss from the C-site of the variant was 
faster than from normal transferrin, suggesting that iron was loosely bound at the site. 
The proposed amino acid substitution of Asp for Ile at position 378 or 381 is relatively 
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close to Asp394, suggesting that as with the Tf DEVM S variant, interactions between the 
substituted residue and Asp394 may be interfering with the normal roles of the latter. 
1.10.3. ISOELECTRIC FOCUSING POLYACRYLAMIDE GELS 
Thymann (1978), and Kühnl & Spielman (1978) found that the wild-type Tf C which 
migrates as a single protein band on nondenaturing polyacrylamide gels at alkaline pH, 
showed further microheterogeneity on isoelectric focusing gels. The two detected 
subtype (variant) alleles were called Tf Cl and Tf C2, with family studies confirming 
that the transferrin phenotypes could be explained by codominant Mendelian 
inheritance. The two bands were still present after removal of the terminal sialic acid 
residues indicating that the differences in electrophoretic mobility were due to variations 
in the amino acid sequence. Both transferrin bands were found to focus around pH 5.8, 
and were separated by about 0.1pH unit. A third subtype, Tf C3 was detected by Kuhnl 
& Spielman (1979) increasing the number of possible Tf C phenotypes to six (i. e. Tf C 1, 
C2, C2-1, C3, C3-1, C3-2). Since then at least 13 other subtype alleles have been 
detected with most occurring at extremely low frequencies (Kornhuber & Ktihnl, 1986; 
Kamboh & Ferrell, 1987). The three alleles that reach polymorphic levels in at least one 
major population are: (i) Tf Cl, which is present in all studied populations; (ii) Tf C2, 
which is found mostly among Asian populations; and (iii) Tf C3, which is found among 
Caucasians (Kamboh. & Ferrell, 1987). The majority of reports concerning the various 
subtypes have been on their incidence and distribution among human populations, with 
relatively few studies on their iron-binding characteristics. A study by Eckfeldt et al., 
(1985) found that serum transferrin concentration, total iron-binding capacity (TIBC; 
total amount of iron that can be bound by the apoprotein), and percentage iron saturation 
of a number of healthy blood donors were not dependent on transferrin phenotype. A 
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further study by Wong & Saha (1986) however found a significant difference between 
the TIBC of Tf Cl (70.4 ± 13.6µmoU1) and Tf C2-1 (65.0 ± 12.8pmol/l, p<0.05) and Tf 
C2 (60.4 ± 11.4pmo1/1, p<0.01) subtypes. Unlike the previous studies, Cleve et al., 
(1988) found a significant difference between the serum transferrin concentrations of Tf 
Cl and Tf C2-1 subtypes in an European sample, with the former subtype showing a 
higher concentration. The study also found that the serum transferrin concentration of an 
African sample was significantly higher than the European sample (528 ± 176mg/dl 
and 362 ± 88mg/dl respectively). The resulting serum iron concentration (transferrin- 
bound iron) of the African sample was found to be decreased, resulting in an increase in 
the free-iron-binding capacity (the residual amount of iron that can be bound by 
partially-saturated transferrin). The findings were suggested to be protective 
mechanisms against chronic microbial and/or parasitic infections in the African sample, 
as higher transferrin concentrations and free-iron-binding capacities would allow 
transferrin to compete effectively for microbial iron. Significant differences between 
transferrin subtypes and TIBC and transferrin levels were also found by Sikstrom et al., 
(1993b) in a female sample, with the Tf C3 allele (Tf C3-1,3-2 and 3 types) associated 
with a significantly lower TIBC. Although there were no significant differences in the 
male sample, they did show increased body iron stores (i. e. increased serum iron, 
transferrin saturation and serum ferritin), and a lower TIBC than females. Kita et al., 
(1994) have also recently reported that transferrin concentration is dependent on 
transferrin type, with the Tf Cl subtype showing the highest concentration (291 ± 
39mg/di), followed by the Tf C2-1 (282 ± 38mg/dl) and Tf C2 (267 ± 33mg/dl) 
subtypes. This confirms the trend shown in the previous studies by Eckfeldt et al., 
(1985), Cleve et al., (1988) and Sikstrom et al., (1993b). 
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1.11. FUNCTIONAL SIGNIFICANCE OF TRANSFERRIN POLYMORPHISM 
As transferrin appears to be essential for iron delivery to most tissues, variant alleles 
raise the question of the adaptive significance of the respective alleles. The two glycan 
chains of human plasma transferrin are known to show limited structural variation with 
nine possible isoforms ranging from the asialotransferrin (no terminal sialic acid 
residues) to the octasialotransferrin (8 sialic acids) forms (Spik et al., 1985; de Jong & 
van Eijk, 1989; de Jong et al., 1990). Although the functional roles of the isoforms 
remain unclear, certain forms have been associated with disease states. The 
asialotransferrin isoform for example shows a high level of incidence in cerebrospinal 
fluid, therefore its presence in extracellular fluids can be used as an early indicator of 
cerebrospinal fluid leakage before the development of meningitis (de Jong & van Eijk, 
1989). The predominant tetrasialotransferrin isoform has also been found to be 
significantly increased during pregnancy, a situation rapidly reversed after pregnancy (de 
Jong & van Eijk, 1988). It was therefore suggested that the change in glycosylation 
pattern may have a functional significance as previous studies by Fletcher & Suter 
(1969) had shown a high degree of correlation between increased levels of highly 
sialylated transferrin and transplacental iron uptake. Other groups have reported 
increased levels of low sialic acid content transferrins in the sera of alcoholics (Stibler et 
al., 1978; van Eijk et al., 1983; Poupon et al., 1985). These carbohydrate-deficient 
transferrin (CDT) isoforms with two, one or no terminal sialic acid, are thought to be the 
result of ethanol-induced disturbances in the glycosylation pathway, and are used as 
markers of alcohol abuse (Stibler, 1991; Rosman & Lieber, 1994). The increase in 
serum CDT levels is thought to involve the decreased activity of liver glycoprotein 
glycosyltransferases involved in transferrin glycosylation, and the increased activity of a 
transferrin deglycosylating enzyme, sialidase. Ghosh et al., (1993) found that chronic 
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ethanol treatment significantly inhibited the activities of liver sialytransferase (ST), one 
of the transferases involved in regulating sialic acid addition, and increased the activity 
of hepatic plasma membrane sialidase which removes sialic acids from the mature 
protein. Similar results were reported by Xin et al., (1995) with ethanol-fed rats showing 
decreased activities of ST, galactosyltransferase (GT), and N-acetylglucosamine 
transferase (N-AGT), and increased CDT serum levels. Their results also suggested that 
the decreased activities of the glycosylating enzymes were due primarily to the oxidation 
product of ethanol, acetaldehyde, as the latter was found to reduce ST, GT and N-AGT 
activities by similar levels in both ethanol-fed and control rats. 
A few reports have suggested an association between a silent/null transferrin allele, Tf , 
and decreased transferrin concentration (atransferrinemia). Goya et al., (1972) for 
example reported a case of inherited atransferrinemia in an 8 year old boy who had a 
plasma transferrin concentration about half that of his parents. A similar case was 
reported by Weidinger et al., (1984) in a putative father-child paternity case, where both 
individuals had significantly reduced transferrin concentrations. Although their Tf C 
subtypes (father - Tf Cl; child - Tf C2) appeared to exclude paternity, 23 other marker 
systems indicated a very high probability for paternity. It was subsequently suggested 
that the child had inherited a Tf allele from the father. The Tf has also been reported in 
a Finnish family where the grandmother, mother and child all had about half the normal 
amount of transferrin (Lukka & Ehnholm, 1985). None of the three individuals however 
showed clinical symptoms of atransferrinemia (e. g. low red cell count, excessive 
hemosiderosis in the liver and pancreas, and a lack of response to iron administration), 
implying that the amount of transferrin provided by the normal gene was sufficient for 
cellular functions. Other studies have reported a number associations between several 
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disease states and the two Tf C subtype alleles, Tf C2 and Tf C3, implying that they may 
be selectively disadvantageous. Beckman et al., (1980) for example reported an 
increased incidence of the Tf C2 allele in mothers with a history of spontaneous 
abortions. Similar results were found in preterm infants (Auconi et al., 1982), and in 
new-borns of mothers with previous histories of spontaneous abortion (Saha et al., 
1990), implying a selective reproductive disadvantage for the Tf C2 allele. Other studies 
found significantly high frequencies of the Tf C2 allele in factory workers with 
photodermatosis of the face following exposure to photoactive substances (Beckman et 
al., 1985), in patients with rheumatoid arthritis (el-Hazmi et al., 1991), and in patients 
with Alzheimer's disease (van Rensburg et al., 1993). Likewise high frequencies of the 
Tf C3 allele have been reported among couples in whom the women had experienced 
three or more first-trimester spontaneous abortions Weitkamp & Schacter (1985), in 
male patients with renal cell carcinoma (Frohlander et al., 1989), and in patients 
surviving myocardial infarction (Sikstrom et al., 1993a). It is generally thought that the 
two alleles act as enhancers of cyto- and geno-toxic damage by influencing the 
concentration or distribution of iron, thereby contributing to the formation of reactive 
oxygen free radicals that react with virtually all biological molecules (Beckman et al., 
1985; van Rensburg et al., 1993). Although the above studies all report a selective 
disadvantage for the Tf C2 and Tf C3 alleles, a recent study by Sikstrom et al., (1996) 
reported a negative association between Tf C3 and smoking-related lung cancer, 
implying that individuals with Tf C3 types (i. e. Tf C3, C3-1, C3-2 subtypes) were 
almost completely protected against the cancer. A negative association has also been 
reported between the Tf CI type and rheumatoid arthritis, suggesting a selective 
protective mechanism for the Tf Cl C1 subtype (el-Hazmi et al., 1991). 
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1.12. AIMS OF PROJECT 
Although a large number of transferrin variants (at least 36) have been detected, 
comparative studies have essentially been restricted to electrophoretic comparisons on 
polyacrylamide gels. Amino acid substitutions have been determined for relatively few 
transferrin variants, namely Tf D,, Tf Dc. and Tf BZ, which occur at polymorphic levels 
(> 1%) in human populations, and the two abnormal transferrin variants, Tf DEvANs and 
Tf BsH,, w (Wang & Sutton, 1965; Wang et al., 1966,1967; Evans et al., 1988b; Welch & 
Langmead, 1990). A few workers have also reported studies on the iron-binding 
capacity, serum iron levels, percentage saturation and plasma concentration of the three 
most common Tf C alleles, Tf Cl, Tf C2 and Tf C3 (Eckfeldt et al., 1985; Wong & 
Saha, 1986; Cleve et al., 1988; Kita et al., 1994). The main aim of this thesis is therefore 
to contribute to the field of research on transferrin variants, by studying the 
characteristics of variant transferrins to determine whether they show normal properties, 
or whether they show abnormal properties like the Tf DEvu., s and Tf Bs.,,,, variants 
which show a lability of the C-lobe binding site. The study will therefore involve a 
survey of human plasma by nondenaturing PAGE to detect variant transferrins showing 
abnormal electrophoretic phenotypes. Variant transferrins will then be isolated and 
purified on the basis of differences in charge density using a combination of ion- 
exchange and gel-filtration chromatography. Isolated transferrins will then be studied to 
determine whether they show similar molecular weights, sialic acid content, metal 
binding and release characteristics, stabilities to urea and thermal denaturation, and 
receptor-binding properties as the wild-type Tf Cl. Variant transferrins showing 
abnormal properties will then be analysed to determine the nature of the change in 
primary structure. 
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The second phase of the thesis will follow up on reports in literature that transferrin 
types may determine plasma transferrin levels and the degree of iron saturation 
(Eckfeldt et al., 1985; Wong & Saha, 1986; Cleve et al., 1988). The study will 
concentrate on the three Tf C alleles, Tf Cl, Tf C2 and Tf C3 which occur at 
polymorphic levels (> 1%) in human populations (Kamboh & Ferrell, 1987). Individuals 
showing the six transferrin phenotypes associated with Tf Cl, Tf C2 and Tf C3 alleles 
(i. e. Tf Cl, Tf C2, Tf C2-1, Tf C3, Tf C3-1, Tf C3-2) will be identified by 
electrophoresis of plasma on polyacrylamide isoelectric focusing gels. Plasma 
transferrin concentrations will be determined by single radial immunodiffusion, and 
plasma iron (transferrin-bound iron) by a quantitative kit. The two parameters will then 
be analysed according to transferrin phenotype to determine whether differences exist 
between phenotypes. 
The third phase of the thesis will follow up on a report in literature by Hershberger et 
al., (1991) that the transferrin sequence published by other workers (MacGillivray et al., 
1982,1983; Schaeffer et al., 1987) represents an unrecognised transferrin variant with 
Asn rather than Asp at position 310 of the amino acid sequence (i. e. adenine rather than 
guanine at base 1086 in exon 8 of the human transferrin gene). The study will 
concentrate on the three most common Tf C alleles, Tf Cl, Tf C2 and Tf C3 to examine 
whether the proposal by Hershberger et al., (1991) that Asp310 predominates in the 
population holds true, and to attempt to detect the proposed transferrin variant with 
Asn3 10 which would be expected to show an electrophoretic mobility similar to that of 
the Tf C alleles. Individuals showing the six transferrin phenotypes associated with Tf 
Cl, Tf C2 and Tf C3 alleles will be identified by electrophoresis of plasma on 
polyacrylamide isoelectric focusing gels. The nucleotide sequence of exon 8 of the 
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transferrin gene will be amplified from extracted genomic DNA by polymerase chain 
reaction. Amplified products will then be analysed for the presence of adenine or 
guanine at base 1086, by digestion with the restriction endonuclease Bsm I which has a 
single recognition site in exon 8 that contains the proposed adenine nucleotide at base 
1086, or with Fok I which also has a single recognition site in exon 8 that contains the 
guanine at base 1086. 
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CHAPTER TWO 
2. MATERIALS AND METHODS 
2.1. MATERIALS 
2.1.1. GENERAL CHEMICALS AND MATERIALS 
Unless otherwise stated, reagents were of analytical grade and were obtained from 
either: Sigma Diagnostics, Poole, Dorset, England; BDH Laboratory supplies, Merck 
Ltd., Lutterworth, Leicestershire, England; Bio-Rad Laboratories, Hemel Hampstead, 
Hertfordshire, England; Aldrich Chemical Company Ltd., Dorset, England; 
Feinbiochemica GmbH & Co., Heidelberg, Germany; or Oxoid Ltd., London, England. 
All chromatographic matrices were obtained from Pharmacia, Uppsala, Sweden. 
2.1.2. ELECTROPHORESIS MATERIALS 
Electrophoretic systems were purchased from either: Pharmacia, Uppsala, Sweden; or 
Bio-rad Laboratories, Hemel Hampstead, Hertfordshire, England. 
2.1.3. IMMUNOLOGICAL MATERIALS 
Rabbit anti-human transferrin IgG was provided by Dr. S. Welch, Queen Mary & 
Westfield College, London, England. Goat anti-rabbit IgG peroxidase-conjugate was 
purchased from Sigma Chemical Company, Poole, Dorset, England. 
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2.1.4. MOLECULAR BIOLOGY MATERIALS 
All reagents were of molecular biology grade and were purchased from either: Bio-rad 
Laboratories, Hemel Hampstead, Hertfordshire, England; or New England Biolabs, 
Beverly, USA. Oligonucleotide probes were obtained from Oswell DNA Service, 
University of Edinburgh, Edinburgh, Scotland. 
2.2. METHODS 
2.2.1. PREPARATION OF CHROMATOGRAPHIC COLUMNS 
All ion-exchange and G-200 chromatographic columns were prepared at room 
temperature and fully equilibrated overnight at 4°C by washing with the appropriate 
buffer. Columns were then run at 4°C. G-25 gel filtration columns were prepared, run 
and stored at room temperature. Unless otherwise stated, all samples were loaded using 
a Pharmacia P1 peristaltic pump and fractions collected using a Pharmacia Frac-100 
fraction collector. Absorbances were recorded using lml silica cuvettes with a 1cm path 
in a Phillips PU 8625 spectrophotometer. 
2.2.1.1. ION-EXCHANGE (ANION) CHROMATOGRAPHY: DEAE SEPHACEL 
Pre-swollen diethylaminoethyl (DEAE) Sephacel in 10% (v/v) methanol was washed 
twice in double-distilled deionised water for 10-15sec. After each wash the gel slurry 
was allowed to settle and excess fluid decanted. The gel matrix was then washed three 
times in an appropriate NaCI/Tris-HC1 buffer. During each wash, the pH of the gel 
slurry was adjusted to that of the NaCI/Tris-HCI buffer (pH 8.3). Excess buffer was 
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decanted after the third wash to leave the gel matrix in an approximate volume ratio of 
1: 1 with buffer. The matrix was resuspended before packing columns (sec. 2.2.1.4. ). 
2.2.1.2. ION-EXCHANGE (CATION) CHROMATOGRAPHY: SP. SEPHADEX 
C50 
Sulfopropyl (SP. ) Sephadex C50 was prepared by slowly mixing the matrix powder into 
20mM trisodium citrate (pH 5.1) buffer. The gel slurry was left at room temperature for 
Ihr to ensure that the gel matrix was fully swollen. Excess buffer was then decanted to 
leave the gel matrix in approximately 1: 1 volume: volume ratio with buffer. The matrix 
was resuspended before packing columns (sec. 2.2.1.4. ). 
2.2.1.3. GEL-FILTRATION CHROMATOGRAPHY: SEPHADEX G-200 & G-25 
Sephadex G-200 & G-25 fine matrices were swollen using the same protocol used for 
the SP. Sephadex matrix (sec. 2.2.1.2. ). The respective buffers used were 0.2M NaCl/ 
O. 1M Tris-HC1(pH 8.0) and double-distilled deionised water. Gel slurry were covered, 
left at room temperature for 24hr to ensure complete swelling of matrices and excess 
buffer decanted to leave an approximate matrix: buffer volume ratio of 1: 1. Swollen 
matrices were degassed at room temperature for 20min, gently resuspended and then 
used to pack the respective columns (sec. 2.2.1.4. ). 
2.2.1.4. PACKING OF CHROMATOGRAPHIC COLUMNS 
Chromatographic columns were first washed with double-distilled deionised water. The 
column outlet was closed when the bottom nylon mesh was immersed in a layer of about 
5mm of water. A small amount of the resuspended gel slurry was run down the sides of 
the column into the water layer, and the gel matrix allowed to settle for about 5min. 
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Additional gel slurry was then run down the sides of the column using a filter funnel 
until the column was either full or two-thirds full depending on the bed volume 
required. The column outlet was raised to a height of approximately 5cm below the 
meniscus of the gel slurry before opening the outlet. The gel matrix was then allowed to 
pack under controlled pressure. As the gel began to pack from the buffer/water, excess 
buffer/water was removed from the top using a syringe. Additional gel slurry was then 
carefully added round the sides of the column using a pasteur pipette. The column outlet 
was gradually lowered until it was below the base of the column and the packing 
pressure simultaneously adjusted to maintain a constant flow rate. When the height of 
the packed matrix was about 5cm above the height of the bed volume required, 
additional buffer/water was carefully added to the top of the column using a pasteur 
pipette. The column was washed for 20 min under controlled pressure to ensure the gel 
matrix was fully packed. The column outlet was then fully opened and the gel matrix 
washed under gravity for 10-15sec before measuring the natural flow rate of the column. 
The latter was determined by measuring the volume of column eluent collected in l5sec, 
and converting that to a flow rate of mUhr. The column was then attached to a 
Pharmacia peristaltic pump and washed overnight at the respective experimental flow 
rate with the appropriate equilibrating buffer. Before loading of samples, the volume of 
buffer/water above the packed gel matrix was adjusted if required to give a gap of about 
l cm. 
2.2.1.5. CALIBRATION OF G-200 GEL FILTRATION COLUMN 
The G-200 gel filtration column (size, IOOx2cm; bed volume, 280m1) was calibrated by 
running a series of different molecular weight proteins through the column. Duplicate 
1.5m1 samples of ß-amylase (200000), alcohol dehydrogenase (141000), bovine serum 
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albumin (66000), ovotransferrin (43000) and cytochrome C (12400) at 1.0mg/ml 
concentrations in the column buffer (0.2M NaCU 0dM Tris-HCI, pH 8.0), were 
individually loaded and run at a flow rate of 10ml/hr. 2.5ml fractions were collected and 
the absorbance determined against a buffer blank at 280nm to give a calibration curve of 
log M,,, versus peak elution fraction (Fig. 3.19. ). 
2.2.1.6. CALIBRATION OF PROTEIN PURIFICATION G-25 FINE GEL- 
FILTRATION COLUMN 
A large G-25 fine column (size, 50x3.2cm; bed volume, 230m1) was prepared for use as 
a desalting column during the protein purification. The column was calibrated using 
bovine serum albumin (BSA) and CuSO4. From initial purification work, a sample 
volume of 30ml was chosen as the maximum volume that would be loaded onto the 
desalting column. This was based on the volume of concentrated samples obtained from 
the purification step (SP. Sephadex) prior to the desalting column. 30m1 of 1mg/ml BSA 
in double-distilled deionised water, and 10% (w/v) CuSO4 solutions were individually 
loaded and run through the column at a flow rate of 45ml/hr. 9. Oml fractions were 
collected and the absorbance at 280nm and 620nm determined against a water blank to 
detect the presence of protein and salt respectively. The resulting elution profile (Fig. 
2.1. ) was used as a reference for purification work. 
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Figure 2.1. Elution profile of large-scale G-25 fine desalting column 
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2.2.1.6.1. CALIBRATION OF METAL-TITRATION G-25 FINE GEL 
FILTRATION COLUMN 
A small G-25 fine column (size, 15x1. Ocm; bed volume, 10m1) was prepared for 
desalting small volumes (1-5m1) of metal-titrated transferrin solutions. The maximum 
ft. I 
sample volume for the column was determined using duplicate 4.0,3.0,2.0 and 1. Oml 
volumes of blue dextran (1.0mg/ml in double-distilled deionised water) and CuSO4 (5% 
w/v). Samples were individually loaded and run as follows. The column was first 
washed under gravity with double-distilled deionised water, and the column outlet 
closed when the last of the water had just entered the top of the gel matrix. Using a 
pasteur pipette, the sample was run down the sides of the column onto the top of the gel 
matrix. The column outlet was fully reopened and 0.5ml fractions manually collected 
under gravity. When the last of the sample had just entered the top of the gel matrix, the 
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column outlet was closed and an equivalent volume of water run down the sides of the 
column onto the top of the matrix. The outlet was reopened and more fractions manually 
collected whilst continuously replenishing the water reservoir. Absorbances were 
determined against a water blank at 620nm using 0.4m1 silica cuvettes (lcm path). 
Sample volumes of 4.0 and 3. Oml were found to give little or no separation between 
protein and salt, both eluting in the same fractions. Sample volumes of 2.0 and 1. Oml 
showed good separation, with a sample volume of 1.0ml giving marginally better 
separation. As the column was intended to desalt samples as quickly and efficiently as 
possible, a sample volume of 2. Oml was chosen as the maximum loading volume (Fig. 
2.2. ). 
Figure 2.2. Elution profile for G-25 fine desalting column used during metal-titration 
studies of transferrin. 
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To determine the degree of protein recovery, 4. Oml of a holo transferrin solution was 
dialysed overnight against 20mM trisodium citrate (pH 4.0). At the low pH, iron 
dissociates from transferrin and is chelated by the citrate leaving the transferrin in the 
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apo form. 2. Oml of the dialysed sample was desalted on the G-25 fine column as 
described above, and fractions monitored against a water blank at 280nm (Fig. 2.3. ). 
Figure 2.3. Elution profile obtained from desalting 2.0m1 of holo transferrin dialysed 
against 20mM trisodium citrate (pH 4.0). 
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IOµ1 aliquots of fractions 11-22 were then analysed on a nondenaturing polyacrylamide 
gel. Fractions 12-17 were found to contain desalted transferrin. Fractions 12-15 were 
pooled and the protein concentration determined by the Lowry method (sec. 2.2.8. ). 
Comparison of the protein content of the pooled sample and that of the 2. Oml dialysed 
transferrin sample showed that 82% of desalted transferrin material was recovered using 
a 2. Om1 sample volume. 
2.2.2. NONDENATURING POLYACRYLAMIDE GEL ELECTROPHORESIS 
(PAGE) 
For large scale surveys of plasma samples for transferrin phenotypes (sec. 3.2.1. ), 
plasma samples were analysed on large nondenaturing polyacrylamide gels (size, 
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16xl4cm) using a Tris-HCI/Borate electrode buffer. For the majority of other 
electrophoretic analyses, mini nondenaturing polyacrylamide gels (size, 7x8cm) were 
used with a Tris-HCI/Glycine electrode buffer. 
2.2.2.1. TRIS-HCLBORATE NONDENATURING PAGE SYSTEM 
Resolving gels (9% v/v) were prepared by mixing: 12m1 30% (w/v) acrylamide/ 0.8% 
(w/v) bisacrylamide; and 27m1 freshly prepared gel buffer (0.4M Tris-HCI, 5.7% (v/v) 
1. OM HCl and 0.02% (v/v) N, N, N', N'-tetramethylethlydiamine (TEMED)). The 
solution was degassed under vacuum for 5min before adding 200µl freshly prepared 
10% (w/v) ammonium persulphate, and 20 i1 TEMED. The gel mixture was poured 
between the two gel plates, and the resolving comb inserted as per the manufacturers 
instructions to ensure that the top of the set gel was level. Polymerisation was completed 
after about lhr. The resolving gel comb was removed under running water prior to 
addition of the stacking gel. Stacking gels (4.3% v/v) were prepared by adding: 
12m1 30% (w/v) acrylamide/ 0.8% (w/v) bisacrylamide; 9. Oml gel buffer (0.4M Tris- 
HCI, 5.7% (v/v) 1. OM HC1 and 0.02% (v/v) TEMED); 50µ1 10% (w/v) ammonium 
persulphate; and 101l TEMED. The mixture was poured onto the top of the resolving 
gel, a well comb inserted, and the stacking gel left to polymerise for about 30min. The 
stacking well comb was removed under running water prior to loading of samples. Set 
gels were placed into an electrophoretic tank containing electrode buffer which 
comprised of a 1/10 dilution of a lOx stock electrode buffer (0.7M Tris-HC1 (pH 8.8)/ 
0.3M boric acid). Additional electrode buffer was added to the upper buffer reservoir as 
instructed by the manufacturers. Plasma samples were prepared by adding 10µl plasma 
to 90µl sample buffer (0.05% (w/v) bromophenol blue and 10% (w/v) sucrose). 25µl 
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aliquots (equivalent to 2.5µ1 undiluted plasma) were loaded through the upper buffer 
reservoir into the stacking gel wells using a syringe, and electrophoresed at room 
temperature for a total of 86,25OVmin (100V x 20"/ 150V x 15"/ 250V x 40"/ 400V x 
180"). During electrophoresis the electrode buffer was cooled by precooled water 
(10°C) running through the cooling apparatus of the Biorad electrophoretic system. 
2.2.2.2. TRIS-HCL/GLYCINE NONDENATURING PAGE SYSTEM 
Resolving minigels (11 % v/v) were prepared by mixing: 7.5m1 30% (w/v) acrylamide/ 
0.8% (w/v) bisacrylamide; 6. Oml resolving gel buffer (1. OM Tris-HCI, pH 8.8); and 
6.5m1 double-distilled deionised water. The solution was degassed for 5min prior to the 
addition of 100µ1 freshly prepared 10% (w/v) ammonium persulphate, and l0µ1 
TEMED. The gel mixture was poured between the two gel plates and overlaid with 
about 100µ1 deionised water as per manufacturers instructions. Polymerisation was 
completed after about 30min. The water layer was removed prior to addition of the 
stacking gel. The stacking gel (3.7% v/v) was made by adding: 1.25m1 30% (w/v) 
acrylamide/ 0.8% (w/v) bisacrylamide; 1.25m1 stacking gel buffer (1. OM Tris-HC1, pH 
6.8); 7.5ml double-distilled deionised water; 50µl 10% (w/v) ammonium persulphate 
and l Oµ1 TEMED. The mixture was poured onto the top of the resolving gel and a well 
comb inserted. Polymerisation was completed after about 15min. The well comb was 
removed under running water prior to loading of samples. Set gels were placed into an 
electrophoretic tank containing the electrode buffer which comprised of a 1/10 dilution 
of a lOx stock electrode buffer (0.3M Tris-HCI (pH 8.3)/ 2. OM Glycine). Additional 
electrode buffer was added until the gel was overlaid with buffer. Samples were loaded 
into the stacking gel wells using a syringe. For analysis of plasma samples, 1 µl plasma 
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was added to l01i1 sample buffer (0.05% (w/v) bromophenol blue and 10% (w/v) 
sucrose). For analysis of protein samples, a maximum loading volume of 50µl was 
generally used, comprising a 1: 1 ratio of sample: sample buffer. Electrophoresis was 
performed at room temperature with the electrode buffer acting as both electrolyte and 
coolant. Samples were generally electrophoresed for a total of 19,000-39,000Vmin 
comprising 50V x 20", and then a corresponding amount of time at 150V. 
2.2.3. SODIUM DODECYL SULPHATE (SDS) PAGE SYSTEM 
SDS minigels (size, 7x8cm) were prepared using a modified version of that described by 
Laemmli (1970). ß-mercaptoethanol was used in the sample buffer to break any inter- 
and intra- protein disulphide bridges. 10% (v/v) resolving minigels were made by 
mixing: 6.65m1 30% (w/v) acrylamide/ 0.8% (w/v) bisacrylamide; 7.5m1 resolving gel 
buffer (l. OM Tris-HCI, pH 8.8); 5.85m1 double-distilled deionised water; and 100µl 
20% (w/v) SDS. The solution was degassed under vacuum for 5min and polymerisation 
initiated by the addition of 100µ1 freshly prepared 10% (w/v) ammonium persulphate 
and IOµl TEMED. The gel mixture was poured between the gel plates as instructed by 
the manufacturers, and overlaid with l00µ1 water. Polymerisation was completed after 
about 30min. The water layer was removed prior to addition of the stacking gel. 5% 
(v/v) stacking gels were prepared by mixing: 1.67m130% (w/v) acrylamide/ 0.8% (w/v) 
bisacrylamide; 1.25m1 stacking gel buffer (1. OM Tris-HC1, pH 6.8); 7. Oml double- 
distilled deionised water; 50µ1 20% (w/v) SDS; 50µ1 10% (w/v) ammonium 
persulphate; and 10µl TEMED. Stacking well combs were inserted and the gel mixture 
left to polymerise for about 15min. The well combs were removed under running water 
prior to loading of samples. Set gels were placed into an electrophoretic tank containing 
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electrode buffer comprising of a 1/10 dilution of a lOx stock electrode buffer (0.25M 
Tris-HCI (pH 8.3), 2. OM Glycine and 1% (w/v) SDS). Additional buffer was added until 
the gels were overlaid with buffer. Samples were generally diluted 1: 4 with sample 
buffer. Sample buffer was pre-prepared by mixing: 20mg bromophenol blue; 1.8g Tris- 
HCI; and 60m1 double-distilled deionised water. The mixture was adjusted to a pH of 
6.8 before adding 12.5m1 ß-mercaptoethanol and 25m1 glycerol. The solution was made 
up to a final volume of 100ml, and stored as 20m1 aliquots at -20°C until required. In 
general, a maximum loading volume of 25µ1 was used. About 1/4 volume of 20% (w/v) 
SDS was added to the sample/sample buffer mixture, and the mixture heated at 100°C 
for about 3min. The mixture was allowed to cool to room temperature before loading 
onto the stacking gels. Gels were run at 50V for 30min to allow the proteins to enter the 
resolving gel, before raising the voltage to 150V. Electrophoresis was continued until 
the bromophenol blue marker was about 2mm from the bottom of the gel. 
2.2.4. UREA - PAGE SYSTEM 
Mini urea polyacrylamide gels (size, 7x8cm) were prepared using a modified version of 
the method of Makey & Seal (1976). Urea was used in the sample buffer to denature the 
proteins. Mini urea gels were developed as a means of obtaining electrophoretic results 
within one day. Previous urea PAGE experiments in the laboratory were performed 
using large (16x14cm) gels which were electrophoresed for a total of about 
150,000Vmin (50V x 60"7 150V x 980"). Results therefore took 2 days to obtain. 
Resolving gels (6.5% v/v) were made by mixing: 30m1 freshly prepared 8M urea; 8.8m1 
30% (w/v) acrylamide/ 0.8% (w/v) bisacrylamide; and 2m1 20x stock electrode buffer 
(2. OM Tris-HCI, pH 8.4; 0.2M boric acid; and 30mM disodium EDTA). The solution 
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was degassed under vacuum for 5min, before adding 50µ1 freshly prepared 25% (w/v) 
ammonium persulphate and 20µ1 TEMED. The mixture was poured between the gel 
plates and overlaid with 100µ1 deionised water. Polymerisation was completed after 
about 30min. The water layer was removed prior to addition of the stacking gel. 
Stacking gels (4.5% v/v) were prepared by adding: 7.5ml 8M urea; 1.4m1 30% (w/v) 
acrylamide/ 0.8% (w/v) bisacrylamide; 0.5m1 20x stock electrode buffer (2. OM Tris- 
HCI, pH 8.4; 0.2M boric acid; and 30mM disodium EDTA); 20µ1 25% (w/v) 
ammonium persulphate and l0µ1 TEMED. The mixture was poured onto the resolving 
gel and well combs inserted. Polymerisation was completed after about 15min. Well 
combs were removed under running water, and set gels placed into an electrophoretic 
tank containing electrode buffer. The electrode buffer comprised a 1/20 dilution of a 20x 
stock buffer (2. OM Tris-HC1 (pH 8.4), 0.2M boric acid and 30mM disodium EDTA). 
Additional buffer was added until the gels were overlaid with buffer. Samples were 
generally diluted 2: 1 with freshly prepared sample buffer (0.2% (w/v) bromophenol 
blue; 9.5% (w/v) sucrose; 76% (v/v) 8M urea; and 4.8% (v/v) 20x stock electrode buffer 
(2. OM Tris-HC1(pH 8.4), 0.2M boric acid and 30mM disodium EDTA)). Samples were 
electrophoresed at room temperature for a total of 31,500Vmin (50V x 30"/ 100V x 
300"). Whereas the electrode buffer of the large gel system was cooled during 
electrophoresis by water (pre-cooled at 18°C) flowing through the internal cooling 
system, the electrode buffer for the minigel system acted as both electrolyte and coolant. 
Therefore to prevent the gels from overheating, the electrode buffer was replaced with 
fresh buffer every hour. 
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2.2.5. ULTRA-THIN LAYER POLYACRYLAMIDE ISOELECTRIC FOCUSING 
(IEF) GELS FOR TRANSFERRIN SUBTPYING 
The protocol used was that developed in the Haematology Department of the London 
Hospital. The method is cost effective as it utilises relatively small amounts of 
ampholines (0.5-1.0ml). Gels produced have a thickness of 0.2mm. Gel mould plates 
were prepared by taping a single layer of insulating tape around the four sides of the 
plates. Plates were cleaned with ethanol before gel preparation. The covering top plates 
were also wiped with the water repellent Sigmacote SL2 and allowed to air dry for about 
5min. Gels (2% v/v) were prepared by gently mixing: 15m12.7% (w/v) acrylamide/ 4% 
(w/v) acrogel 5 premix; 5m150% (w/v) sucrose; and 1m12.2% (w/v) ampholine (pH 5- 
7). 200µ1 of freshly prepared 0.1% (w/v) riboflavin was added to the mixture after 3min 
and briefly stirred. 5m1 gel mixture was poured onto each mould plate and evenly spread 
by slowly lowering the Sigmacote coated side of the covering plates onto the mould 
plates. The gels were allowed to polymerise at room temperature for 3hr over an ultra 
violet (UV) illuminator, and then stored at -4°C until required. Plasma samples (6x1) 
were saturated with iron by incubating for 50min at room temperature in 38µl freshly 
, 
O4. The covering gel plate was carefully removed prior to prepared 0.8M Fe 
electrophoresis. The mould plate was placed on the ceramic gel block of the Pharmacia 
Multiphor II electrophoretic system, which was cooled by running water (pre-cooled at 
10°C). Electrode wicks (Whatman 3MM paper strips, 10mm width) were soaked in 
1. OM orthophosphoric acid for the anode, or in L OM NaOH for the cathode. Electrode 
wicks were placed vertically on the corresponding side of the gel, and the latter pre- 
focused for 30min at 250V to coincide with the completion of sample incubation. 
Whatman No. 1 inserts (5x3mm) were dipped into the iron-saturated plasma samples, 
briefly blotted and loaded down the centre of the pre-focused gels with I mm gaps 
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between inserts. Samples were focused at 10°C for a total of 167,500Vmin (500V x 20"/ 
1000V x 30"/ 1500V x 45"/ 2000V x 30"). Samples were then fixed in 12% (w/v) 
trichloroacetic acid (TCA) for 5min, washed in double-distilled deionised water for 
lmin, and then stained with 0.04% (w/v) SERVA Blue W dye (preheated at 55°C) for 
10min. The stained gel was washed for 2min in deionised water to produce a clearer 
background. 
2.2.6. PROTEIN STAINING 
Two methods of protein staining were used depending on the amount of available 
protein in the respective samples. Coomassie blue staining was used where the protein 
content in the loading sample was more than 5µg. For samples containing less than 5µg 
protein, silver staining was used. 
2.2.6.1. COOMASSIE BLUE STAINING OF POLYACRYLAMIDE GELS 
After electrophoresis, gels were fixed in 10% (w/v) TCA for 30min. They were then 
washed in deionised water for 5min, followed by a 15min wash in destain solution 
comprising 45% (v/v) methanol and 10% (v/v) glacial acetic acid. Gels were stained 
overnight in staining solution comprising 95vo1 stock stain (0.025% (w/v) Coomassie 
blue, 50% (v/v) methanol) and 5vol glacial acetic acid. Stained gels were washed for lhr 
in destain solution (45% (v/v) methanol, 10% (v/v) glacial acetic acid) to produce a 
clearer background. Finally, gels were prepared for vacuum drying by washing for at 
least Ihr in 10% (v/v) glacial acetic acid/ 2% (v/v) glycerol. 
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2.2.6.2. SILVER STAINING OF POLYACRYLAMIDE GELS 
The procedure used for silver staining was a modified version of the Rabilloud method 
(Rabilloud et al., 1988). In all cases, the solution volumes used were 100ml/gel. Gels 
were first fixed in 10% (w/v) TCA for 15min, and then washed for a further 15min in 
30% (v/v) ethanol/ 10% (v/v) acetic acid. This was followed with a 15min wash in 30% 
(v/v) ethanol, and then with 3x 15min washes in double-distilled deionised water. Gels 
were sensitised by a lmin wash in freshly prepared 0.025% (w/v) sodium dithionite 
solution. Excess sodium dithionite was removed by a lmin wash in double-distilled 
deionised water. Sensitised gels were then washed for 20min in a 0.1% (w/v) AgNO3/ 
0.017% (v/v) formaldehyde solution. Excess uncomplexed silver was removed by a 
brief water wash (1min). The silver stain was developed by incubating the gels in a 4% 
(w/v) KZCOJ 0.05% (v/v) formaldehyde/ 0.5% (v/v) sodium thiosulphate solution 
(lmg/ml). Development of the stain was stopped by the addition of IOml glacial acetic 
acid. The developed gel was washed in double-distilled deionised water for 20min, and 
then washed in 10% (v/v) acetic acid/ 2% (v/v) glycerol for at least lhr before drying 
under vacuum. 
2.2.7. WESTERN BLOT FOR THE ELECTROPHORETIC TRANSFER AND 
IMMUNOBLOTTING OF PROTEINS FROM SDS POLYACRYLAMIDE GELS 
After SDS PAGE (sec. 2.2.3. ) stacking gel sections were removed and gels marked at 
the top left hand corner by cutting a small section of the resolving gel above lane 1. Gels 
were equilibrated for transfer by soaking in cold (precooled at 4°C) freshly prepared 
transfer buffer (25mM Tris-HCI/ 0.2M Glycine/ 20% (v/v) methanol) for 20min. For 
each gel, two sheets of Whatman 3MM paper and porous fibre pads, and one sheet of 
nitrocellulose membrane with the top left hand corner cut off, were soaked in the 
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transfer buffer for an equivalent period of time. To minimise the possibility of protein 
loss during transfer, the Whatman paper, porous pads and nitrocellulose membrane were 
all slightly larger than the size of the gel. After equilibration, a gel sandwich was 
prepared under cold transfer buffer as shown in the diagram below (Fig. 2.4. ). 
Figure 2.4. Construction of gel sandwich for the electrophoretic transfer of protein 
from SDS polyacrylamide gels to nitrocellulose membrane. 
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A porous pad was placed on the cathode plate of the Mini Trans-Blot gel cassette and 
gently squeezed to expel trapped air. One of the Whatman 3MM sheets was placed on 
top of the pad, and the equilibrated gel positioned onto the sheet with the marked edge 
aligned towards the top left hand comer of the gel sandwich. The nitrocellulose 
membrane was then gently lowered onto the gel with the marked section aligned to that 
of the gel. The second Whatman 3MM sheet was laid over the nitrocellulose membrane, 
and the gel sandwich completed with the second porous pad. Throughout the 
construction of the sandwich, all components were kept under transfer buffer, and air 
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bubbles expelled by gently smoothing each layer with a gloved hand. The completed 
sandwich and an ice pack were placed into the Mini Trans-Blot electrophoretic tank, and 
the latter filled with cold (4°C) transfer buffer to a level just below the full height of the 
gel cassette and ice pack. Transfer of protein from gel to nitrocellulose membrane was 
achieved by electrophoresis at 100V for Ihr. During transfer, the electrode buffer was 
cooled by the ice pack. After electrophoresis, the nitrocellulose membrane was washed 
for 20min at room temperature in 100m1 freshly prepared blocking solution (10% (w/v) 
dried milk powder/ 7.6% (w/v) Glycine). This was followed by 3x 5min washes in 50ml 
of freshly prepared washing solution (0.5% (w/v) dried milk powder/ 20% (v/v) IOx 
PBS (27mM KCU 1.4M NaCl/ 15mM KHZPO, / 73mM Na2HPO4)/ 0.2% (v/v) Tween 
20). The blocked membrane was then incubated with the primary antibody by gently 
shaking overnight in 12m1 washing solution containing 0.2% (v/v) rabbit anti-human 
transferrin IgG (20mg/ml). Unbound primary antibody was removed by 3x 5min washes 
in washing solution. The membrane was then incubated with the second antibody by 
washing for Ihr in 12m1 washing solution containing 0.05% (v/v) goat anti-rabbit IgG- 
peroxidase conjugate (300U/ml). Excess second antibody was removed by 2x 5min 
washes in 50m1 freshly prepared prestain solution (0.5% (w/v) dextran sulphate/ 10% 
(v/v) 0.1M citrate/EDTA (pH 5.0)). This was followed by a 5min wash in 50m1 freshly 
prepared staining' solution (0.01% (w/v) tetramethylbenzidine/ 5% (v/v) ethanol/ 10% 
(v/v) 0.1M citrate/EDTA (pH 5.0)). The stain was developed by the addition of 20µl 
30% (v/v) HZOZ to 50m1 of fresh staining solution, and stopped with a water wash. 
114 
2.2.8. DETERMINATION OF PROTEIN CONCENTRATION 
The method used was a modification of that described by Lowry et al., (1951). A 
calibration curve was prepared by using bovine serum albumin (BSA) as a standard. 
27.0mg BSA was dissolved in 15m1 double-distilled deionised water and then made up 
to a final volume of 27m1.10-100µl aliquots of the stock albumin were assayed in 
duplicate using the following protocol. A reaction solution was freshly prepared by 
mixing 49vo1 of a 2% (w/v) sodium carbonate/ 0.02% (w/v) sodium potassium tartrate 
solution with lvol 5% (w/v) CuSO4.1. Oml reaction solution was pipetted into 1.5ml 
plastic capillary tubes and 100µ11. OM NaOH added to each tube. 100µl double-distilled 
deionised water was added to the reagent blank tube and 10-100µ1 stock albumin 
solution added to sample tubes. For samples of less than 100µl volume, additional 
double-distilled deionised water was added to the tubes to bring the total sample volume 
up to 100µl. The solutions were mixed and incubated at room temperature for 10min. 
100µl of a freshly prepared solution comprising 1: 1 volumes of Folin & Ciocalteu 
phenol reagent and double-distilled deionised water, were added to each tube and 
immediately mixed. Samples were incubated for 30min in the dark, and the absorbance 
at 660nm monitored against the reagent blank using 1.5m1 plastic cuvettes (lcm path). 
The assay was repeated a second time and the mean absorbances plotted against the 
respective amount of albumin in each aliquot to give a calibration curve (Fig. 2.5. ). The 
protein contents of unknown samples were determined from the calibration curve using 
the same protocol. Protein concentrations were then determined by dividing the amount 
of protein by the volume of the sample used in the assay. 
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Figure 2.5. Calibration curve for protein determination by the Lowry method. 
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2.2.9. DETERMINATION OF PLASMA TRANSFERRIN CONCENTRATION: 
SINGLE RADIAL IMMUNODIFFUSION 
The method for the determination of plasma transferrin concentration was a modified 
version of that described by Mancini et al., (1964). The method relies on the formation 
of an insoluble antigen-antibody complex when the concentrations of the two are in 
equilibrium. The antigen (transferrin) is placed into wells cut in agar which contains the 
antibody (rabbit anti-human transferrin IgG). As the antigen diffuses radially from the 
wells, a ring of precipitation forms and appears to move outwards. The precipitate ring 
eventually becomes stationary at the point of equivalence, the ring diameter being a 
function of the antigen concentration. A calibration curve can therefore be obtained by 
plotting the precipitate ring area ", at equivalence against known antigen 
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concentrations, thereby allowing the concentration of antigen in unknown samples to be 
determined. 
2.2.9.1. INITIAL CALIBRATION EXPERIMENTS 
Initial calibration trials were performed in small plastic petridishes (area 58cm2). A IOpl 
sample volume was chosen as the lowest volume that could be accurately pipetted using 
a 20gl pipette. The volume of agar required to accommodate lOµ1 sample was 
determined to be 18.6m1. To allow for solution losses during the heating stages, a final 
volume of 20m1 of 1% (w/v) agar was chosen for the initial trial. 200mg agar was 
dissolved in 19m1 physiological saline (0.85% w/v) by heating at 100°C for 5min. The 
solution was cooled to 55°C in a water bath, and iml rabbit anti-human transferrin IgG 
(20mg/ml in physiological saline) added and mixed. The gel was poured into a petridish 
(on a levelling table), left to solidify at room temperature for 30min, and then at 4°C for 
lhr. Wells were cut at 2cm intervals in the set gel, and lOµl of 0.5-5.0mg/ml transferrin 
solutions (determined by the Lowry method) loaded in duplicate into the wells. 
Precipitate ring areas were determined at 24hr, 48hr and 120hr and plotted against the 
corresponding transferrin concentration (Fig. 2.6. ). The precipitate ring areas for 48hr 
and 120hr were found to be within 1.0mm2 of each other. In contrast, the precipitate ring 
areas for 24hr and 120hr were about 3. Omm2 apart. These results suggested that antigen- 
antibody equivalence under the experimental conditions was reached between 48hr and 
120hr. 
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Figure 2.6. Calibration curve for the determination of transferrin concentration by 
single radial immunodiffusion using a gel antibody concentration of I. Omg/ml. 
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2.2.9.2. OPTIMISATION OF PROTOCOL 
To increase precipitate ring sizes and so minimise measurement areas, two further gel 
antibody concentrations of 0.5mg/ml and 0.3mg/ml were attempted. Stock transferrin 
standards were made by preparing a starting solution of approximately 6mg/ml 
apotransferrin in physiological saline. The protein concentration was determined in 
triplicate using the Lowry method (2.2.8. ), and then diluted with saline to give a 
calculated transferrin concentration of 4mg/ml. The protein concentration was 
determined in triplicate, and a further dilution made to give a final calculated transferrin 
concentration of 4mg/ml. Serial dilutions of the stock 4mg/ml solution were made to 
give transferrin concentrations of 1,2 and 3mg/ml. The four solutions were stored as 
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I ml aliquots at -20°C and used as standards. Following the same procedure described 
above (sec. 2.2.9.1. ), the four standards were loaded in duplicate onto two separate gels 
(gel antibody concentrations 0.5mg/ml and 0.3mg/ml), and the precipitate ring areas 
determined at 24hr, 48hr and 72hr (Fig. 2.7. ). 
Figure 2.7. Calibration curves for the determination of transferrin concentration by 
single radial immundiffusion using 0.5mg/ml and 0.3mg/ml gel antibody concentration. 
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The results indicated that for a gel antibody concentration of 0.5mg/ml, antigen. 
antibody equivalence was reached between 48hr and 72hr. In contrast, a gel antibody 
concentration of 0.3mg/ml appeared to require at least 72hr for equivalence to be 
attained. The higher antibody concentration of 0.5mg/ml was therefore chosen as the 
experimental gel concentration because it satisfied the requirement for larger precipitate 
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ring sizes and results could be obtained within a reasonable time period of 72hr. A 
blind study was then conducted to determine the accuracy of the procedure. Nine plasma 
samples of unknown concentrations and the four standards were loaded in the same 
positions on two separate gels. The transferrin concentrations were determined against 
the corresponding calibration curve. Information relating to the source of the plasma 
samples then revealed that: (a) two samples were from the one individual; (b) four 
samples were from a pooled plasma sample; and (c) three samples were a diluted 
version of the pooled plasma sample (diluted 4: 1 with physiological saline). Table 2.1. 
shows the results obtained for the study. 
Table 2.1. Plasma transferrin concentrations of plasma samples determined by single 
radial immunodiffusion. 
Source of plasma sample Mean plasma transferrin Range (mg/ml) 
(mg/ml) 
Individual 1 3.04 3.00-3.08 
(n = 2) 
Pooled plasma sample 2.63 2.35-2.90 
(n =4) 
Diluted pooled plasma 2.05 2.00-2.09 
(n=3) 
In general, the transferrin concentrations per plasma source were within ± 0.1mg/ml. In 
addition, the mean concentration derived for the diluted sample after accounting for the 
dilution factor was within 0.05mg/ml of the expected concentration (i. e. 2.10mg/ml 
compared to 2.05mg/ml). The results therefore indicated that the protocol was capable 
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of providing accurate determinations of transferrin concentration. For further 
determinations of transferrin concentrations, larger plastic petridishes (area 145cm2) 
capable of accommodating four standards and twenty duplicate samples were used. 
2.2.10. DETERMINATION OF TOTAL SERUM IRON CONCENTRATION 
The protocol used for the determination of total serum iron was that supplied with the 
quantitative kit. The procedure relies on the principle that at acidic pH and in the 
presence of a suitable reducing agent, transferrin-bound serum iron dissociates to form 
Fee;. The latter react with the compound ferrozine to produce a water-soluble magenta 
complex with an absorption maximum at 560nm. The total serum iron concentration is 
therefore proportional to the difference in colour intensity following addition of 
ferrozine. O. 5m1 iron buffer reagent (1.5% (w/v) hydoxylamine hydrochloride in acetate 
buffer, pH 4.5) was pipetted into 1. Oml plastic cuvettes (lcm path). l00µ1 double- 
distilled deionised water, iron standard (500µg/dl) and serum, were added to the blank, 
standard and sample cuvettes respectively. Standard and serum samples were always 
assayed in duplicate. The solutions were mixed and the initial absorbances of standard 
and samples monitored against the reagent blank at 560nm. l0µl iron colour reagent 
(0.85% (w/v) ferrozine in hydroxylamine hydrochloride solution) was added to the 
cuvettes, the solutions mixed and then incubated at 37°C for 10min. The final 
absorbances of standard and samples were determined against the blank at 560nm. Total 
serum iron concentrations were determined using the following equation: 
Total serum concentration = FINAL ASAMPLE - INITIAL ASAMPLE X Iron standard 
(mg/ml) FINAL AsTANDARD - INITIAL Aswn iw concentration 
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2.2.11. METAL-ION TITRATIONS OF TRANSFERRIN 
Solutions of apotransferrin were titrated with 1mM metal-nitriloacetate (NTA) solutions 
as described below. Apotransferrin solutions were prepared by dissolving the 
appropriate amounts of freeze-dried transferrin in a buffer solution comprising 0.5M 
Tris-HCI (pH 7.5 or 5.5) and 30mM NaHCO3.100mM metal-NTA solutions were 
freshly prepared by dissolving 0.19g NTA in 2m1 1M NaOH and 5m1 double-distilled 
deionised water. 2m1 freshly prepared 0.5M metal salt solution was added to the 
mixture, mixed and the final volume made up to 10ml with double-distilled deionised 
water. 1mM metal-NTA solutions were obtained by a 1/100 dilution of the 100mM 
stock solution. lml apotransferrin solution was pipetted into two spectrally identical lml 
silica cuvettes (I cm path). Samples were titrated with metal ion by the addition of 5µl 
1mM metal-NTA. The reagent blank was simultaneously adjusted by the addition of 51il 
1mM NTA. After each addition, the sample absorbance was monitored at the respective 
wavelength against the reagent blank. 
2.2.12. DNA EXTRACTION PROTOCOLS 
Two DNA extraction protocols were used during the course of polymerase chain 
reaction (PCR) amplification studies of the nucleotide sequence corresponding to exon 8 
of the human plasma transferrin gene. 
2.2.12.1. PHENOL-CHLOROFORM EXTRACTION OF GENOMIC DNA 
FROM HUMAN WHOLE BLOOD 
The protocol for the isolation of genomic DNA from whole blood was that used in the 
Haematology Department at the London Hospital. 700µ1 whole blood was added to 
7O0µ1 lx standard saline citrate ((SSC) ; 0.15M NaCI/ 15mM sodium citrate) in sterile 
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1.5m1 plastic Eppendorf tubes. The solution was vortexed briefly and centrifuged for 
2min at 13000rpm. Iml supernatant was removed and the packed cells washed a second 
time in 700µl lx SSC. The supernatant was carefully poured off after centrifugation 
leaving the cell pellet in approximately 100µ1 of fluid. 400µ10.4M sodium acetate was 
added to the tubes and the solution vortexed thoroughly to resuspend the cell pellet. 
2Oµ1 10% (w/v) SDS and 20gl Proteinase K (10mg/ml) were added to the solution, and 
samples mixed by inversion before incubating at 56°C for 2hr. 500µ1 1: 1 phenol- 
chloroform was added to the samples, the latter mixed by repeated inversion for 5min 
and centrifuged at 13000rpm for 4min. The lower organic phase was removed using a 
plastic pasteur pipette and the phenol-chloroform extraction repeated. 500µ1 20: 1 
chloroform-isoamyl alcohol was added, samples mixed by inversion and centrifuged at 
13000rpm for 4min. 400µl of the upper aqueous phase was removed into new sterile 
1.5m1 Eppendorf tubes. lml cold ethanol was added and the DNA precipitated by 
repeated inversion. The DNA was allowed to settle to the bottom of the tubes, 
centrifuged at 13000rpm for 1min and the supernatant carefully discarded. The tubes 
were drained on tissues and excess supernatant carefully wiped off. 50µ1 10mM Tris- 
HCI/ 1 mM EDTA (pH 8.0) was added to the tubes, the samples briefly vortexed (-. 
10sec) to resuspend the DNA, and then incubated overnight at 56°C. Samples were 
centrifuged briefly (-- 10sec) at 2500rpm to collect condensation, vortexed briefly and 
then stored at -20°C until required. 
2.2.12.2. GENOMIC DNA EXTRACTION FROM HUMAN WHOLE BLOOD 
USING INSTAGENE MATRIX 
The protocol used was that recommended by the suppliers of the Instagene matrix. The 
benefits of this procedure are that it uses very little whole blood (about 1/100 of the 
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volume used in phenol-chloroform extractions), and extraction is quicker and safer 
compared to phenol-chloroform extractions. 6µl whole blood was added to lml sterile 
double-distilled deionised water in sterile 1.5m1 plastic Eppendorf tubes, mixed by 
repeated inversion and incubated at room temperature for 30min. Samples were 
centrifuged at 12000rpm for 3min and the supernatant carefully discarded leaving the 
cell pellet in approximately 30µl of fluid. 2O0µ1 Instagene matrix (constantly stirred) 
was added to the cell pellet and samples incubated at 56°C for 30min. The tubes were 
briefly vortexed (- 10sec) and centrifuged at 12000rpm for 3min to allow the matrix to 
settle to the bottom. Aliquots of the supernatant were used for the PCR reaction. The 
remainder of the solutions were stored at -20°C until required. When using stored 
Instagene DNA preparations, samples were first vortexed for 10sec after thawing, and 
then centrifuged for 3min at 12000rpm. 
2.2.13. QUANTIFICATION AND PURITY ESTIMATION OF DNA 
Quantification and purity of extracted genomic DNA was determined by diluting 5µ1 
DNA solution with 495µ1 sterile double-distilled deionised water to give a final volume 
of 0.5m1 in a 0.5m1 silica cuvette (1cm path). The absorbances at 260nm and 280nm 
were determined against an equivalent volume water blank in a spectrally identical 
0.5m1 silica cuvette. The ratio between the readings at 260nm and 280nm (i. e. A260ra1/ 
A280i, ) provided an estimate of the purity of the DNA. Values around 1.8 were 
indicative of pure DNA. The concentration of the DNA sample was determined by the 
equation: 
DNA concentration (µg/ml) = A26on,,, X 50 x dilution factor 
(where the dilution factor= 500µU 5 t1=100) 
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2.2.14. AGAROSE GEL ELECTROPHORESIS 
3% (w/v) agarose gels were prepared by dissolving the appropriate amount of agarose in 
a suitable volume of lx Tris/ Borate/ EDTA (TBE) (90mM Tris-HCI/ 90mM Boric 
acid/ 0.4mM disodium EDTA). Set gels were electrophoresed in lx TBE containing 
ethidium bromide at a concentration of 0.5µg/ml. Samples were prepared by adding 41A 
40% (w/v) sucrose to 5 i1 sample before loading onto gels. 
2.2.15. RESTRICTION DIGEST ANALYSIS OF AMPLIFIED PRODUCT 
Amplified samples were prepared for restriction digest as follows. A reaction volume of 
30µ1 was prepared by adding: 2Oµ1 amplified product; 6µl sterile double-distilled 
deionised water (for Fok I digests) or 6.2µl (for Bsm I digests); 3 t1 lOx restriction 
buffer (for Fok I- 50mM potassium acetate/ 20m1VI Tris acetate/ 10mM magnesium 
acetate/ 1mM DTT, pH 7.9; for Bsm I- 50mM NaCI/ 10mM Tris-HCU 10mM MgCI2/ 
1mM DTT, pH 7.9); and 11l Fok I (4U/µ1) or 0.8µ1 Bsm I (5U/µl). Samples were mixed 
and incubated at 37°C for ihr. Digestion was stopped by the addition of 5µl 6x stop 
buffer (0.45% (w/v) sucrose/ 0.2M disodium EDTA/ 50% (v/v) 5x TBE). 
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CHAPTER THREE 
3. CHARACTERISATION OF VARIANT TRANSFERRINS SHOWING 
ABNORMAL ELECTROPHORETIC MOBILITY 
3.1. INTRODUCTION 
Since the discovery of transferrin polymorphism by Smithies (1957), at least 36 variant 
transferrin have been detected when human plasma is analysed by nondenaturing 
polyacrylamide gel electrophoresis (PAGE) at alkaline pH (Kamboh & Ferrell, 1987; 
Farhud et al., 1988). The majority of reports in literature concern the incidence and 
distribution of the variant proteins among human populations, with comparisons 
essentially restricted to differences in electrophoretic mobility. The differential 
electrophoretic mobilities of the variant transferrins are generally believed to be the 
result of a 
. 
single substitutional amino acid change that can be explained by a single 
nucleotide change in the respective codons (Yang et al., 1984; Kamboh & Ferrell, 
1987). The corresponding substitutions have been determined in relatively few variant 
transferrins, namely Tf D, (Wang & Sutton, 1965), Tf B2 (Wang et al., 1966), Tf Dctu 
(Wang et al., 1967), Tf DEv,,,,, s (Evans et al., 1988b) and Tf Bs.. ', (Welch & Langmead, 
1990). Likewise, iron-binding properties have been studied in relatively few transferrin 
variants, with only the Tf DE. (Evans et al., 1982,1984,1988b, 1994) and Tf BS,,,, W 
(Welch & Langmead, 1990) variants showing abnormal characteristics concerning iron 
bound at the C-lobe binding site. In this chapter, the iron binding and release properties 
of six transferrin variants and the wild-type Tf CI are compared to determine whether 
the variant transferrins show normal or abnormal characteristics. 
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3.2. RESULTS AND DISCUSSION 
3.2.1. COMPARISON OF DETECTED HUMAN TRANSFERRIN VARIANTS 
BY NONDENATURING PAGE 
Seven individuals showing abnormal transferrin phenotypes on nondenaturing PAGE 
were detected during a plasma survey of 653 students at Queen Mary & Westfield 
College. All seven individuals were found to show an electrophoretically abnormal 
transferrin band as well as a transferrin band indistinguishable from that of the wild-type 
Tf Cl (Fig. 3.1. ). 
Figure 3.1. Human transferrin variants detected by nondenaturing PAGE of plasma at 
pH 8.8. 
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Underlined names represent individuals in this study in whom abnormal transferrin phenotypes were 
detected. Other names denote abnormal phenotypes found by Evans et al., (1982) and Welch & Langmead 
(1990). 
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The abnormal transferrin bands in five individuals were characteristic of the slower 
moving transferrin bands associated with Tf Dv, R S, and were named Tf DBLUND , 
Tf DBB, Tf DSINGH, Tf DTAN and Tf DwoNo after the individuals in whom the abnormal 
phenotype was detected. The corresponding bands in the two other individuals were 
characteristic of the faster moving transferrin bands associated with TF BvAn.. TS, and 
were named Tf B I, and Tf B,,, ¢DD. An additional Tf B,,,, R,,, « was discovered in a 
plasma pack obtained from the London Hospital. As the source of the latter was not 
known, the variant protein was named Tf BFo, crRoT after a name found on the pack. As 
with most abnormal phenotypes, the variant transferrins were found in approximately 
equal proportions with Tf C implying codominant expression of both variant and normal 
transferrin alleles (Kamboh & Ferrell, 1987). As electrophoretic mobilities can be more 
accurately determined by the more sensitive system of isoelectric focusing, plasma 
samples of the eight individuals were analysed further by polyacrylamide isoelectric 
focusing (PAIEF) over a pH range of 5-7 (sec. 2.2.5. ). 
3.2.2. COMPARISONS OF ABNORMAL TRANSFERRIN PHENOTYPES BY 
PAIEF 
Figure 3.2. shows the resulting PAIEF gel for analysis of plasma from the eight 
individuals showing abnormal transferrin phenotypes. Figure 3.2. allowed certain 
tentative deductions to be made regarding the identity of the variant transferrins, on the 
basis of electrophoretic mobility and ethnic origin of the individuals in whom the 
proteins were found. None of the five Tf Dv s, namely Tf DBL E,, Tf DB, , 
Tf DSINGH, Tf DT,, Nand Tf DWONG correspond to the abnormal Tf DEVA,,, 5 variant (Evans et 
al., 1982), as none have an electrophoretic mobility identical to that of the latter. 
Tf DSINGH, Tf DT^,,., and Tf DWONG however appear to have identical mobilities suggesting 
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that they are the same protein. As Ms. Singh, Ms. Tan and Mr. Wong are all of Asiatic 
origin, it is proposed that they share the Tf D(.,,, variant which is found at polymorphic 
frequencies among Asiatic populations (Kamboh & Ferrell, 1987). 
Figure 3.2. PAIEF gel of the plasma of individuals showing abnormal electrophoretic 
transferrin phenotypes. 
(Origin) 
If B band, 
?; 
Tf D bands 
if (, 
(Anode Jý 'J 
j< XVC 
2 
W Ga Nr3möW 
F-- H Ew, HQQQQDQ H F- F- F- F- F- 
S. 
The ethnic origin of Ms. Burke also suggests that she may be carrying the Tf D, allele 
prominent among Afro-American and Afro-Caribbean populations. These observations 
are also supported by the established relative mobilities of the two variant transferrins, 
with Tf D(.,,, showing a more anodal mobility than IT D, (Fig. 1.16. ). Like the TI 
DVARVwrs, none of the Tf BVARIANTS detected in this study had an electrophoretic mobility 
identical to that of the abnormal Tf BSAW variant (Welch & Langmead, 1990), although 
they all showed very similar electrophoretic mobilities. Although the ethnic origin of the 
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individual in whom the Tf BFOXrROT variant was detected is not known, the ethnic origins 
of Mr. Khalili and Mr. Medd suggest that they all share the Tf B2 allele found at 
polymorphic levels among Caucasian populations. Therefore the only variant that 
appears to be new on the basis of electrophoretic comparisons in this study is Tf 
DBLU, DFLL, with an electrophoretic mobility between that of Tf DEv s and the three 
proposed Tf DcHI variants. 
3.2.3. CONFIRMATION OF MENDELIAN INHERITANCE OF DETECTED 
TRANSFERRIN PHENOTYPES 
Family studies were carried out to determine whether the abnormal transferrin 
phenotypes detected in individuals in this study were inherited from their parents. Blood 
samples were obtained from family members of Ms. Blundell, Ms. Burke, Ms. Singh 
and Mr. Medd, and the transferrin phenotypes determined by nondenaturing PAGE. The 
results in Figure 3.3. showed that in each case, the variant transferrin could be detected 
in one parent, and in the case of Ms. Burke, Ms. Singh and Mr. Medd, in at least one of 
their siblings. The abnormal transferrin phenotypes, and the observation that the variant 
transferrins are found in apparently equal proportions to TF C in polyacrylamide gels 
(sec. 3.2.1. ), can therefore be explained by maternal or paternal codominant inheritance 
of the respective variant alleles (Smithies & Hillier, 1958; Kamboh & Ferrell, 1987). 
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Figure 3.3. Family studies showing the inheritance of abnormal transferrin phenotypes. 
(i) Blundell Family (ii) Burke Family 
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The above symbols denote the following: 0= Tf C phenotype; Q= abnormal transferrin phenotype; 
individual in whom variant transferrin was detected in this study. 
3.2.4. PURIFICATION OF VARIANT TRANSFERRINS 
Six of the eight detected variant transferrins (i. e. Tf DBLº, t, DELL, Tf DBURKE, Tf DsºNGH, Tf 
BKHALILI, Tf BFOXTROT and Tf BMEDD) were purified by a series of chromatographic 
procedures. In addition, two of the most polymorphic Tf C subtypes, Tf Cl and Tf C2, 
were also purified for comparative studies. The following protocol is a description of the 
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procedures used to isolate and purify Tf DB, u,. EL,. All chromatographic procedures were 
performed at 10°C unless otherwise stated. 
Venous blood (approximately 50m1) was taken from the individual into 20m1 Seward 
tubes containing ethylenediamine tetraacetic acid (EDTA) and mixed to prevent 
coagulation. The sample was centrifuged at 2500rpm for 20min and the plasma 
removed. Packed red cells were washed with an equivalent volume of physiological 
saline (0.85% w/v) and centrifuged under the same conditions to remove the remaining 
plasma. 30µl of 100mM ferric nitriloacetate (FENTA) (sec. 2.2.11. ) and 500µl 0.5M 
sodium bicarbonate (NaHCO, ) were added to the pooled plasma sample (45ml, 
approximately 1: 1 dilution with saline). Under such conditions, binding of iron to 
transferrin is favourable and the transferrin in the pooled sample would be expected to 
be in the holo form. The iron-saturated plasma sample was dialysed overnight against 
20mM NaCU 10mM Tris-HCI (pH 8.3), and then loaded onto a diethylaminoethyl 
(DEAE) Sephacel anion exchange column (size, 25x3.2cm; bed volume, 130m1) 
equilibrated with the same buffer (sec. 2.2.1.1. & 2.2.1.4) at a flow rate of 30m1/hr. 
Bound proteins were eluted at the same flow rate using a linear salt gradient of 20- 
150mM NaCU 10mM Tris-HCI (pH 8.3). Samples were collected at 15min intervals 
(7.5m1 fraction volume). As holo transferrin has a distinctive salmon pink colour with 
an absorption maximum at 470nm, fractions were monitored against a buffer blank at 
470nm and also at 280nm (for protein), to produce an elution profile for the column 
(Fig. 3.4. ). 
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Figure 3.4. Elution profile for the chromatography of Blundell plasma on a DEAE 
Sephacel anion exchange column. 
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Figure 3.4. proved to be ineffective for locating the position of holo transferrin in the 
eluted fractions on the basis of 470nm readings, since there were a number of 470nm 
peaks from other proteins such as albumin which -has a red/orange colour with an 
absorption maximum around the 470nm region. Aliquots from fractions spanning the 
elution profile were therefore analysed on 10% (v/v) nondenaturing polyacrylamide gels 
(sec. 2.2.2.2. ). Fractions subsequently found to contain both normal and abnormal 
transferrin (Fig. 3.4. ) were pooled and concentrated by pressure filtration (9.2m1). The 
concentrated sample was then loaded at a flow rate of 
IOml/hr onto a Sephadex G-200 
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gel filtration column (size, 100x2cm; bed volume, 280m1) equilibrated with 0.2M NaCV 
0.1 M Tris-HCI (pH 8.0) (sec. 2.2.1.3. & 2.2.1.6. ), and eluted at the same flow rate with 
the equilibrating buffer. Fractions were collected every 20min (2.5ml fraction volume). 
Absorbances were monitored at 280nm and 470nm to produce an elution profile (Fig. 
3.5. ). 
Figure 3.5. Elution profile for the fractionation of pooled Blundell transferrin on a 
Sephadex G-200 gel filtration column. 
I 
4.50 
4.00 
3.50 
3.00 
2.50 
2.00 
1.50 
1.00 
0.50 
0.00 
nf CA 
J. I. )U 
3.100 
0 
L,. 
w 0 
V4 
A 
1 
0 
Ad 
N 
P 
O 
0.050 
0.000 
______ Absorbance 
(470nm) 
1 
, 
ii 
o °ý . 
°r s) . 
°o 
C4 
Fraction number 
From the elution profile, fractions containing holo transferrin were pooled (approx. 
38ml) and dialysed overnight against 55mM NaCl/ 10mM Tris-HCI (pH 8.3). The 
dialysed sample was loaded onto a second DEAE Sephacel anion exchange column 
I 
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(size, 25x 1.6cm; bed volume, 80m1) equilibrated with the dialysis buffer, at a flow rate 
of 30ml/hr. From the buffer gradient and elution profile of the first DEAF Sephacel 
column, it was estimated that transferrin was eluted between a buffer concentration of 
60-80mM NaCU 10mM Tris-HCl (pH 8.3). A shallow salt gradient of 55-75mM NaCl/ 
10mM Tris-HCI (pH 8.3) was therefore used on the second DEAE column, and 
fractions collected at 15min intervals (7.5m1 volume). Absorbances were again 
monitored at 280nm and 470nm. However, because the shallow buffer gradient used to 
elute the bound proteins resulted in much slower elution of proteins (relative to the first 
DEAE column), fractions were found to contain samples of a more diluted nature. 
Subsequently, the 470nm absorbances were found to be much lower than those of the 
first DEAE column (i. e. lower than 0.01) with no distinct peaks to indicate the location 
of iron-saturated transferrin. The 280nm readings were therefore used to produce the 
corresponding elution profile (Fig. 3.6. ). Aliquots of fractions were analysed on 10% 
(v/v) nondenaturing polyacrylamide gels (Fig. 3.7. ). Analysis showed partial separation 
of the two transferrins with the abnormal transferrin being eluted in the early half of the 
elution profile, and the normal transferrin trailing (Fig. 3.6. ). Fractions predominantly 
containing the abnormal transferrin (Tf DBLuNDE,, ) were pooled, concentrated by pressure 
filtration (11m1) and stored at -20°C. Middle crossover fractions containing both 
transferrins (Fig. 3.6. ) were pooled, concentrated (10.5ml) and diluted with one quarter 
volume double-distilled deionised water to reduce the salt concentration. 
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Figure 3.6. Elution profile for the chromatography of pooled Blundell transferrin on a 
DEAE Sephacel column. 
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Figure 3.7. Nondenaturing PAGE of fractions eluted from a DEAE Sephacel column 
using a shallow buffer gradient of 55-75mM NaCI/ 10mM Tris-HCI (pH 8.3. ). 
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The middle crossover fraction was re-chromatographed on the DEAE Sephacel column 
used in the previous purification step following re-equilibration of the column with 
55mM NaCU 10mM Tris-HC1(pH 8.3). The flow rate and fraction size were maintained 
at 30m1/hr and 7.5m1 respectively. It was however noted that as the sample was loaded 
onto the column, the leading interface of the salmon pink transferrin band became more 
diffuse suggesting that the conditions of the column were sufficient for elution of the 
protein. The elution buffer was therefore maintained at 55mM NaCl/ 10mM Tris-HC1 
(pH 8.3). For the reason described above regarding low 470nm absorbances, fractions 
were monitored against a buffer blank at 280nm (Fig. 3.8. ). Aliquots analysed on 10% 
(v/v) nondenaturing polyacrylamide gels showed a comparatively greater degree of 
separation between the two transferrin forms using the single elution buffer step. 
Fractions containing predominantly abnormal Tf Df LuNDEU were pooled, concentrated 
and added to the Tf DBLUNDELL sample from the previous column. The residual crossover 
fractions containing minimal amounts of abnormal transferrin (Fig. 3.8. ) were pooled 
and stored at -20°C. The Tf DBLUNDELL sample was put through a final anion exchange 
chromatography step on the DEAE Sephacel column used in the last stage, to remove 
any trace of normal transferrin. Conditions were maintained as above and fractions 
monitored at 280nm to determine the elution profile (Fig. 3.9). Fractions were analysed 
on 10% (v/v) nondenaturing polyacrylamide gels (Fig. 3.10. ), and those only containing 
Tf DBLuNDELL pooled and concentrated (5.9m1) (Fig. 3.9. ). 
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Figure 3.8. Elution profile following chromatography of pooled crossover fractions on 
a DEAE Sephacel anion exchange column. 
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Figure 3.9. Elution profile following chromatography of pooled Tf DBL,. NDELL on a 
DEAE Sephacel anion exchange column. 
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Figure 3.10. Analysis of fractions on 10% (v/v) nondenaturing polyacrylamide gels 
following chromatography of pooled Tf DBLUNDELL on a final DEAE Sephacel anion 
exchange column. 
y. . Iº* "0-0&a uI/ fto on* a" fto rfto so* 0-0 - 
The above symbols denote the following: I& 20 = plasma; 2-19 = fractions 63-103 
The concentrated Tf DBLUNDELI. sample was dialysed overnight against 20mM trisodium 
citrate (pH 5.1). Under the low pH condition, the affinity of transferrin for iron is low 
and the iron dissociates from the diferric transferrin leaving it in the colourless 
apotransferrin form. The released iron is chelated to the buffer citrate and therefore 
prevented from re-binding to the apotransferrin. The dialysed sample was then loaded 
onto a Sulfopropyl (SP. ) Sephadex C50 cation exchange chromatography column (size, 
25x 1.6cm; bed volume, 45ml) equilibrated with the dialysis buffer (sec. 2.2.1.2. & 
2.2.1.4. ), at a flow rate of 15rnl/hr. The column was washed with the same buffer and 
fractions collected at 20min intervals (5ml volumes). The absorbance at 280nm was 
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monitored against a buffer blank until the 280nm readings had returned to baseline. The 
main contaminating protein removed by this procedure is plasma haemopexin (Welch & 
Langmead, 1990). The bound transferrin was subsequently removed by washing the 
column with the same buffer at a higher pH of 5.6. Absorbances at 280nm were 
monitored to produce the following elution profile (Fig. 3.11. ). 
Figure 3.11. Elution profile of apo Tf DBLL, NDELL following chromatography on a SP. 
Sephadex C50 cation exchange column. 
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From the above elution profile, fractions 23-27 were pooled (approximately 25ml) and 
freeze-dried to approximately 2m1. The apotransferrin sample was then loaded onto the 
G-200 gel filtration column used for the second purification step. Conditions were 
maintained as described before and the absorbance monitored at 280nm (Fig. 3.12. ). 
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Figure 3.12. Elution profile for the final fractionation of IT DLUNDELL on a Sephadex 6- 
200 gel filtration column. 
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Figure 3.13. Analysis of fractions on 10% (v/v) nondenaturing polyacrylarnide gels 
following fractionation on a Sephadex G-200 gel filtration column. 
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Fractions were analysed on 10% (v/v) nondenaturing polyacrylamide gels (Fig. 3.13. ), 
and fractions 68-82 pooled, concentrated (23ml) and desalted at room temperature on a 
Sephadex G-25 fine gel filtration column (size, 50x3.2cm; bed volume, 230m1) 
equilibrated with double-distilled deionised water (sec. 2.2.1.3. & 2.2.1.4. ) at a flow rate 
of 45ml/hr. Fractions were collected at 12min intervals (9.0ml volume) and monitored 
at 280nm against a water blank. The resultant elution profile (not shown) was found to 
be very similar to that found for calibration of the desalting column (Fig. 2.1. ). Fractions 
11-19 were pooled, freeze-dried and stored as a powder at 4°C. 
Purification of the other variant transferrins followed a similar protocol. The main 
difference was that for the faster moving Tf B s, the variant transferrins were found 
to be eluted after normal transferrin, presumably as a result of their relatively higher net 
negative charges. The more common Tf Cl and Tf C2 proteins were isolated from 
individuals showing only Tf Cl and Tf C2 phenotypes respectively. Since there was 
therefore only one type of transferrin in each case, a single DEAE Sephacel anion 
exchange column was used after the first G-200 gel filtration column, and the proteins 
eluted with 55mM NaCl/ 10mM Tris-HC1(pH 8.3). Samples were then put through the 
SP. Sephadex and second G-200 gel filtration column as described above. The purities 
of the isolated transferrins were then assessed by silver stained (sec. 2.2.6.2. ) 
nondenaturing and SDS (sec. 2.2.3. ) polyacrylamide gels. 
3.2.5. PURITY AND RECOVERY OF ISOLATED TRANSFERRINS 
Figures 3.14. and 3.15. show the purity of the isolated proteins on silver stained 
nondenaturing and SDS polyacrylamide gels respectively. Both gels showed that the 
variant transferrins were free of normal transferrin and that contamination with other 
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Figure 3.14. Nondenaturing PAGE of purified apo transferrins at pH 8.8. 
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Figure 3.15. SDS PAGE of purified apo transferrins. 
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proteins was minimal. The recovery of variant and normal transferrins are shown in 
Table 3.1. Starting and final transferrin concentrations were determined by single radial 
immunodiffusion (sec. 2.2.9. ). 
Table 3.1. The recovery of variant and normal transferrins after purification. 
Transferrin Volume of 
starting 
plasma (ml) 
Total plasma 
transferrin 
concentration 
(mg/ml) 
Total plasma 
transferrin 
(mg) 
Total 
purified 
transferrin 
(mg) 
% 
recovery 
TfCI 700 2.6 1820 580 32 
Tf C2 64 2.4 154 43 28 
Tf DBLUNDELL 25 2.8 70 8 11 
Tf DBB 29 2.1 61 5 8 
Tf DSINGH 30 2.4 72 6 8 
Tf BFOXTROT 190 2.9 551 66 12 
Tf Biuw. iu 28 2.4 67 5 8 
Tf BMEDD 30 2.6 78 11 14 
Table 3.1. shows that the successive loss of material during the various chromatographic 
steps required to separate the variant transferrin from normal transferrin and other 
proteins, limited the amount of recovered protein to about 1/10 of the transferrin content 
in the plasma samples. It should however be noted that whereas the Tf Cl and Tf C2 
proteins were purified from plasma samples containing only the respective transferrins, 
variant transferrins were purified from plasma containing both normal and variant 
transferrin. The percentage recoveries for the variant transferrins therefore represent a 
fraction of the total transferrin content, approximately half of which consists of variant 
transferrin. 
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3.2.6. CONFIRMATION OF ISOLATED PROTEINS AS TRANSFERRIN 
To ensure that the isolated proteins were transferrins, aliquots of the purified proteins 
were analysed by Western Blot using a rabbit anti-human transferrin specific antibody 
(sec. 2.2.7. ). Figure 3.16. shows the subsequent analytical gel which shows that the anti- 
human transferrin antibody was bound by all isolated proteins, confirming that they 
were indeed transferrin. 
Figure 3.16. Western Blot analysis of isolated proteins following SDS PAGE. 
(Origin) 
Tf 
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The above numbers denote the following: 1& 10 = Tf C1 plasma; 2= Tf C 1; 3= Tf C2; 4= Tf DBLUNII II; 
5= Tf DBURKE; 6= Tf DSINGH; 7= IT BPOXTROT; 8= Tf BKf1ALILb 9= Tf BMFDD. 
3.2.7. DETERMINATION OF MOLECULAR WEIGHTS OF VARIANT 
TRANSFERRINS 
The primary sequences of the five transferrin variants, Tf D, (Wang & Sutton, 1965), If 
B, (Wang et al., 1966), Tf D,, i, (Wang et al., 1967), Tf (Evans et al., 1988b) and 
Tf BS,,,, w (Welch & Langmead, 1990) all show a single amino acid substitution. The 
molecular weights of the variant proteins would therefore be expected to be the same as 
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that of Tf C. The molecular weights of the apo and holo forms of the isolated proteins 
were therefore determined by both SDS PAGE and gel filtration chromatography as 
described below. 
3.2.7.1. MOLECULAR WEIGHT ESTIMATION BY SDS PAGE 
The molecular weights of the denatured apo and holo forms of variant and normal 
transferrins were determined in triplicate by SDS PAGE. Molecular weights were 
estimated from calibration curves of Log, o K. protein standards versus migration 
distance (Fig. 3.17. ), where the latter was taken as the distance from the start of the 
resolving gel to the centre of the respective transferrin protein. In all cases, the estimated 
molecular weights of the apo (79833 ± 493) and holo (79216 ± 328) variant transferrins 
were found to be the same as that of Tf Cl. As the apo and holo transferrin samples 
were analysed on separate gels, a further gel containing triplicate samples of apo and 
holo Tf Cl was run to establish whether the small difference between the two values 
were due to inter-gel disparities (Fig. 3.18. ). Figure 3.18. confirmed that the molecular 
weights of the apo and holo forms of Tf C1 (and therefore the other variant transferrins) 
were indistinguishable from each other on 10% (v/v) SDS polyacrylamide gels, at 79433 
(n=3). 
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Figure 3.17. Calibration curve for the determination of molecular weights of denatured 
proteins by SDS PAGE. 
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The above numbers denote the following marker proteins: I= Phosphorylase B (94000); 2= Bovine 
serum albumin (67000); 3= Ovalbumin (43000); 4= Carbonic anhydrase (30000); 5= Soybean trypsin 
inhibitor (20100); 6= a-Lactalbumin (14400). 
Figure 3.18. Confirmation of molecular weights of apo and hold Tf CI by S1S PAG1?. 
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3.2.7.2. MOLECULAR WEIGHT DETERMINATION BY GEL FILTRATION 
CHROMATOGRAPHY 
The molecular weights of the native apo and holo forms of the purified proteins were 
determined using a G-200 gel filtration chromatography column (sec. 2.2.1.5. ). The 
column was calibrated by running duplicate samples of molecular weight marker 
proteins through the column. The molecular weights of the apo and holo proteins were 
then estimated in duplicate against a calibration curve of Logo M, r marker proteins 
versus the peak elution fraction of the respective proteins (Fig. 3.19. ). 
Figure 3.19. Calibration curve for the determination of molecular weights of native 
proteins by gel filtration chromatography. 
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The above numbers denote the following marker proteins: I= ß-amylase (200000); 2= Alcohol 
dehydrogenase (141000); 3= Bovine serum albumin (66000); 4= Ovalbumin (43000); 5= Cytochrome C 
(12384). 
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The estimated molecular weights of the native apo and holo forms of Tf Cl and the 
other variant transferrins were found to be indistinguishable at 83170 (n=2). The 
apparent molecular weights obtained by both the SDS PAGE and G-200 gel filtration 
systems therefore showed that all variants had the same molecular weight as Tf Cl. The 
values obtained in this study are in agreement with those reported in literature. Although 
the denatured molecular weight of 79433 obtained in this study is higher than the value 
of 77000 reported by Bobäk et at., (1984) and Welch & Skinner (1989), and the value of 
77230 reported by Welch (1990), it is within the range of published molecular weights 
reported by Bobäk et al., (1984) of 66000-95000. Likewise, although the native 
molecular weight of 83170 is higher than the calculated value of 79570 (MacGillivray 
et al., 1982,1983), it is similar to the value of 81500 reported by Welch & Langmead 
(1990). Differences between the apparent molecular weights of the two systems were 
not unexpected as they represent two different states of the proteins. Neither system was 
however capable of differentiating between the apo and holo forms in this study, 
although iron-binding increases the net negative charge of the protein by the loss of 
three protons per bound iron, and also induces a conformational change that makes the 
protein more compact (Aisen & Listowsky, 1980). The results are therefore similar in 
this respect to the results of Welch & Langmead (1990), who found that the apo and 
holo forms were indistinguishable by gel filtration chromatography. They are however 
different to those reported by Welch & Skinner (1989) of a higher native molecular 
weight for apotransferrin (84500) than for holotransferrin (83000). 
149 
3.2.8. EFFECT OF SIALIC ACID REMOVAL ON ELECTROPHORETIC 
MOBILITIES OF TRANSFERRIN VARIANTS 
As transferrin is a glycoprotein with two N-linked glycan chains, electrophoretic 
differences may also be attributed to the nature of the sidechain as these may vary in 
terms of the degree of branching and the number of negatively charged terminal sialic 
acid residues (Spik et al., 1985; de Jong & van Eijk, 1989; de Jong et al., 1990). The 
effect of sialic acid removal on the electrophoretic mobilities of the variant transferrins 
was therefore investigated by digesting plasma samples with the enzyme neuraminidase 
(Vibrio cholera), which removes sialic acid residues. 5 t1 of plasma (duplicates) was 
added to 5µl of a reaction buffer containing 0.1M sodium acetate/ 0.01M CaNO3 (pH 
5.0), mixed and then digested with 2µl neuraminidase (0.5U/µ1). Samples were 
incubated for 24hr at 37°C before adding 1. OM Tris-HC1 (pH 8.8) to raise the reaction 
pH. 2µl 0.5M NaHCO3 and lpl 100mM FENTA were added to fully saturate the 
transferrin content, and the samples left for 30min to ensure complete binding. Normal 
and sialic acid-free samples were analysed by nondenaturing PAGE (Fig. 3.20) which 
showed that removal of sialic acids resulted in an expected decrease in anodal mobility 
for all variant transferrins and Tf C. However, sialic acid removal did not affect the 
differences in mobility between Tf C and the respective variant transferrins. The 
uniformity of the reduction in electrophoretic mobility implied that the abnormal 
transferrin phenotypes were not due to sialic acid content. 
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Figure 3.20. Nondenaturing PAGE showing the comparative electrophoretic mobilities 
of normal and sialic acid-free variant transferrins. 
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3.2.8.1. SIALIC ACID CONTENT OF ISOLATED VARIANT TRANSFERRINS 
The sialic acid content of the variant transferrins were determined by sequential removal 
using neuraminidase. The protocol was established using Tf Cl and then extended to the 
other proteins. 10µ1 neuraminidase (0.5U/µl) was added to 500µl of a 0.5mg/ml apo Tf 
C1 solution in OA M sodium acetate/ 0.01M CaNO3 (pH 5.0). The solution was 
thoroughly mixed and then incubated at 37°C. 12µl aliquots of the reaction sample were 
removed at 2,4,6,12,18,24,30,36,42,48 and 72hr after addition of neuraminidase. 
2 i1 1. OM Tris-HC1 (pH 8.8), 2µl 0.5M NaHCO3 , and I µl 100mM FENTA were 
immediately added to each aliquot after removal, mixed, left for 1 min to ensure 
complete binding and then stored at -20°C until required. A control sample was 
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obtained by adding the same volume of 1. OM Tris-HCI (pH 8.8), 0.5M NaHCO3 , and 
100mM FENTA to 12µ1 of an apo Tf CI solution (500µl apo Tf C1 in OA M sodium 
acetate/ 0.01M CaNO3 added to 10µl water). 5µJ of each aliquot was then added to 5µ1 
urea sample buffer and analysed by 6M urea-PAGE (sec. 2.2.4. ). The results (not 
shown) indicated that full sialic acid removal was obtained by 24hr. The study was then 
extended to the other proteins using similar protein concentrations. Aliquots were 
removed at 0.25,0.5,0.75,1.0,1.5,2.0,2.5,3.0 and 24hr, and analysed on 6M urea 
gels. The results for Tf DS, NG, i are shown in Figure 3.21. The gel shows that Tf DSING has 
a total of 4 sialic acid residues, a result also found for Tf Cl and the other variant 
transferrins. 
Figure 3.21.6M urea-PAGE of Tf DSINGt, following digestion with neuraminidase to 
remove terminal sialic acids. 
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The above numbers denote the following: 4= fourth sialic acid residue; 3= third sialic acid residue; 2= 
second sialic acid residue; I= first sialic acid residue; 0= sialic acid-free transferrin 
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All eight isolated transferrins therefore appeared to possess the tetrasialotransferrin 
isoform predominant in human plasma (Spik et al., 1985; de Jong & van Eijk, 1989; de 
Jong et al., 1990). The effect of sialic acid removal on iron binding was studied using 
350µ1 of the remaining reaction solution. The aliquots were added to l0µl 1. OM Tris- 
HC1(pH 8.8), 10µl 0.5M NaHCO3 and 2 i1 100mM FENTA, mixed and left for 30min 
at room temperature. The same procedure was carried out for the control apo Tf C1 
sample. Absorbances at 470nm were then monitored against an equivalent sample 
blank. In all cases, absorbances of the test samples were found toAalmost identical to that 
of the control sample, indicating that removal of terminal sialic acid residues had no 
effect on iron binding. Since both the sialic acid content and apparent molecular weights 
of the variant transferrins appear to be identical to that of Tf C 1, it is proposed that their 
different electrophoretic mobilities on polyacrylamide gels are due to a substitutional 
change in their primary sequence in a manner similar to that described for Tf D. (Wang 
& Sutton, 1965), Tf B2 (Wang et al., 1966), Tf Dc« (Wang et al., 1967), Tf DEV, ws 
(Evans et al., 1988) and Tf Bs,., p, W (Welch & Langmead, 1990). 
3.2.9. ISOELECTRIC POINTS OF ISOLATED TRANSFERRINS 
The different charge density that results in the different electrophoretic mobilities of the 
variant transferrins mean that their isoelectric points would be different to that of Tf Cl. 
Isoelectric points of the apo and holo forms of variant and normal transferrin were 
determined by PAIEF. Apo and holo samples were first desalted through a G-25 fine 
desalting column (sec. 2.2.1.6.2. ) to reduce the volumes and to increase the protein 
concentrations. Samples and markers were loaded in triplicate as described (sec. 2.2.5. ). 
Isoelectric points estimated from a calibration curve of isoelectric point of marker 
proteins against migration distance (Fig. 3.22. ), where the latter is the distance from the 
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Figure 3.22. Calibration curve for the determination of isoelectric points of transferrin 
variants. 
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The above numbers denote the following marker proteins: 1,2 &3= Lentil lectin; 4= Human 
haemoglobin C; 5= Human haemoglobin A; 6= Equine haemoglobin; 7= Human carbonic anhydrase; 8 
= Bovine carbonic anhydrase; 9= ß-Lactoglobulin B; 10,11 & 12 = Phycocyanin 
Table 3.2. Comparative isoelectric points of apo and holo transferrins measured by 
PAIEF 
Transferrin Isoelectric point - apo 
transferrin (mean ± s. d.; n= 3) 
Isoelectric point - holo 
transferrin (mean ± s. d.; n= 3) 
Tf Cl 5.92 ± 0.02 5.26 ± 0.02 
Tf C2 5.97 ± 0.02 5.32 ± 0.02 
Tf DBLUNDELL 6.05 ± 0.00 5.56 ± 0.02 
Tf DBURKE 6.00 ± 0.00 5.45 ± 0.00 
Tf DSINGH 6.00 ± 0.00 5.40 ± 0.00 
Tf BFOXTROT 5.76 ± 0.02 5.13 ± 0.00 
Tf BKHALILI 5.75 ± 0.00 5.12 ± 0.02 
Tf BMEOD x. 74 ± 0.01 5.13 ± 0.00 
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cathode to the centre of the respective protein band, is shown in Table 3.2. As expected, 
the estimated isoelectric points of the apo and holo variant transferrins were different to 
those of Tf C 1. It was however noticeable that the three proposed Tf B2 variants, namely 
Tf BFOxTROT, Tf B1H1 ,, I, 1 and Tf BMEDD (sec. 3.2.2. ) all had very similar isoelectric points 
for both the apo and holo forms. The isoelectric points for both states of Tf Cl fall 
within the range reported by Hovanessian & Awdeh (1976) of 5.2 -- 5.9 (apo --* holo), 
with the holo isoelectric point showing a similar value to the isoelectric point of 5.35 
reported by Welch (1990). They are however different from the range suggested by de 
Jong et al., (1990) and Bean & Peter (1994) of about 5.4 -* 6.1 (apo -* holo). 
3.2.10. DIFFERENCE SPECTRA FOR METAL-TRANSFERRIN COMPLEXES 
The primary function of human plasma transferrin is to transport iron within the body. 
However, transferrin in circulation is only about 30% saturated with iron (Liebman & 
Aisen, 1979) and is therefore potentially capable of binding other metal ions in the body. 
Various metals including first transition series metals, lanthanides and actinides are 
known to bind to the protein (Harris, 1977,1983,1986; Harris & Aisen, 1989; Zak & 
Aisen, 1988; Taylor et al., 1987). The various metal-transferrin interactions produce 
either coloured or colourless complexes with , max in the UV or visible spectrum. Other 
than Fe'+, the most studied metal-transferrin complexes are those of Cu"' (Garratt et al., 
1991; Smith et al., 1992; Hirose et al., 1996), Al" (Tomimatsu & Donovan, 1976; 
Harris & Pecoraro, 1983; Tang et al., 1995) and Ga" (Harris & Pecoraro, 1983; Kubal et 
al., 1993). All four metal-transferrin complexes show , max in the UV region because of 
perturbations of ionised Tyr or Trp at the metal-binding site (Harris & Aisen, 1989; 
Baker, 1994). Unlike the colourless Al" and Ga 3+ complexes, Cuz+ and Fei interactions 
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also produce pale yellow and salmon-pink complexes respectively, with , max in the 
visible spectrum as a result of a Tyr phenolate --* metal charge transfer. Although Cue+, 
Zn2'' and Al' are known to bind to both metal-binding sites of transferrin, studies by 
Evarset al., (1984,1994) found that binding of the three metal ions was restricted to the 
N-lobe site of the variant transferrin, Tf DEVMZS. The ability of the variant transferrins 
isolated in this study to bind Fe'+, Cu*. eAl" and Ga" ions were therefore studied to 
determine whether they showed normal or abnormal transferrin metal-binding 
characteristics. The difference spectra (Fig. 3.23. ) for binding of Fe", Cue+, All" and Ga'+ 
Figure 3.23. Difference spectra for the binding of Fe'*, Cu, Al" and Ga" to Tf Cl at 
pH 7.5. 
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was left for lhr at room temperature to ensure complete binding, and the absorbance 
determined against a sample blank (0.5 ml apo Tf Cl plus 2µl 100mM NTA) over a 
wavelength range of 200-600nm. Based on the above spectra, the binding of Al" and 
Ga" to transferrins in the ensuing titration studies were monitored at 238nm and 242nm 
respectively (i. e. at their largest , max). Binding of Fe" and Cu"' were however 
monitored at 470nm and 440nm respectively, because changes in , max in the visible 
spectrum were large enough to allow accurate titration, and were separated from the 
cluster of , max in the UV region. 
3.2.10.1. IRON-BINDING PROPERTIES OF VARIANT TRANSFERRINS 
The iron binding and release characteristics of the variant transferrins were studied at 
two pH values, 7.5 and 5.5, representing the physiological and endosomal pH 
respectively (Aisen & Listowsky, 1980; Yamashiro et al., 1983). Binding studies were 
performed in triplicate, and the mean absorbances used to produce the spectra shown in 
the following sections. 
3.2.10.1.1. ABSORPTION SPECTRA FOR HOLO TRANSFERRINS 
Site-directed mutagenesis studies have shown that most mutations of amino acids in and 
around the metal-binding sites of transferrin and lactoferrin alter the value of , max and 
affect the strength of metal-binding (Woodworth et al., 1991; Nicholson et al., 1996). A 
similar observation was found for the Tf DEVANs variant (Evans et al., 1982) which had a 
lower Xmax at 435nm, indicating that the protein formed an abnormal ligand with at 
least one of the bound irons. Subsequent studies indicated that the iron-ligand Asp392, 
was withdrawn from the iron-coordination sphere at the C-lobe site, as a result of 
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interactions with a substituted Arg394 residue (Evans et al., 1994). The absorbance 
spectra for variant holo transferrins in this study were therefore monitored over a 
wavelength range of 400-600nm, to determine whether they showed a similar blue shift 
in their visible spectrum. 0.5m1 solutions of apotransferrin (1.6-5.0 x 10-'M; buffered in 
0.5M Tris-HC1 (pH 7.5)/ 30mM NaHCO3) were fully saturated with iron (2 t1 100mM 
FENTA), and the absorbance monitored against a sample blank (0.5m1 apotransferrin 
plus 2µl 100mM NTA). The spectra obtained for all variant transferrins (results not 
shown) were similar to that of Tf Cl with Xmax between 465-470nm, implying that the 
proposed amino acid substitutions of the variant transferrins were not interfering with 
normal iron binding. The results are therefore similar to that found for the abnormal Tf 
BS,, AW variant which showed a , max at 463nm (Welch & Langmead, 1990). 
3.2.10.1.2. TITRATION OF TRANSFERRINS WITH IRON AT PH 7.5 
The two metal-binding sites of transferrin are known to show different characteristics at 
pH 7.5, with the C-lobe site showing a higher affinity for iron (log K, = 20.6) than the 
N-lobe site (log K2 = 19.4) (Aisen et al., 1978). The iron-binding properties at pH 7.5 of 
the isolated variant transferrins were studied using FENTA, which gives preferential 
iron loading at the C-lobe site at alkaline pH (Evans & Williams, 1978). 1. Oml solutions 
of apotransferrin (1.6-5.0 x 10-'M; buffered in 0.5M Tris-HC1 (pH 7.5)/ 30mM 
NaHCO3) were titrated with iron by the addition of Spl 1.0mM FENTA. Iron binding 
was monitored against a sample blank by following the increase in absorbance at 470nm 
after each addition of 1.0mM FENTA (1.0mM NTA for sample blank) until there were 
no further increases. Absorbances were taken at equilibrium (lmin after addition of 
metal) and plotted against r (ratio of the total number of moles of iron to the total 
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Figure 3.24. Titration spectra for the addition of 1.0mM FENTA to apotransferrins at 
pH 7.5. 
I 0 
N 
du 
C 
OJE 
0.1E 
0.14 
0.12 
0.10 
0.080 
0.060 
0.040 
0.020 
0.000 IF 1 -1-- 1 l« 00000 oýoýo OO .r .rN 
r (moles Fe/moles Tf) 
o Tf DBLUNDIIL 
o Tf DB(JRKE 
o Tf DSINGH 
e Tf Cl 
  TfC2 
" Tf BFOXTROT 
" Tf B11U 
IT Tf B&IM 
Table 3.3. Moles of iron bound per mole transferrin determined from iron titration at 
pH 7.5. 
Transferrin Moles iron bound per mole 
transferrin (mean ± 5. d.; n= 3) 
TfC1 2.07 ± 0.15 
Tf C2 2.07 ± 0.09 
Tf DBLUNDELL 2.23 ± 0.09 
Tf DBURKE 1.91 ± 0.05 
Tf DSINGH 2.06 ± 0.14 
Tf BFOXTROT 2.02 ± 0.10 
Tf BKHALuj 2.04 ± 0.09 
Tf BMEpp 2.21 ± 0.10 
159 
number of moles of transferrin) to give the respective titration curves (Fig. 3.24. ). The 
resulting spectra for each variant transferrin showed that a linear plot was generated in 
the early stages of titration as essentially all added iron was bound by the protein. 
However, as the titration proceeded, saturation of the first iron-binding site, and 
accumulation of free NTA which can compete with the protein for iron, resulted in 
smaller increases in absorbance as less iron bound to the protein. The titration curves 
show a plateau at full saturation with further additions of iron failing to bind to the 
proteins. The amount of iron required to saturate the various transferrins in the three 
experiments were then used to determine the mean number of moles of iron bound per 
mole transferrin (Table 3.3. ), which indicated that iron was bound at both sites of the 
variant transferrins. Although the titration spectra shown in Fig. 3.24. serves as a means 
of determining the amount of iron bound, it is not a true qualitative indicator of the 
binding affinities of the various transferrins as the spectra were obtained using different 
concentrations of apoproteins. A more comparative graph was therefore obtained by 
plotting percentage iron saturation of transferrins against r (Fig. 3.25. ) where percentage 
saturation was obtained by the equation: [(absorbance / absorbance at saturation) x 100]. 
The plots showed that Tf CI and all variant transferrins appeared to have similar 
binding affinities for iron. The distribution of iron between the two binding sites 
following titration was then assessed to determine whether the variant transferrins also 
showed the preferential C-site loading expected for iron titration with FENTA. Aliquots 
of 1.0mM FENTA calculated to give 12.5,25,37.5,50,62.5,75,87.5 and 100% iron 
saturation (from Figure 3.25) were added to 1. Oml samples of the apoproteins, and 5µl 
sample aliquots removed after each addition. The sample aliquots were analysed by 6M 
urea-PAGE. Figure 3.26. shows the resulting analytical gel for titration of Tf Dß,, urroEU.. 
Figure 3.25. Percentage saturation versus r for apotransferrins titrated with iron at pH 
7.5. 
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Figure 3.26.6M urea-PAGE of Tf DR,, uNDE,, L at different degrees of iron saturation at pl l 
7.5. 
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The above gel confirmed that iron binding at pH 7.5 by Tf DBLUNDELL followed the 
expected pattern with iron binding first to the C-site, before binding to the N-site 
(Princiotto & Zapolski, 1975; Harris, 1977; Aisen et al., 1978; Aisen & Listowsky, 
1980). The analytical gels for Tf Cl and other variant transferrins showed similar 
distributions of the four iron-containing transferrin forms. The above qualitative 
comparisons therefore showed that all variant transferrins appeared to have similar iron- 
binding affinities. Quantitative comparisons of the iron-binding affinities were obtained 
from plots of DE versus r, where As is the absorbance at 470nm divided by the total 
transferrin concentration (taking into account sample dilution after each addition of 
iron). Figure 3.27. shows the resulting spectra obtained from Figure 3.24. 
Figure 3.27. Plots of As versus r for titration of apotransferrins with iron at pH 7.5. 
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The continued increases in As values beyond r=1, supported the earlier observations 
that both metal-binding sites of Tf Cl and variant transferrins were occupied by iron. 
The slopes of the initial linear portions of the spectra represent the molar absorptivity of 
the iron-transferrin complex (AE470. ) which provides a quantitative comparison of the 
iron binding-affinities as it relates to the region of the titration curve where virtually all 
added iron is bound to the proteins (Harris & Pecoraro, 1983; Harris, 1983). Table 3.4 
shows the DEoi, values for Tf Cl and variant transferrins derived from plots of As 
versus r. 
Table 3.4. Calculated molar absorptivity (DE(,,,,, ) values for iron-transferrin complexes 
at pH 7.5. 
Transferrin DEoom (M''cm'') 
(mean ± s. d.; n= 3) 
Tf Cl 1692 ± 33 
Tf C2 1680 ± 53 
Tf DBLUNDELL 1724 ± 42 
Tf DBURKE 1457 ± 50 
Tf DswGH 1704 ± 58 
Tf BFOXTROT 1593 ± 23 
Tf BKHALat 1865 ± 61 
Tf BMEDD 1838 ± 51 
The various is470t,,,, values for Tf Cl and the variant transferrins were all very similar, 
supporting the qualitative observations made above that the variant transferrins had 
normal iron-binding characteristics at physiological pH. 
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3.2.10.1.3. RELEASE OF IRON BOUND BY TRANSFERRINS AT PH 7.5 
Normal iron loss from human transferrin occurs over a pH range of 6.0-4.0, with release 
occurring from the N-site before the C-site (Princiotto & Zapolski, 1975; Aisen & 
Listowsky, 1980; Baldwin et al., 1982). The different iron release properties of the two 
binding-sites is believed to be related to earlier activation of the N-lobe Lys-Lys domain 
opening trigger mechanism (Dewan et al., 1993). As the normal function of the N-lobe 
dilysine and C-lobe Lys-Asp-Arg trigger mechanisms (and hence opening of the 
binding-cleft) may be affected by amino acid substitutions in their immediate vicinity, 
the effect of pH on iron bound by the isolated transferrins was investigated by studying 
iron release over the pH range 6.0-4.0. The iron-titrated samples were first desalted on a 
G-25 fine desalting column (sec. 2.2.1.6.1. ) to remove excess unbound iron. The 
desalted samples were freeze-dried to about 200µl and then made up to about 1. Oml 
with deionised water. The protein concentrations were determined as described earlier 
(sec. 2.2.8. ) and 0.5ml of the stock apotransferrin samples adjusted to give similar 
concentrations. 80pl of apo and holo samples were added to 320µ10.2M sodium acetate 
(pH 7.5), mixed and the absorbance of the holo samples determined against the sample 
blank. The protocol was repeated with 0.2M sodium acetate solutions ranging in pH 
from 6.0-4.0 (0.5 pH unit steps). Percentage iron saturation values were then plotted 
against the respective pH, where percentage saturation was determined by the equation: 
[(absorbance / absorbance at pH 7.5) x 100]. The resulting spectra in Figure 3.28 
showed that Tf Cl gave the expected profile of an initial rapid loss of iron up to about 
pH 5.3, followed by another rapid loss from about pH 5.0 to about pH 4.3. The other 
transferrins showed a similar profile of iron loss, although they appeared to lose iron at a 
slightly faster rate than Tf C 1. The distribution of iron between the two binding-sites 
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Figure 3.28. The effect of pH on iron bound by transferrins at pH 7.5. 
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was determined by analysing 20µl of the transferrin-sodium acetate solutions on 6M 
urea-polyacrylamide gels. The pattern of iron distribution for Tf DBLUNDELL is shown in 
Figure 3.29. The gel confirmed the observations made from Figure 3.28 and in other 
studies (Princiotto & Zapolski, 1975; Aisen & Listowsky, 1980; Baldwin et al., 1982) 
that iron was gradually lost in two phases, first from the acid-labile N-site and then from 
the acid-stable C-site. A similar pattern of iron loss was also observed for Tf Cl and the 
other variant transferrins. The variant transferrins in this study therefore appear to show 
normal iron binding and release characteristics at pH 7.5, although their slightly faster 
rates of iron loss suggest that iron may not be bound as tightly as in Tf Cl. The results 
are therefore similar to the observation by Kamboh & Ferrell (1987) that most variant 
transferrins show normal iron binding properties. They are also similar in some respects 
to the results of Evans et al., (1982) and Welch & Langmead (1990) as both Tf DEvars 
and Tf BsHnw showed normal spectroscopic iron binding properties, and a faster rate of 
iron loss in the case of Tf BSHAW. They are however different to the two latter studies 
with respect to urea stability, as the iron-titrated variant transferrins showed normal , 
stabilities and hence electrophoretic patterns in 6M urea-polyacrylamide gels, unlike 
both Tf DEVANs and Tf B5. which showed a lability in urea with iron loss from the C- 
site 
3.2.10.1.4. TITRATION OF TRANSFERRINS WITH IRON AT PH 5.5 
Unlike the C-lobe site, the N-lobe site of human transferrin does not bind iron below pH 
5.7 (Princiotto & Zapolski, 1975; Harris, 1977). This property together with its tendency 
to lose iron at acidic pH favours iron release in endosomes during receptor-mediated 
iron uptake (de Jong et al., 1990; Qian & Tang, 1995). Iron titration at pH 5.5 therefore 
allows studies of iron binding to the C-lobe site, occupancy of which is thought to 
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favour receptor binding and subsequent cellular uptake of iron-containing transferrin 
(Bali & Aisen, 1991; Egan et al., 1993; Pakdaman & el Hage Chahine, 1996). 1.0ml 
apotransferrin solutions (1.3-2.0 x 10'5M; buffered in 0.5M Tris-HC1 (pH 5.5)/ 30mM 
NaHCO3) were therefore titrated as described earlier (sec. 3.2.10.1.2. ). Whereas binding 
equilibrium was achieved after I min at pH 7.5, the equivalent state at pH 5.5 was 
difficult to assess as 470nm absorbances were found to slowly drop over a period of 
5min. Absorbances were therefore taken 5min after each successive addition of 1. OmM 
FENTA, and continued to a value of r=3.50 as addition of iron beyond r=2.50 
continued to give small increases in absorbance (about 0.002 units). A series of 
percentage saturation versus r spectra (Fig. 3.30) were then generated as described 
earlier (sec. 3.2.10.1.2. ), using the absorbance at r=3.50 as the saturation absorbance. 
Figure 3.30. Spectra of percentage saturation versus r for the titration of apotransferrin 
with iron at pH 5.5. 
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The above spectra followed a pattern similar in some respects to that generated at pH 
7.5, where plots had an initial linear increase as all added iron was bound, followed by a 
more downward curve towards saturating values of r. However, unlike titrations at pH 
7.5, the plots continued to show an increase beyond r=2.50. It was therefore not 
possible to determine the amount of iron required for full saturation, and hence 
comparative values for the number of moles of iron bound per mole transferrin. The 
distribution of iron between the two binding-sites were therefore determined by 6M 
urea-PAGE as described earlier (sec. 3.2.10.1.2. ). An example of the results obtained is 
shown in Figure 3.31. 
Figure 3.31.6M urea-PAGE of Tf DBLINDE: I. L after iron titration at pH 5.5. 
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a 
The above gel clearly shows that the titrated Tf DBLE, L sample was predominantly in 
the C-lobe monoferric form even at a value greater than r=3.50 (i. e. +100%). Therefore 
although the binding of iron in the initial stages appeared to be similar to that at pH 7.5 
(Fig. 3.25. ), very little of the iron added in the later stages was bound to the N-lobe site 
as expected. This inability of the N-lobe site to bind iron was shown by all the 
transferrins studied, and explained why the 470nm absorbances were generally lower 
(about 2/3) than equivalent absorbances at pH 7.5. Quantitative comparisons of Os47,.. 
values determined from plots of Ac against r (Fig. 3.32) are shown in Table 3.5. 
Figure 3.32. Spectra of Ac versus r for the titration of apotransferrins with iron at pH 
5.5. 
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Although the above spectra was misleading in that the continued increase in DE values 
beyond r=1.0 suggested that both binding-sites were occupied, AE470,,,,, values supported 
the observations made from the analytical gels that iron was predominantly bound at 
only one site, as the values were appreciably lower than equivalent values at pH 7.5 
(Table 3.4. ). 
Table 3.5. Calculated i8470i,, U values for 
iron-transferrin complexes at pH 5.5. 
Transferrin 1 647oom (n'i"'cm') 
(mean ± s. d.; n= 3) 
TfC1 1160 f 110 
Tf C2 980 t 128 
Tf DBLUNDELL 900 f 85 
Tf Daug 1000 t 96 
Tf DSINGH 880 t 112 
Tf BFOXTROT 1180 t 68 
Tf BKjv uu 1080 t 81 
Tf BMEDD 1200 t 62 
3.2.10.1.5. EFFECT OF PH ON IRON BOUND BY TRANSFERRINS AT PH 5.5 
Following the protocol outlined earlier (sec. 3.2.10.1.3. ), a series of iron release curves 
were obtained for the various iron-titrated transferrins over the pH range 6.0-4.0 (Fig. 
3.33. ). All transferrins showed a steady, almost linear loss of iron as the pH was 
dropped, in contrast to the almost biphasic pattern found with transferrins titrated at pH 
7.5 (Fig. 3.28). 6M urea-PAGE of the transferrin-sodium acetate samples (20µl) 
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Figure 3.33. Effect of pI-i on iron bound by transferrins at pH 5.5. 
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Figure 3.34.6M urea-PAGE showing the effect of pH on Tf DBLUNDFI I titrated with iron 
at pH 5.5. 
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confirmed that iron loss was from the C-site only (Fig. 3.34). Similar results were found 
for all other transferrins indicating that they all showed the expected properties of iron- 
binding at acidic pH with preferential iron loading and loss from the C-site. 
3.2.10.2. TITRATION OF TRANSFERRINS WITH CUAT PH 7.5 
Cu2+ binding by transferrin is associated with small conformational changes in both 
binding-sites from the displacement of one of the protein iron-ligands (Garratt et al., 
1991; Smith et al., 1992). The steric constraints of Cu" binding is reflected in lower 
binding constants (log K, = 12.3 & log K2 = 11.1) ( Hirose et al., 1996), and means that 
alterations in or around the transferrin binding sites that may not affect iron-binding, 
may be detected by Cue+-binding studies. Protein fluorescence studies of the binding of 
Cu" to Tf C and the abnormal Tf DEV,.,, s variant found that unlike Tf C, Tf DEV, v,, s bound 
Cu2+ at the N-lobe site only (Evans et al., 1994). The binding of Cu2+ was therefore in 
contrast to iron binding which occurred at both sites. Cu2-binding properties of the 
variant transferrins isolated in this study were therefore investigated to determine 
whether they showed normal or abnormal Cue+-binding characteristics. 1. Om1 
apotransferrin solutions (2.0-5.4 x 10-5M; buffered in 0.5M Tris-HC1 (pH 7.5)/ 30mM 
NaHCO3) were titrated as described earlier (sec. 3.2.10.1.2. ) with 1. OmM CUNTA. 
Absorbances were read at equilibrium (2min after addition of metal ion) at 440nm (sec. 
3.2.10. ). Cu2+ titrations were found to resemble Fe" titrations at pH 5.5 in that the 
titration endpoint was difficult to assess. At values of r=2.0-2.5, the titration spectra 
appeared to show a plateau indicative of saturation, with very small increases in 
absorbance (about 0.001 unit). However, addition of further aliquots of 1.0mM CUNTA 
resulted in appreciable increases in absorbance (about 0.005 unit) to values around r= 
3.50. In view of the fact that all plots appeared to plateau around r=2.50, and that 
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a. 
Figure 3.35. Plots of percentage copper saturation versus r for titrations of 
apotransferrins with Cu" at pH 7.5. 
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Figure 3.36. Spectra of As versus r for the titration of apotransferrins with Cu' at pH 
7.5. 
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further increases in absorbance were probably due to interference by the metal itself (i. e. 
the added pale blue colour of the CUNTA solution), absorbances at r=2.50 were taken 
as the saturation absorbance. Plots of percentage copper saturation against r (Fig. 3.35. ) 
were then generated as described earlier (sec. 3.2.10.1.2. ). Figure 3.35. showed that Tf 
Cl and the variant transferrins appeared to show very similar binding affinities for Cue+, 
although the number of moles bound could only be estimated as 2 per mole transferrin 
because of the difficulties in determining a definite titration endpoint. Quantitative 
comparisons of As440ini values (Table 3.6) derived from plots of Ae versus r (Fig. 3.36. ) 
appeared to support the above qualitative observations. 
Table 3.6. Calculated 1 C440in, values for copper-transferrin complexes at pH 7.5. 
Transferrin AEoom (M''cm'') 
(mean ± s. d.; n= 3) 
Tf Cl 2326 t 165 
Tf C2 2700 ± 230 
Tf DBLUNDELL. 3245 ± 214 
Tf DBB 2326 ± 300 
Tf DSINGH 2833 ± 198 
Tf BFOXTROT 2284 ± 247 
Tf B nc, u. c 2444 ± 346 
TfBNEDn 3167 ± 284 
Although there appears to be a relatively wide spread of Ae440n,,, values for Cue+-titrated 
transferrins compared to Fe"-titrated transferrins at pH 7.5 (Table 3.4. ), the differences 
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may reflect the inability to obtain defmite titration endpoints as a similar wide spread of 
results was obtained for Fe3; -titrations at pH 5.5 (Table 3.5. ). It is therefore proposed 
that Tf Cl and the variant transferrins all bind Cu2+ at both binding sites, as none of the 
transferrins had a As44o. value less than '/s that of the highest As440, n, value (3245 ± 
214 for Tf DBLUNDELL) that would indicate that only one Cu2+ was being bound. The 
results are therefore unlike those found for Tf DEVnrrs" 
3.2.10.3. TITRATIONS OF TRANSFERRINS WITH AL'* AT PH 7.5 
As with Cue+, the binding of All' to transferrin is associated with small conformational 
changes due to steric effects at the metal-binding sites (Kubal et al., 1992; Tang et al., 
1995), and so has a lower affinity than iron for transferrin (log K, = 13.5 & log K2 = 
12.5) (Harris & Sheldon, 1990). Substitutional changes near the binding sites may 
therefore impose further restrictions on Al' binding. The ability of the variant 
transferrins isolated in this study to bind Al' were therefore investigated to determine 
whether they bound Al" at both sites, or whether binding was restricted to one site as 
reported for Tf DEV, u., s (Evans et al., 1984). 1. Oml apotransferrin solutions (1.1-1.6 x 
10'4M; buffered in 0.5M Tris-HC1(pH 7.5)/ 30mM NaHCO3) were titrated as described 
before (sec. 3.2.10.1.2. ) with 1.0mM ALNTA. Absorbances were determined at 
equilibrium (5min after addition of metal ion) at 238nm (sec. 3.2.10.1.1. ). From a series 
of percentage saturation versus r plots (Fig. 3.37. ), the number of moles of All" bound 
per mole transferrin (Table 3.7. ) indicated that Al` was bound at both sites for Tf Cl 
and all variant transferrins. This was supported by DE238ini values (Table 3.8. ) derived 
from plots of AE versus r (Fig. 3.38), which suggested that the variant transferrins had 
similar binding affinities to Tf Cl. The 1 z238rim values obtained in this study are similar 
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Figure 3.37. Plots of percentage aluminium saturation versus r for the titration of 
apotransferrins at pH 7.5. 
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Table 3.7. The number of moles of Al' bound per mole transferrin determined from 
titrations of apotransferrins at pH 7.5. 
Transferrin Moles Al" bound per mole 
transferrin (mean ± s. d.; n= 3) 
TfC1 2.15 ± 0.08 
Tf C2 2.23 ± 0.13 
Tf DBWNDELL 1.84 ± 0.16 
TfDBCi 2.21 ± 0.10 
Tf DswGH 1.95 ± 0.05 
Tf BFOXTROT 2.15 ± 0.10 
Tf Bjuia. aº 2.00 ± 0.07 
Tf BMEDD 2.38 ± 0.14 
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Figure 3.38. Spectra of As versus r for the titration of apotransferrins with A13' at pH 
7.5. 
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Table 3.8. Calculated Os238n n values for aluminium-transferrin complexes at pH 7.5. 
Transferrin AEzmm, (M-'cm') 
(mean ±s. d.; n=3) 
Tf Cl 16292 f 746 
Tf C2 16944 t 1002 
Tf DBUnNDELL. 14754 t 1376 
Tf DBCrnxs 17727 t 1038 
Tf Dswcx 14090 t 1560 
Tf BFOxTROT 16129 t 971 
Tf BKtint, at 14000 ± 1292 
Tf BMEDD 16670 ± 1204 
177 
to the values of 15080 reported by Tomimatsu & Donovan (1976) and 15790 reported 
by Evans et al., (1984), and are generally about twice the A8247i,,,, value found for Tf 
DE,,,,,, 5 (Evans et al., 1984). 
3.2.10.4. TITRATIONS OF TRANSFERRINS WITH GA3+ AT PH 7.5 
Gallium is of pharmacological importance as gallium-67 is widely used as an imaging 
agent in diagnostic medicine for a variety of tumours and inflammatory abscesses 
(Parker, 1990). Like A13+, Ga3+ is similar in charge and size to Fe 3+ (ionic radius 0.621) 
and 0.65A respectively) and has been shown to bind to both metal-binding sites of 
transferrin with a binding affinity less than that of Fe 3+ (log K, = 18.1 & log K2 = 17.1) 
(Tomimatsu & Donovan, 1976; Harris & Pecoraro, 1983; Kubal et al., 1993). The 
binding of Ga 3+ to the variant transferrins in this study was investigated using 1.0mM 
GANTA as described earlier (sec. 3.2.10.1.2. ). 1. Oml apotransferrin solutions (1.8-2.0 x 
10''M; buffered in 0.5M Tris-HC1 (pH 7.5)/ 30mM NaHCO3) were titrated at 242nm 
(sec. 3.2.10.1.1. ) and absorbances taken at equilibrium (5min after addition of metal 
ion). As with Fei+, Cue+, and A13+, all variants were found to show similar binding 
affinities for Ga 3+ from plots of percentage gallium saturation against r (Fig. 3.39. ) and 
appeared to bind Ga 
3+ at both metal-binding sites on the basis of the number of moles 
bound per mole transferrin (Table 3.9. ). Comparisons of Os242m values (Table 3.10. ) 
derived from plots of DE against r (Fig. 3.40. ) supported the qualitative observations, 
although the AE242nm values were much higher than the value of 13530 reported by 
(Tomimatsu & Donovan, 1976). 
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Figure 3.39. Plots of percentage gallium saturation versus r for titrations of 
apotransferrins at pH 7.5. 
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Table 3.8. The number of moles of Ga 3+ bound per mole transferrin determined from 
titrations of apotransferrins at pH 7.5. 
Transferrin Moles Ga" bound per mole 
transferrin (mean ± s. d.; n= 3) 
Tf CI 1.75 ± 0.17 
Tf C2 1.80 ± 0.13 
Tf DBLUNDELL 2.00 ± 0.08 
Tf DBURKE 1.91 ± 0.19 
Tf Dswcx 1.84 ± 0.09 
Tf BFOXTROT 1.90 ± 0.15 
Tf BKHALL1 1.75 ± 0.16 
Tf BMEDD 2.21 ± 0.11 
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Figure 3.40. Spectra of As versus r for the titration of apotransferrins with Ga 3+ at pH 
7.5. 
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Table 3.9. Calculated AE242t values for gallium-transferrin complexes at pH 7.5. 
Transferrin Ac242om (M-'cm'') 
(mean ± s. d.; n= 3) 
Tf Cl 21470 f 1289 
Tf C2 19375 ± 934 
Tf DBLUNDELL 20000 f 1268 
Tf DBuRxE 20909 t 825 
Tf DsINGH 19230 ± 1413 
Tf BFOXTROT 19583 ± 1327 
Tf B nuu 23000 t 997 
Tf BMEDD 22407 f 1299 
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3.2.10.5. DISPLACEMENT METAL-BINDING STUDIES 
A series of metal binding studies were carried out to determine whether Cue+, A13+and 
Ga3+ bound to the same metal-binding sites as Fei+, and whether the four metal ions 
were capable of displacing each other. The protocols were first established using Tf Cl 
and then extended to the other transferrins. Calculated volumes of either 1.0mM 
FENTA or 1.0mM Fe(NIL)ZSO4 were added to 0.5m1 (duplicate) of an apo Tf Cl 
solution (2.0 x 10'5M; buffered in 0.5M Tris-HCI (pH 7.5)/ 30mM NaHCO3) to give 
50% iron-saturated Tf Cl. Titration of transferrin with FENTA or Fe(N1-4)2SO4 is 
known to result in preferential iron loading to the C-site and N-site respectively at 
alkaline pH (Evans & Williams, 1978; Harris & Aisen, 1989). Titrations to 50% iron- 
saturation therefore produce C-lobe monoferric and N-lobe monoferric transferrins 
respectively, allowing studies of metal binding to the unoccupied site. The respective 
monoferric Tf CI samples were then titrated with Cu2', Ala+and Ga3+ as described 
earlier (sec. 3.2.10.1.2. ) and absorbances monitored at the respective wavelengths. An 
example of the resulting spectra is shown in Figure 3.41. for the titration of monoferric 
Tf Cl with A13+. The spectra for Cu2+ and Ga 3+ showed similar patterns with essentially 
one mole of Cue+, A13+ or Ga 
3+ binding to either of the monoferric Tf Cl samples. This 
suggested that the three metal ions were binding to the unoccupied metal-binding site, 
but could not displace Fe3+ bound at the other site. The results are very similar to that 
reported by Harris (1983) where titrations of C- and N-lobe monoferric transferrins with 
Zn" resulted in occupancy of the unoccupied site only. Although the three metal ions in 
this study gave similar titration spectra with respect to number of moles bound, it was 
noticeable that the C-lobe monoferric plot for A13+ titrations had higher absorbances 
than the corresponding N-lobe monoferric plot (Fig. 3.41. ). The converse pattern was 
noted for both Cu2+ and Ga 
3+ titrations. 
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Figure 3.41. Spectra for the titration of monoferric Tf C1 with Al". 
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As the higher absorbances of the C-lobe monoferric plots for Al" titrations would 
produce a higher DE238nm value if translated into Ac as described earlier (sec. 
3.2.10.1.2. ), Figure 3.41. also indicates that the unoccupied N-site of human transferrin 
has a higher affinity for Al" than the unoccupied C-site. The results therefore support 
the observations of Kubal et al., (1992) that unlike Fe", Al" in the presence of 
bicarbonate, binds first to the N-lobe of transferrin. In contrast the spectra for Cu2+ and 
Ga 3+ titrations indicate that the unoccupied C-site of transferrin has the higher affinity. 
The results again agree with the observations of Hirose et al., (1996) and Kubal et al., 
(1993) who reported that the binding constants of Cu2+ and Ga 3+ for the N-site were 
respectively 15 and 10 times less than that for the C-site, indicating that they bound to 
the latter site first. The above studies indicated that all three metals bound to the same 
metal-binding sites as Fe', but could not displace bound Fe". Further studies were 
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therefore carried out to determine whether they were capable of displacing each other. 
0.5ml samples of the apo Tf Cl stock were first titrated to saturation with either Cue+, 
A13+ or Ga 3+ at their respective wavelengths, and then titrated with one of the other two 
metal ions at the wavelength of the second metal ion. Each metal ion was therefore 
titrated with the other, with increases in absorbance at the second wavelength indicating 
displacement of the first metal ion and vice versa. The results (not shown) indicated that 
Cu2+ was displaced by both Al3+ and Ga3+, whilst A13+ was displaced by Ga3+. As 
titrations of monoferric transferrins with Cue+, A13+ or Ga3+ had shown that the three 
metals were incapable of displacing Fei+, Cue+-, A13+- and Ga 3+-saturated Tf CI samples 
were titrated with Fe3+ to see if they could be displaced. The results obtained for 
titration of Cue+-saturated Tf Cl with Fe 3+ is shown in Figure 3.42. 
Figure 3.42. Titration spectra for the displacement of bound Cu2+ by Fei+. 
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The results indicated that Fe 3+ was capable of displacing bound Cu2+ as 2 moles of Fe 31 
were bound following titration. Similar results were also obtained for A13+- and Ga3+- 
saturated samples indicating that Tf Cl had a higher affinity for Fe 3+ than for the three 
other metals. The studies therefore indicated that in terms of binding affinities for 
transferrin, Fe 3+ > Ga 3+ > A13+ > Cu2+. The results are supported by their respective 
binding constants for transferrin with Fe 3+ showing the highest binding constants (logKi 
= 20.6 and logK2 = 19.4) and Cu2+ the lowest (log KI = 12.3 and log K2 = 11.1) (Aisen 
et al., 1978; Harris & Pecoraro, 1983; Harris & Sheldon, 1990; Hirose et al., 1996). 
They are also supported by the observations of Li et al., (1996) that the more acidic Fe 3+ 
ion would bind more strongly to transferrin than less acidic metal ions such as Ga3+, 
A13+ and Cu2+ (Fig. 1.15. ). Variant transferrins successively titrated with Cue+, Ala+, 
Ga3+ and then Fei+, were all found to show a similar pattern of metal displacement, 
confirming their normal metal-binding characteristics. 
3.2.11. TRANSFERRIN STABILITY IN UREA 
The stabilities of apo and holo transferrins in urea were studied by the method of Makey 
& Seal (1976) (sec. 2.2.4. ), on the basis that electrophoresis in urea polyacrylamide gels 
results in differential electrophoretic mobilities as a result of the amount of iron bound 
to, and the degree of denaturation (unfolding of the two domains) of the two lobes of 
transferrin. 
3.2.11.1. STABILITY OFAPOTRANSFERRINS IN UREA 
Studies by Evans & Williams (1980) found that apotransferrin showed a two-step 
denaturation pattern in urea. The electrophoretic mobilities of the monoferric 
transferrins indicated that the first denaturation step corresponded to denaturation of the 
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C-lobe (2.8-4. OM) and the second to denaturation of the N-lobe (4.1-4.5M). Studies by 
Evans et al., (1982) however found that the C-lobe of apo Tf DEV, 4,,, s, denatured at a 
lower urea concentration than normal, although the N-lobe was found to show the same 
denaturation step as Tf C. The denaturation of the variant transferrins detected in this 
study were therefore examined by monitoring the abilities of the proteins to bind iron in 
the presence of different concentrations of urea, to determine whether they showed the 
normal denaturation pattern or abnormal patterns. The studies were conducted on the 
basis that denaturation would reduce iron-binding abilities which could then be 
monitored by electrophoresis in 6M urea-polyacrylamide gels. Because of the 
destructive nature of the studies, the protocol was first established using Tf Cl and then 
extended to the other transferrins. 20011 aliquots (triplicate) of an apo Tf Cl solution 
(1.3 x 10'5M in O. 1M NaHCO3) were added to 2O0µ1 aliquots of urea solutions ranging 
from 2.0-16. OM (1. OM steps). The resulting 1: 1 dilution gave a reaction concentration of 
6.2 x 10'M transferrin in 0.05M NaHCO3 and 1.0-8. OM urea (0.5M steps). A sample 
blank was prepared by adding 2O0µ1 apotransferrin solution to an equal volume of 
16AM urea. Samples were left for Ihr at room temperature and then fully saturated with 
iron by the addition of 20µ1 1. OmM FENTA (20µ1 1. OmM NTA to the sample blank). 
An incubation period of lhr was chosen following pre-experiment trials which showed 
that apotransferrin samples in 6M urea showed almost identical 470nm absorbances 
after 1,2,4,8 and 24hr. The pH of the transferrin-urea samples were also found to be 
sufficiently alkaline (pH 8.7 and 9.0 for 1. OM and 8. OM transferrin-urea samples 
respectively) for normal iron-binding using FENTA as the iron donor (Evans & 
Williams, 1978; Harris & Aisen, 1989). Absorbances of iron-saturated transferrins were 
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Figure 3.43. Spectra for the binding of iron by apo Tf C1 in the presence of urea. 
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Figure 3.44. Percentage iron saturation of Tf Cl under different urea concentrations. 
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determined 20min after addition of iron against the sample blank at 470nm, and the 
mean absorbances plotted against the respective urea concentrations (Fig. 3.43. ). The 
spectra obtained is similar to that found by Evans & Williams (1980), where the ability 
of Tf Cl to bind iron decreased with increasing urea concentration. To determine 
whether the initial absorbances were indicative of holo transferrin, 200µl aliquots 
(duplicate) of stock apotransferrin solution were added to 200µ1 of deionised water, 
saturated with 20p1 1.0mM FENTA, and the absorbance at 470nm determined after 
20min against a sample blank containing 20µ1 1. OmM NTA. The absorbances were 
found to agree very closely with those of the lower transferrin-urea concentrations (1.0- 
3. OM urea), indicating that the transferrins were in the holo state. The absorbance at 
1. OM urea was therefore used as the saturation absorbance for plots of percentage 
saturation versus urea concentration (Fig. 3.44. ), where percentage saturation was 
determined as: [(absorbance / absorbance at saturation) x 100]. The profile indicated 
that apo Tf Cl was capable of binding iron at both sites up to about 4. OM urea. However 
beyond that, the ability of the protein to bind iron was increasingly affected by urea such 
that iron-binding was restricted to one of the two metal-binding sites by about 6.5M 
urea. 10µl aliquots of the transferrin-urea samples were therefore analysed by 6M urea- 
PAGE (Fig. 3.45. ) to determine which of the two metal-binding sites were first affected 
by urea. The pattern of iron distribution for transferrin samples in 1.0-3.0 urea are not 
shown in Figure 3.45. because the samples were found to show an identical pattern to 
that of the normal holo transferrin. The gel however showed that Tf CI gradually 
progressed from being predominantly in the holo form to a more partially-saturated form 
between 4.0-8. OM. The predominant monoferric transferrin between 4.0-S. OM urea was 
found to be the C-lobe monoferric complex. Increases in urea concentration to about 
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6.5M showed a transition from C-lobe monoferric transferrin to the N-lobe monoferric 
and apo transferrin forms, so that the latter two were the predominant forms in 7. OM 
urea. The analytical gel therefore supported the observations deduced from the spectra 
in Figure 3.44. that by a urea concentration of 6.5M, iron was predominantly bound to 
one site, the N-site. 
Figure 3.45.6M urea-polyacrylamide gel showing the effect of urea on the binding of 
iron by apo Tf Cl. 
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The above symbols denote the following: N hold transferrin in the absence of urea; It . ipotr nsfrrrin; 
I f-Fe = C-lobe monoferric transferrin; Fe-"ff N-lobe monolcrric transterrin; "1'f'-I c2 holo transterrin. 
The studies therefore indicated that of the two metal-binding sites of transfcrrin, the 
iron-binding abilities of'the ('-lobe was the first to be severely affected in the presence 
of' urea concentrations greater than 4. OM. The results are therefore in good agreement 
with the studies of Evans & Williams ( 1980). The different stabilities cif the Iwo lobes 
appear to be contradictory as the C-lobe with its three extra disulphide 
bridges (11micy Ct 
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al., 1988; Baldwin, 1993) would be expected to be more stable than the N-lobe. Evans 
& Williams (1980) found that the unoccupied N-lobe in the C-lobe monoferric complex 
denatured at a higher urea concentration than the N-lobe of apotransferrin. They 
subsequently proposed that the unoccupied C-lobe denatured before the unoccupied N- 
lobe in respective monoferric complexes, because unlike the former, an unoccupied N- 
lobe may receive some protection against urea denaturation from the presence of iron at 
the C-site. 
3.2.11.1.1. EFFECT OF UREA ON THE BINDING OF IRON BY VARIANT 
APOTRANSFERRINS 
Because of the relatively small amounts of available transferrins left at this stage (0.5- 
2.0mg), the protocol established with Tf C1 (sec. 3.2.11.1. ) was followed using 1/10 of 
the stated volumes. As the volumes were too small for 470nm absorbance readings, the 
effect of urea on the iron-binding abilities of the variant transferrins (duplicate samples) 
was predominantly studied by 6M urea-PAGE. For accurate comparisons of 
electrophoretic mobilities, all transferrins incubated at the same urea concentration were 
analysed on one gel after iron saturation. Figures 3.46. and 3.47. for example show the 
resulting analytical gels for all apotransferrins incubated in a urea concentration of 4.5M 
and 6.5M respectively. Both gels showed a similar iron distribution pattern to that 
established for Tf Cl (Fig. 3.45. ), where both monoferric transferrins were present at a 
urea concentration of 4.5M (Fig. 3.46. ), whilst the N-lobe monoferric complexes were 
predominant at a urea concentration of 6.5M (Fig. 3.47. ). The analytical gels for the 
other urea concentrations are not shown because of their similarity to the established 
pattern of urea denaturation (Fig. 3.45. ), and because as with the 4.5M and 6.5M gels, 
1d IL - 
189 
Figure 3.46.6M urea-polyacrylamide gel showing the effect of 4.5M urea on the 
binding of iron by variant apotransferrins. 
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The above symbols denote the following: Tf-Fe = C-lobe monoferric transferrin; Fe-Tf = N-lobe 
monoferric transferrin; Tf-Fe2 = holo transferrin. 
Figure 3.47.6M urea-polyacrylamide gel showing the effect of 6.5M urea on the 
binding of iron by variant apotransferrins. 
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The above symbols denote the following: Tf = apotransferrin; Tf-Fe = C-lobe monoterric transtcrrin; Ic- 
Tf = N-lobe monoferric transfer: in; Tf-Fe2 = holo transferrin. 
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the electrophoretic mobilities of the four iron-containing transferrin forms of all variants 
were very similar. The results therefore indicated that all variant transferrins had very 
similar stabilities in urea judging from their ability to bind iron, and from their resulting 
electrophoretic mobilities. Because of the limitations of available transferrin material, 
quantitative percentage saturation values derived from 470nm absorbance readings were 
restricted to the two urea concentrations, 4.5M and 6.5M. The two concentrations were 
chosen because they represented two important stages of urea denaturation, namely: (i) 
the change from predominantly holo to monoferric transferrin at about 4.5M urea; and 
(ii) the change from predominantly C-lobe to N-lobe monoferric transferrin. 1501l 
(duplicate) of the various apotransferrins were added to l50µl of 9. OM and 13. OM urea, 
left for lhr at room temperature and then saturated with l51i1 of 1.0mM FENTA. A 
control holo sample was also prepared using 2. OM urea. The absorbances of the test 
samples and the control holo sample were determined at 470nm against a sample blank 
(150µ1 apotransferrin + 150µl 13. OM urea + 15µl deionised water). The percentage iron 
saturation of the test samples were then determined using the equation: [(test absorbance 
/ control absorbance) x 100]. Table 3.11. shows the results obtained for the different 
transferrins. The narrow range of results supported the qualitative observations made 
above that unlike Tf DEVM4S, all variant apotransferrins showed similar stabilities in urea 
to that of Tf Cl. 
t. 'Y 
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Table 3.11. Comparative percentage iron saturation values for apotransferrins exposed 
to urea prior to iron binding. 
Transferrin Percentage iron saturation at 
4.5M urea (mean ± s. d.; n= 2) 
Percentage iron saturation at 
6.5M urea (mean ± s. d.; n= 2) 
TfC1 87.2 ± 4.0 57.4 ± 4.4 
TfC2 85.8 ± 7.4 61.3± 1.5 
Tf DBr UNDELL 83.2 ± 0.4 55.4 ± 3.5 
TfDBURKE 91.3 ± 5.7 59.6 ± 3.9 
Tf DSINGH 83.6 ± 4.7 60.9 ± 6.2 
Tf BFOXTROT 87.1 ± 1.3 58.0 ± 1.8 
TfB ui 82.6 ± 1.8 56.5 ± 5.0 
Tf BMEDD 87.3 ± 1.1 54.7 ± 5.2 
3.2.11.2. STABILITY OF HOLO TRANSFERRINS IN UREA 
Earlier iron binding studies indicated that iron-titrated variant transferrins from this 
study showed normal patterns of iron distribution during electrophoresis in 6M urea- 
polyacrylamide gels (sec. 3.2.10.1.2. ), unlike Tf DEV,,,, s (Evans et al., 1982) and Tf BS, uW 
(Welch & Langmead, 1990) which both showed iron loss from the C-site. As iron 
binding protects transferrin against urea denaturation, normal holo transferrin in contrast 
to the apo and monoferric forms remains undenatured up to 6M urea (Evans & 
Williams, 1980; Evans et al., 1982). Holo Tf DEAJ. S was however found to show a 
single denaturation step before 6M urea corresponding to unfolding of the C-lobe of 
apotransferrin, confirming that the C-lobe of Tf DEVA ,, s was unusually labile in urea 
(Evans et al., 1982). The stabilities of variant holo transferrins from this study were 
therefore examined over a urea range of 1.0-8. OM (0.5M steps) to determine whether 
they continued to show normal characteristics in urea. The protocol was again 
r1 c 
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established with Tf CI and then extended to the other transferrins. 200µl (duplicate) of 
the apo Tf Cl solution used in earlier studies (3.2.11.1. ) were fully saturated with iron 
by the addition of 20µl I. OmM FENTA. A control holo sample (200µ1 apo Tf Cl + 20µl 
1.0mM FENTA + 220µl deionised water) was also prepared. The samples were left for 
20min to ensure complete binding and then added to 220µl of urea solutions ranging 
from 2.0-16. OM (IM steps) to give a reaction urea concentration range of 1.0-8. OM 
(0.5M steps). Samples were left for l hr before determining the absorbance at 470nm 
against a sample blank (2O0pl apo Tf C1+ 20µl 1. OmM NTA + 220µ1 16. OM urea). The 
results (not shown) indicated that urea had very little effect on holo Tf Cl, as 470nm 
absorbances of test samples were very similar to each other (within 0.005 absorbance 
units), and to the control holo sample. Aliquots (2Oµ1) of test samples analysed by 6M 
urea-PAGE confirmed that the samples were still in the holo form (Fig. 3.48. ). 
Figure 3.48.6M urea-polyacrylamide gel showing the effect of urea on holo Tf C 1. 
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The above symbol Tf-Fe2 denotes holo transferrin. 
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3.2.11.2.1. EFFECT OF UREA ON VARIANT HOLO TRANSFERRINS 
The protocol established above (sec. 3.2.11.2. ) was extended to the variant transferrins 
using 1/ 10 of the volumes used for Tf C 1. To conserve material, the effect of urea on the 
variant holo transferrins was examined by 6M urea-PAGE only. Figure 3.49. shows the 
comparative electrophoretic mobilities for holo transferrins incubated in 6.5M urea, 
which showed that variant holo transferrins all had similar electrophoretic mobilities to 
that of Tf Cl, with very little C- or N-lobe monoferric complexes present. Similar 
results were obtained for the other urea concentrations confirming that the variant 
transferrins had normal urea stabilities. 
Figure 3.49.6M urea-polyacrylamide gel showing the effect of 6.5M urea on holo 
transferrins. 
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3.2.12. THERMAL STABILITY OF TRANSFERRINS 
The previous studies on urea denaturation showed that all variant transferrins in this 
study showed normal stabilities in urea, a characteristic different to that of the two 
abnormal variants Tf DEVANs and Tf BS,.,.. However, whereas Tf DEV, e,,,, s was also found 
to show unusual thermal stabilities with the iron-free C-lobe denaturing at a lower 
temperature than Tf C (63.4°C and 65.2°C respectively) (Evans et al., 1982), studies by 
Welch & Langmead (1990) found that Tf BSH,, W showed normal thermal stabilities 
between 50-100°C. The thermal stabilities of the variant transferrins from this study 
were therefore examined using a modification of the procedure used by Welch & 
Skinner (1989). In the ensuing studies, thermal denaturation was monitored by the 
precipitation of protein from solution after heating, and by the ability of nonprecipitated 
transferrin to bind iron. 
3.2.12.1. THERMAL STABILITY OF APO TRANSFERRINS 
The protocol for studies on thermal stabilities was first established with Tf Cl and then 
extended to the other transferrins. 60µl aliquots (duplicate) of apo Tf Cl in water (6.2 x 
10-6M) were pipetted into 0.5ml thin-wall plastic micro Eppendorf tubes which were 
then capped and sealed with parafilm. The samples were heated for 20min in a water 
bath over a temperature range of 30-100°C (S°C steps). After individual incubations, 
samples were removed from the water bath and immediately quenched in ice for 2min, 
briefly centrifuged (- 15sec) at 2500rpm in a microcentrifuge (Centrifuge 5414), and 
then stored at -4°C until required. Each sample was then centrifuged through cellulose 
nitrate millipore filters (0.2µm) for 2min at 2500rpm in a Chilspin centrifuge to remove 
precipitated protein. lOµ1 (duplicate) of the collected eluent were assayed for protein 
., 
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concentration by the Lowry method (sec. 2.2.8. ). A control sample was also prepared by 
centrifuging 60µl (duplicate) of the apo Tf Cl solution through millipore filters before 
determination of the protein concentration. A temperature profile of percentage 
nondenatured protein versus temperature (Fig. 3.50. ) was then generated where 
percentage nondenatured protein was determined by the equation: [(sample 
concentration / control concentration) x 100]. 
Figure 3.50. Plots of percentage nondenatured protein versus temperature for apo Tf 
C1. 
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Two stages of denaturation could be detected from the profile, the first starting at about 
65°C and the second around 85°C. Further incubations at temperatures between 60- 
70°C and 80-90°C (PC steps) indicated that the first stage began at 64°C and the 
second at 85°C. The two-step denaturation pattern obtained in this study agrees with 
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previous work on the thermal stability of transferrin. Donovan & Ross (1976) reported 
that apo transferrin showed two thermal denaturation peaks at 62°C and 72°C. The two 
peaks were suggested by Evans & Williams (1980) to correspond to denaturation of the 
C- and N-lobe respectively, following studies of urea denaturation. The first 
denaturation temperature of 64°C obtained in this study therefore agrees with the 
findings of Donovan'& Ross (1976), and with the value of 65.2°C reported by Evans et 
al., (1982). However, whereas both studies found that the two denaturation steps were 
separated by about 10°C, results from this study showed a greater separation of about 
21°C, with a higher N-lobe denaturation temperature of 85°C. The disparity in results 
may reflect the difference in methods used in this study and the two previous studies 
which both used differential scanning calorimetry to study thermal denaturation. The 
higher N-lobe denaturation temperature is however similar to the findings of Welch & 
Skinner (1989) who found that the denaturation step occurred between 80-90°C. The 
similarity in results may therefore reflect the fact that the protocol used in this study was 
a modification of the protocol used in the latter study. The study was extended to the 
variant transferrins from this study using only the two denaturation temperatures, 64°C 
and 85°C, because of the limited amount of available transferrin material left at this 
stage. 6Oµ1 (duplicate) samples of the variant apotransferrins were incubated and 
analysed as described above, and the percentage of nondenatured proteins at the two 
temperatures determined against respective control samples. Although the results in 
Table 3.12. showed a slightly wider spread of results for incubations at 64°C, the 
similarity of the values for variant transferrins to that of Tf CI at both temperatures 
suggested that they all had similar thermal stabilities. 
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Table 3.12. Comparisons of percentage nondenatured apotransferrins after incubation 
at either 64°C or 85°C. 
Transferrin Percentage nondenatured 
protein at 64°C 
(mean ± s. d.; n= 2) 
Percentage nondenatured 
protein at 85°C 
(mean ± s. d.; n= 2) 
Tf Cl 76.4 ± 3.8 54.3 ± 1.3 
TfC2 69.4 ± 5.1 52.9± 3.7 
Tf DBLUNDELL 75.9 ± 6.3 49.6 ± 1.0 
Tf DBB 70.9 ± 3.8 46.1 ± 4.9 
Tf DSINGH 71.1 ± 7.4 50.7 ± 2.0 
Tf BFOXTxoT 71.5 ± 2.4 45.1 ± 5.0 
TfBKHALn, I 68.6 ± 3.7 41.7 ± 1.7 
Tf BMEDD 78.6 ± 6.6 53.5 ± 6.2 
3.2.12.1.1. EFFECT OF TEMPERATURE ON THE BINDING OF IRON BY 
APOTRANSFERRINS 
The pattern of iron distribution following incubation at 64°C or 85°C was examined by 
6M urea-PAGE. 591 of 1. OM Tris-HC1 (pH 8.8), 5µ1 of 0.5M NaHCO3, and lµl of 
1.0mM FENTA were added to l0µ1 aliquots of the incubated samples, mixed and left at 
room temperature for 30min before analysis (Figs. 3.51. & 3.52) to ensure complete 
binding. The presence of the holo form in both gels indicated that all apotransferrins 
were still capable of binding iron after incubation at the respective temperatures. 
However, the increasing presence of the apotransferrin forms after incubation at 85°C 
suggested that the ability to bind iron became progressively more difficult with 
increasing temperature, a characteristic expected from the progressive denaturation of 
the C- and N-lobes. 
t" ý _I 
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Figure 3.51.6M urea-polyacrylamide gel showing the pattern of iron distribution after 
incubation of apotransferrins at 64°C. 
(Origin) 
If Ic 
IT 
lI Ir, 
n n ro co 
crgo 
ö " f 6 s 
(Anode) 
The above symbols denote the following: Tf = apotransferrin; Tf-Fe = C-lobe monoferric transferrin; Fe- 
Tf = N-lobe monoferric transferrin; Tf-Fez = holo transferrin. 
Figure 3.52.6M urea-polyacrylamide gel showing the pattern of iron distribution after 
incubation of apotransferrins at 85°C. 
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The above symbols denote the following: Tf = apotransferrin; Tf-Fe = C-lobe monoferric transferrin; Fe- 
Tf = N-lobe monoferric transferrin; Tf-Fe2 = holo transferrin. 
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The results therefore show that all variant apotransferrins like Tf BSW (Welch & 
Langmead, 1990) show similar thermal stabilities to Tf C, unlike the Tf DEVANS variant 
(Evans et al., 1982) which shows a lower thermal stability of the iron-free C-lobe. 
3.2.12.2. THERMAL STABILITY OF HOLO TRANSFERRINS 
As with urea denaturation, the binding of iron to transferrin protects the protein against 
thermal denaturation (Harrington, 1992) presumably because iron-binding induces a 
conformational change with the transferrin molecule becoming more compact (Aisen & 
Listowsky, 1980). The thermal stabilities of variant holo transferrins were therefore 
examined to establish whether they continued to show normal transferrin characteristics. 
As with the apotransferrin studies, the protocol was first established using Tf Cl before 
studies of the variant transferrins. 6O11 aliquots (duplicate) of a holo Tf Cl solution (5.0 
x 10-6M) were incubated for 20min over a temperature range of 30-100°C (5°C steps), 
and then analysed as described earlier (sec. 3.2.12.1. ). The resulting temperature profile 
of percentage nondenatured proteins versus temperature (Fig. 3.53. ) showed a single 
denaturation step at about 85°C. Further incubations between 80-90°C (1°C steps) 
confirmed that the denaturation step started at 84°C. The profile therefore confirms that 
iron binding increases the stability of holo transferrins, with about 75% of the protein 
still in a soluble, nondenatured form even at 100°C, compared to about 45% for 
apotransferrin (Fig. 3.50. ). The results are similar to that reported by Welch & Skinner 
(1989), who found that holo transferrin began to be denatured between 80-90°C, with 
about 50% of the protein remaining in a soluble form at 100°C. Variant holo transferrins 
incubated at 84°C, were also found to show very similar amounts of nondenatured 
protein, confirming that the majority of the proteins were present in a soluble state. The 
6- '" 
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Figure 3.53. Thermal profile for the effect of temperature on hold Tf Cl. 
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Table 3.13. Comparative amounts of nondenatured holo transferrins after incubation at 
84°C. 
Transferrin Percentage nondenatured protein at 
84°C (mean ± s. d.; n= 2) 
TfCI 70.6 ± 3.4 
Tf C2 75.3 ± 6.1 
Tf DBLUNDELL 71.6 ± 2.8 
Tf DBURKE 67.1 ± 3.9. 
Tf DsINGH 61.8 ± 3.6 
Tf BFOXTROT 64.4 ± 2.8 
Tf BKHALu, i 67.1 ± 4.5 
Tf BMEDD 60.9 ± 2.1 
ýý 
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results are therefore similar to studies by Welch (1990) who found that 77% of holo 
transferrin remained in solution after incubation at 85°C. 
3.2.12.2.1. EFFECT OF TEMPERATURE ON THE IRON BOUND IN HOLO 
TRANSFERRINS 
The pattern of iron distribution following incubation of holo transferrins at 84°C was 
examined by analysing IOµ1 (duplicate) of the incubated samples on 6M urea- 
polyacrylamide gels. Figure 3.54. shows that all variant transferrins were predominantly 
in the holo state, confirming that iron-binding protects transferrin against denaturation. 
Figure 3.54.6M urea-polyacrylamide gel showing the effect of temperature on holo 
transferrins. 
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The above symbols denote the following: Tf-Fe = C-lobe monoferric transferrin; Fe-Tf = N-lobe 
monoferric transferrin; Tf-Fe2 = holo transferrin. 
The results from this study can therefore be summarised as follows. Six transferrin 
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detected by nondenaturing PAGE during a plasma survey (sec. 3.2.1. ), and the Tf C2 
variant, have been successfully purified from human sera using a combination of ion- 
exchange and gel-filtration chromatography (sec. 3.2.4. ). Variant transferrins have been 
found to show iron-binding properties (secs. 3.2.10.1.2. and 3.2.10.1.4. ) similar to the 
two abnormal variants, Tf DEvANs and Tf BsH, W which were reported to show normal 
spectroscopic iron-binding properties indicating that iron was bound at both sites (Evans 
et al., 1982; Welch & Langmead, 1990). Tf DEVANS and Tf BsHAw were however found 
to lose iron from their C-lobe binding site during 6M urea-PAGE (Evans et al., 1982; 
Welch & Langmead, 1990). Variant transferrins in this study show normal 
electrophoretic patterns in 6M urea-polyacrylamide gels (secs. 3.2.10.1.2. and 
3.2.10.1.4. ) indicating that iron is tightly bound at both binding sites. The lability of the 
C-site iron in Tf BsI-i&w was also revealed by a faster rate of iron loss from Tf Bsxnw 
compared to Tf C (Welch & Langmead, 1990). Although variant transferrins appear to 
lose iron bound at pH 7.5 at slightly faster rates than Tf CI (sec. 3.2.10.1.3. ), the 
differences do not appear to be significant. Furthermore, they show similar rates of iron 
release when titrated with iron at pH 5.5 (sec. 3.2.10.1.5. ). The results therefore indicate 
that all variant transferrins in this study show normal iron-binding and release 
properties. Whereas holo Tf DEVANS showed a blue shift in its absorption spectra 
indicating that one of the iron atoms was liganded in an abnormal manner (Evans et al., 
1982), similar absorption spectra are shown by holo Tf Cl and variant transferrins (sec. 
3.2.10.1.1. ). The results are therefore similar to that found for holo Tf BSHAW (Welch & 
Langmead, 1990). The C-site lability of Tf DEVANS was also found to affect the binding 
of Zn2+, Cu2+ and A13+, with Tf DEVANS unable to bind either metal at the C-site. (Evans 
et al., 1984,1994). Studies on the binding of Cue+, A13+ and Ga3+ to variant transferrins 
from this study (secs. 3.2.10.2., 3.2.10.3., and 3.2.10.4. ) show that the three metals bind 
e 
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to both binding sites of all variants. Metal-displacement studies also reveal that all 
variant transferrins show the same order of binding affinity in the order Fe 3+ > Ga 3+ > 
A13+ > Cu2+ (sec. 3.2.10.5. ). These studies therefore reaffirm the normal metal-binding 
characteristics of the variant transferrins in this study. Studies on the urea stability of Tf 
DEVANS revealed that the C-lobe of the iron-free variant denatured at a lower urea 
concentration than normal (Evans et al., 1982). Variant apotransferrins in this study in 
accordance with their normal metal-binding properties show normal urea stabilities (sec. 
3.2.11.1.1. ). Likewise, variant holo transferrins show normal stabilities in urea (sec. 
3.2.11.2.1. ) unlike holo Tf DEVANs which continued to behave as a monofemc 
transferrin in urea (Evans et al., 1982). The normal conformational structures of the 
variant transferrins are also supported by the normal stabilities of the apo and holo 
forms to thermal denaturation (secs. 3.2.12.1., 3.2.12.1.1., 3.2.12.2., and 3.2.12.2.1. ). 
The results are again different to that reported for Tf DEVANS which showed earlier 
thermal denaturation of the C-lobe (Evans et al., 1982). Characterisation of the amino 
acid change in Tf DEVANS revealed that Arg had replaced Gly at position 394 (Evans et 
al., 1988b), whilst the corresponding change in Tf BSEAw was thought to be Asn for Ile 
at either position 378 or 381 (Welch & Langmead, 1990). Although the amino acid 
change in variant transferrins from this study have not been determined, their identical 
molecular weights (secs. 3.2.7.1., and 3.2.7.2. ) and sialic acid content (secs. 3.2.8., and 
3.2.8.1. ) support the premise that differences in their electrophoretic mobilities are due 
to a similar substitutional change. The differences in electrophoretic mobilities are as 
expected reflected in the isoelectric points obtained for apo and holo variant transferrins 
(sec. 3.2.9. ). 
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3.3. CONCLUSIONS 
Six transferrin variants showing abnormal electrophoretic mobilities on nondenaturing 
polyacrylamide gels, and the second most common Tf C variant, Tf C2, have been 
isolated and purified from human plasma. A number of comparative studies have been 
carried out to determine whether the seven variant transferrins exhibit similar 
characteristics to the wild-type protein, Tf Cl. The six variant transferrins, Tf DB. , 
Tf DBB, Tf DSINGH, Tf BFO, TRoi, Tf Bm,,, II,, and Tf BMEDD, and the Tf C2 variant, were all 
found to have the same molecular weight and sialic acid content as Tf Cl. It is therefore 
proposed that the differences in electrophoretic mobility are due to changes in the 
primary structure as a result of an undefined amino acid substitution. From the 
electrophoretic mobilities, isoelectric points of apo and holo proteins, and ethnic origin 
of the individuals from whom the variant transferrins were isolated, it is proposed that: 
(i) the variant Tf DBu, is the Tf D, variant predominant among Afro-American and 
Afro-Caribbean populations; (ii) Tf DSINGH is the Tf D variant found at polymorphic 
levels among Asiatic populations; and (iii) Tf BFo, oT, Tf B, cHALn and Tf BmDD are the 
Tf B2 variant predominant among Caucasians. The identity of Tf DBL,,,,, pm, remains to be 
established. Other than slightly faster rates of iron loss from variant holo transferrins at 
physiological pH, all variants were found to show similar metal-binding abilities to that 
of Tf Cl. Likewise, all variant transferrins showed similar stabilities to urea and thermal 
denaturation. It is therefore concluded that the proposed changes in the primary 
structures of the variant transferrins do not affect their protein conformation or metal- 
binding abilities. 
ýýýý ný 
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CHAPTER FOUR 
4. RELATIONSHIP BETWEEN PLASMA TRANSFERRIN 
CONCENTRATIONS AND Tf C SUBTYPES 
4.1. INTRODUCTION 
Chapter three dealt with transferrin phenotype heterogeneity determined by 
electrophoresis of human plasma on nondenaturing polyacrylamide gels at alkaline pH. 
On such systems, the wild-type Tf C migrates phenotypically as a single protein band. 
Further heterogeneity of Tf C can however be observed with the more sensitive method 
of polyacrylamide isoelectric focusing (PAIEF). At least 16 subtype (variant) Tf C 
alleles have been detected in different human populations (Kornhuber & Ktihnl, 1986; 
Kamboh & Ferrell, 1987). Most of the subtype alleles are rare and show restricted ethnic 
or geographic distributions. However, the three Tf C subtype alleles, Tf C1 and Tf C2 
(Kühnl & Spielman, 1978; Thymann, 1978) and Tf C3 (Kühnl & Spielman, 1979) are 
found at polymorphic levels in at least one major population. Individuals with these 
three alleles show the six most common Tf C phenotypes, Tf Cl, Tf C2, Tf C2-1, Tf C3, 
Tf C3-1 and Tf C3-2. Previous studies on the relationship between these transferrin 
types and iron-binding have generally been inconclusive. A study by Eckfeldt et al., 
(1985) failed to find a significant difference between the 6 most common Tf C subtypes 
with respect to serum iron (transferrin-bound iron), iron-binding capacity (total amount 
of iron that can be bound by apotransferrin), percentage transferrin saturation and 
transferrin concentration. Wong & Saha (1986) also found no significant differences 
between Tf B, Tf C and Tf D variants, and the three Tf C subtypes, Tf Cl, Tf C2 and Tf 
C2-1, with respect to serum transferrin concentrations. Although the total iron-binding 
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capacity (TIBC) between the Tf B, Tf C and Tf D variants were not significant, the 
study did find the TIBC in individuals with the Tf Cl subtype was significantly higher 
than those of the Tf C2-1 and Tf C2 subtypes (p< 0.05 and p< 0.01 respectively). Cleve 
et al., (1988) also examined the relationship between transferrin types and iron-binding 
in two population samples (one from Europe and one from Africa). The Tf C3 allele was 
absent in the African sample, therefore the study was essentially that of the Tf C 1, Tf C2 
and Tf C2-1 subtypes. Both populations showed a tendency for slightly higher 
transferrin concentrations in the Tf Cl subtype compared to that of the other subtypes. 
The only statistically significant difference found was between the Tf Cl and Tf C2-1 
European groups (F=2.64, p< 0.01). In all three samples, the sample size studied was 
relatively small. 84 individuals were studied by Eckfeldt et al., (1985), 297 individuals 
by Wong & Saha (1986) and 327 individuals by Cleve et al., (1988). It was therefore 
suggested by Cleve et al., that analysis of a larger sample was required to establish 
whether there was a relationship between transferrin types and serum transferrin 
concentrations. In this chapter, the relationship between five of the six most common Tf 
C subtypes (i. e. Tf Cl, Tf C2, Tf C2-1, Tf C3-1 and Tf C3-2) and plasma transfemn 
concentration has been studied in 931 individuals in an attempt to elucidate whether 
plasma transferrin concentration is dependent on transferrin phenotype. 
4.2. RESULTS AND DISCUSSION 
4.2.1. DIURNAL VARIATION OF SERUM TRANSFERRIN AND TOTAL 
SERUM IRON CONCENTRATIONS 
During the course of gathering data for the study of Tf C subtypes and plasma 
transferrin concentration, a report was found in literature regarding the diurnal variation 
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of plasma iron levels in humans. The study by Hamilton et al., (1950 and references 
therein) reported that plasma iron levels showed regular diurnal variations where plasma 
iron levels were generally low in the evening, rising during the night to a peak in the 
early morning, and then falling during the day to another low in the evening. Possible 
explanations for the variation included an association with activity and sleep as studies 
by Hoyer (1944) and Waldenströn (1946) showed a reverse of the pattern in night shift 
workers. Another possible explanation was an association with the excretion of 
adrenocorticol steroids. A study by Romanoff et al., (1949) found that adrenocorticol 
activity showed constant diurnal variation with greater excretion during the morning and 
the rest of the day, than during sleep. It was therefore postulated by Hamilton et al., 
(1950) that the decrease in plasma iron level during the day might be associated with the 
increase in adrenocorticol activity and vice versa. A more recent proposal is that diurnal 
variation is associated with fluctuating iron release from reticuloendothelial cells, as a 
strong correlation was found between iron release from haem catabolism and the rate of 
change in serum iron levels (Uchida et al., 1983; Fillet et al., 1989). Although the study 
by Hamilton et al., (1950) and those quoted within the report do not mention a similar 
diurnal variation in plasma transferrin concentrations, it was important to establish 
whether a similar pattern existed for the latter as diurnal variation would affect studies 
on plasma transferrin concentrations. A series of experiments were therefore carried out 
to study the diurnal pattern of both serum transferrin and total serum iron 
concentrations. The protocol was established using myself as the subject, and then 
extended to 10 other individuals. Fingertip blood samples (about 0.5ml) were collected ' 
into 1.5m1 plastic Eppendorf tubes every 4hr for a 36hr period. Samples were allowed to 
clot, centrifuged briefly (- 10sec) at 2500rpm and the clear serum removed into fresh 
Eppendorf tubes. Serum transferrin and total serum iron concentrations were determined 
k'" 
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in duplicate as described in Materials and Methods (secs. 2.2.9. & 2.2.10. respectively). 
The study was conducted twice with a two week period between experiments. Figures 
4.1. and 4.2. show the profiles obtained for both parameters. Both profiles gave a similar 
pattern for the two parameters when comparing the results obtained for each 
independent study (i. e. A or B), suggesting a close relationship between serum 
transferrin and total serum iron concentrations. Similarly, the inter-study profile 
obtained for serum transferrin concentrations in studies A and B suggested a common 
profile where the level of serum transferrin was high in the afternoon, then dropping 
during the day to a low in the evening. This was then followed by a rise during the night 
and morning to another high in the afternoon. A similar profile could also be discerned 
for the level of total serum iron. 
i. `* 1 
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Figure 4.1. Variation of serum transferrin concentration over a 36hr period in one 
individual. 
Time 
12am 12pm 12am 12pm 12am 
4am gam 4pm 8pm 4am 8am 4pm 8pm 
3.20 
3.00 
2.80 
2.60 
2.40 
2.20 
2.00 
1 sin 
oA 
"B 
`w 
<V CM .rN .o aý OaO .4N4, 
The above letters denote the following: A= First study; B= Second study 
Figure 4.2. Variation of total serum iron concentration over a 36hr period in one 
individual. 
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The study was extended to 10 other individuals comprising 5 males and 5 females. 
Because of the difficulties in obtaining samples from subjects at 4hr intervals, time 
points at which samples were to be taken were determined from Figures 4.1. and 4.2. On 
the basis that the latter showed a high in the afternoon and a low in the evening, the 
three time points chosen were at 10am, 2pm and 6pm. Samples were taken from 
subjects in a rota system over a4 week period, and all sera frozen until the last 
individual was bled. Measurements were then made in duplicate as described above. 
Figures 4.3. and 4.4. show the profiles observed for the plasma transferrin 
concentrations of males and females respectively. The two groups were split to see if 
there were any differences in profile relating to sex of subjects. In both cases it was 
noticeable that there was a wide spread of profiles with some individuals showing high 
concentrations in the morning and others a high in the afternoon. It was also noticeable 
that in most instances; the profile in the first half of the study (i. e. loam - 6pm) was not 
repeated in the second half of the study as expected. The majority of both sexes however 
appeared to show a similar profile of a peak in the afternoon sample of the first half of 
the study, with a low in the afternoon sample of the second half of the study. 
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Figure 4.3. Profiles of serum transferrin concentrations in 5 males over a 32hr period. 
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Figure 4.4. Profiles of serum transferrin concentrations in 5 females over a 32hr period. 
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Figure 4.5. Profiles of total serum iron concentrations in 5 males over a 32hr period. 
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Figure 4.6. Profiles of total serum iron concentrations in 5 females over a 32hr period. 
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The resulting profiles obtained for the total serum iron concentrations of both sexes are 
shown in Figures 4.5. and 4.6. The profile observed for most of the males and females 
were similar to that seen for the serum transferrin concentrations (i. e. a peak in the 
afternoon in the first half, and a low in the afternoon in the second half of the study). 
The most noticeable difference was the pattern of male 2 with a steady decline in total 
serum iron concentration over the experimental period (Fig. 4.5. ). The mean serum 
transferrin and total serum iron concentrations for the 10 individuals, as a function of 
the three time points (i. e. all loam, 2pm and 6pm samples) are given in Table 4.1. 
Table 4.1. Mean serum transferrin and total serum iron concentrations according to the 
time of day. 
Time Mean serum transferrin (mg/ml) 
(mean ± s. d.; n= 20) 
Mean total serum iron (mg/ml) 
(mean ± s. d.; n= 20) 
10am 3.04 ± 0.31 11.4 ± 3.5 
2pm 3.15 ± 0.39 12.5 ± 2.9 
6pm 3.16 ± 0.37 11.0 ±2.8 
Statistical analysis of the two parameters by analysis of variance failed to find a 
significant difference between the samples for the three time periods (F = 1.13, p> 0.10 
(2,57df) and F=0.65, p> 0.10 (2,57df) for serum transferrin and total serum iron 
respectively). The only observations that could therefore be made with respect to this 
study was that although both serum transferrin and total serum iron concentrations 
fluctuated during the day, the fluctuations were not constant in a particular direction. 
The latter observation was therefore similar to the observation by Hamilton et al., (1950) 
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that in most reports on the diurnal variation of plasma iron some individuals are found 
to show variations of the general trend. It is however noticeable that as in this study, the 
number of individuals in the study by Hamilton et al., (1950) and those reported within 
the latter study are relatively small (i. e. ranging from 1- 48). A larger sample may shed 
further light on the matter. However, despite the small sample studied in this 
investigation, it was concluded that studies of plasma transferrin concentrations would 
not be adversely affected by the time the samples were taken, particularly if large 
samples are used. At the start of the study on Tf C subtypes, the initial aim was to 
investigate the relationship between the latter and plasma transferrin and total iron 
concentrations. However, the quantitative kit purchased for the determination of total 
serum iron (sec. 2.2.10. ) was found to be ineffective for plasma samples. Trials with 
serum and plasma samples found that the final plasma absorbance was excessively high 
(i. e. Abs56onm 0.100 and 1.704 for serum and plasma respectively), giving a total plasma 
iron concentration of 1985µg/dl compared to a serum concentration of 98µg/dl. Whereas 
the serum sample was a clear solution after incubation with the iron colour reagent, the 
plasma sample was found to be turbid. It was therefore hypothesised that the disparity 
was due either to the presence of the anticoagulant dipotassium EDTA present in the 
tubes containing plasma samples, or to the various blood clotting factors present in 
plasma but not in serum. Analysis of a serum sample collected in the presence of the 
anticoagulant showed a final absorbance less than that of the starting absorbance. This 
suggested that dipotassium EDTA was capable of forming a stable soluble complex with 
free serum iron thereby reducing the amount of free iron present for binding by the iron 
colour reagent. The same result was also found when the iron standard was incubated 
with the anticoagulant before analysis. A series of experiments were therefore carried 
out in an attempt to remove the anticoagulant from plasma. The first method tried was 
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dialysis of plasma against physiological saline (0.85% w/v). A sample dialysed against 
fresh saline for 96hr was found to have a final absorbance less than that of the same 
plasma sample dialysed for 24hr (Abs56o,,,,, 1.020 and 1.423 respectively). The 
absorbance was however still excessively high indicating that the majority of the 
anticoagulant was still present in the plasma sample. As dipotassium EDTA is a strong 
chelating agent and is known to bind a number of transition metals, a series of 
investigations were then performed in an attempt to find a metal with a higher affinity 
than Fe 2+ for the anticoagulant. This would then allow the free iron to be bound by the 
iron colour reagent. The four metals chosen for the study, Mn2+, Zn2+, Cu2+ and Co2+ 
show a dipotassium EDTA - metal complex stability in the order of Mn2+ < Fe2+ < Co2+ 
< Cu2+ > Zn2+. Aliquots (20µl) of the four metal salts (MnC12i ZnSO4, CuSO4 and cobalt 
acetate) were added to 38Oµ1 physiological saline-dipotassium EDTA, mixed and left 
for 20min to allow binding of the metal ion. l00µ1 of the iron standard (500µg iron) was 
added to the mixture and left for 5min, before using l00µ1 as the test sample. Control 
samples were without dipotassium EDTA. Samples analysed after incubation with the 
iron colour reagent showed that the Co2+ and Cu2+ samples and controls were 
ineffective, as the Cu2+ samples gave high absorbances (probably as a result of the 
strong brown colour on mixing with the iron colour reagent), whilst the Co2+ samples 
and controls showed little change from the initial absorbances. Although the I 2+ - 
EDTA sample had a lower absorbance than that found for the Cu2+ samples, the control 
sample showed a higher absorbance (i. e. Abs560,,,,, 0.084 compared to 0.064) suggesting 
that free iron was still being prevented from binding to the iron colour reagent. The only 
metal that appeared to work was Zn2+, the Zn2+ - EDTA and control samples both 
showing near identical absorbances in the region expected for normal binding of iron by 
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the iron colour reagent. This suggested that Zn 2+ was bound by dipotassium EDTA 
thereby allowing the free iron from the added iron standard to be bound as expected. 
The method was however found to be ineffective for use with plasma samples as 
addition of various aliquots (20,10 and 2µl) of ZnSO4 to plasma samples resulted in 
either a white precipitate (20µl) or a solution with a whitish colour (10 and 2p1). In 
addition, plasma samples were still found to be turbid and gave very high absorbances. 
Because of the continued inability to resolve the situation, a decision was then taken to 
stop further investigations. The decision was made on the basis that even if the protocol 
was established for use with plasma, another problem would arise with regard to the 
volume of sample used in the protocol. Although the protocol had already been 
modified by using a 1/5 of the reaction volumes recommended by the manufacturers of 
the quantitative kit, the study would still require a sample volume of 100µl. As all 
samples were to be measured in duplicate, a minimum volume of 300µl would be 
required for each plasma sample studied. This would mean that the majority of the 
plasma samples obtained for the ensuing study would probably have insufficient 
volumes for accurate determination of the total plasma iron concentration, thereby 
affecting the results of the study. The ensuing study was therefore restricted to the 
determination of Tf C subtypes and plasma transferrin concentration. 
4.2.2. RELATIONSHIP BETWEEN Tf C SUBTYPES AND SERUM 
TRANSFERRIN CONCENTRATION 
The Tf C phenotypes of 653 students at Queen Mary & Westfield College were 
determined as described in Materials and Methods (sec. 2.2.6. ). In addition, the 
transferrin phenotypes of a further 278 individuals were provided by the Haematology 
Department of the London Hospital, giving a total of 931 individuals studied. The 
14 
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electrophoretic mobility for five of the six most common TF C subtypes are shown in 
Figure 4.7. 
Figure 4.7. PAIEF gel of human plasma showing five of the six most common 
transferrin subtypes. 
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Table 4.2. Distribution of Tf C subtypes and allele frequencies in 931 individuals. 
Transferrin 
subtype 
Observed 
subtype 
frequency 
(%) 
Expected 
subtype 
frequency 
(%) 
Observed 
subtype 
number 
Expected 
subtype 
number 
Allele 
frequency 
Cl 58.9 56.0 548 521 0.748 
C2 6.0 3.7 56 34 0.192 
C3 0.0 0.4 0 4 0.060 
C2-1 23.2 28.7 216 267 
C3-1 8.7 9.0 81 84 
C3-2 3.2 2.3 30 21 
Total 100.0 100.1 931 931 
The distribution of the different Tf C subtypes found in the study is shown in Table 4.2. 
The latter shows the Tf C3 subtype was not encountered. However, the observed 
distribution for the five other Tf C subtypes showed a close agreement with expected 
numbers following the Hardy-Weinberg assumption of population equilibrium. The 
mean plasma transferrin concentrations for the 931 individuals, measured in duplicate 
by single immunodiffusion (sec. 2.2.9. ) are shown as a function of transferrin phenotype 
in Table 4.3. 
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Table 4.3. The mean plasma transferrin concentrations for five Tf C subtypes. 
Transferrin 
subtype 
Mean transferrin concentration 
(mg/dl) 
Range 
(mg/dl) 
Tf Cl 286 ± 31 153 - 480 
Tf C2 266 ± 25 178 - 400 
Tf C2-1 287 ± 31 165 - 469 
Tf C3-1 272 ± 31 155 - 470 
Tf C3-2 268 ± 14 200 - 351 
Table 4.4. Statistical analysis of the relationship between plasma transferrin 
concentration and Tf C subtypes. 
Transferrin subtype t Distribution 
(for unequal populations) 
probability 
Tf CI vs Tf C2 2.82 < 0.01 
Tf C2-1 vs Tf C2 2.73 < 0.01 
Tf C2-1 vs Tf C3-2 2.43 < 0.05 
Tf C1 vs Tf C3-2 2.35 < 0.05 
Tf C1 vs Tf C3-1 2.11 < 0.05 
Tf C2-1 vs Tf C3-1 2.07 < 0.05 
Tf C3-1 vs Tf C2 0.66 > 0.10 
Tf C3-1 vs Tf C3-2 0.43 > 0.10 
Tf C1 vs Tf C2-1 0.22 > 0.10 
Tf C3-2 vs Tf C2 0.21 > 0.10 
F-ratio = 3.4, p< 0.01(4,926df) 
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The results for the 931 individuals were analysed statistically by both analysis of 
variance and by the t Distribution test to establish whether there were any significant 
differences between the five Tf C subtypes with respect to plasma transferrin 
concentration. The results are shown in Table 4.4. A significant difference was found to 
exist between the transferrin concentrations of the various Tf C subtypes when analysed 
by analysis of variance (F = 3.4, p< 0.01). Further analysis by the t Distribution test 
revealed a significant difference between the transferrin concentrations of the Tf Cl and 
Tf C2 subtypes (p< 0.01), and between the Tf C2-1 and Tf C2 subtypes (p< 0.01). These 
findings are different to those obtained in two studies by Eckfeldt et al., (1985) and 
Wong & Saha (1986) who failed to find any significant differences. The results are 
however similar to those reported by Cleve et al., (1988) who found a significant 
difference between the Tf Cl and Tf C2-1 European groups studied (F = 2.64, p< 0.01), 
and to those reported by Kita et al., (1994) that transferrin concentrations vary according 
to transferrin type. The results of the latter study, and that of Eckfeldt et al., (1985), 
Wong & Saha (1986), Cleve et al., (1988) and of this study are shown in Table 4.5. 
Transferrin concentrations are shown in mg/dl units for comparative reasons. Values for 
the studies by Eckfeldt et al., (1985) and Wong & Saha (1986) were converted using a 
transferrin M,  of 80000. 
t 
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Table 4.5. Comparison of mean plasma transferrin concentrations for various Tf C 
subtypes from 5 studies. 
Tf 
subtype 
Eckfeldt et 
al., 
(1985) 
N mg/dl 
Wong & 
Saha 
(1986) 
N mg/dl 
Cleve et al., 
(1988) 
European 
African 
N mg/dl N mg/dl 
Kita et 
al., 
(1994) 
N mg/ml 
This 
study 
N mg/dl 
All 84 272 210 64 1536 931 
Tf C1 20 323 137 213 142 374 54 520 933 291 548 286 
Tf C2 16 291 30 218 4 279 3 399 60 267 56 266 
If C2-1 20 317 105 220 49 342 7 461 543 282 216 287 
Tf C3 2 308 -- ---- - -- 
Tf C3-1 20 291 - 10 360 -- - 81 272 
Tf 0-2 6 310 -- 5 329 -- -- 30 268 
Table 4.5. shows that the mean transferrin concentrations obtained in this study for the 
Tf Cl, Tf C2 and Tf C2-1 subtypes were very similar to those found by Kita et al., 
(1994). The similarity is probably related to the larger sample sizes used in both studies 
and the fact that both measured the transferrin concentration using single radial 
immunodiffusion. Although the previous study by Eckfeldt et al., (1985) failed to find a 
significant difference between the Tf C subtypes, they did find that the Tf Cl subtypes 
had the highest transferrin concentrations, the Tf C2 subtypes the lowest, with the 
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Tf C2-1 subtypes in between the two (Table 4.5. ). This observation is also seen in the 
studies by Cleve et al., (1988), Kita et al., (1994) and in this study, although the Tf Cl 
and Tf C2-1 subtypes in this study had similar mean concentrations. However, unlike 
the other reports, the present study also found reasonably significant differences 
between the Tf Cl and Tf C3-1 subtypes, as well as between the Tf C2-1 and Tf C3-1 
and Tf C3-2 subtypes (p< 0.05 for all). These results therefore suggest an association of 
the Tf C2 and Tf C3 alleles with low plasma transferrin concentrations. Both alleles are 
believed to have a disadvantageous selective role in humans, and have been associated 
with a number of disorders. Beckman et al., (1980) for example reported a high 
incidence of the Tf C2 allele in mothers with a previous history of spontaneous abortion. 
Their proposal of a selective mechanism of the Tf C2 allele for reproductive disorders 
was supported by the findings of Auconi et al., (1982) who also reported a significant 
increase of the Tf C2 type in extremely premature infants. Weitkamp & Schacter (1985) 
on the other hand reported an association between the Tf C3 allele and spontaneous 
abortion in couples with first-trimester recurrent spontaneous abortion. Saha et al., 
(1990) reaffirmed the association between the Tf C2 type and spontaneous abortion, 
reporting a significantly higher incidence of the allele and related subtypes in new-borns 
whose mothers had a history of previous spontaneous abortion. Other associations have 
been found between the Tf C2 and Tf C2-1 types and occupational photodermatosis of 
the face (Beckman et al., 1985), between the Tf C2 allele and rheumatoid arthritis (el- 
Hazmi et al., 1991), and between the Tf C2 subtype and Alzheimer's disease (van 
Rensburg et al., 1993). The Tf C3 subtypes have also been found to be associated with 
adenocarcinoma, particularly in males (Frohlander et al., 1989), and is present in high 
frequencies in patients surviving myocardial infarction (Sikstrom et al., 1993a). A recent 
study by Sikstrom et al., (1996) however found that individuals with the Tf C3 subtypes 
V 
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appeared to protected against smoking-associated lung cancer. Although the report by 
el-Hazmi et al., (1991) suggested that a possible genetic linkage of the Tf C2 allele to 
another locus might be influencing susceptibility to rheumatoid arthritis, the general 
consensus is that the association of the Tf C2 and Tf C3 alleles with the various 
disorders is related to increased formation of free radicals. It has been postulated that the 
mechanism behind the various associations is that of increased iron transport to tissues 
resulting in increased body iron stores (Beckman et al., 1985; Sikstrom et al., 1993b). 
The latter may result in increased free cellular iron which can catalyse the 
decomposition of H202 via the iron-catalysed Haber-Weiss reaction, with subsequent 
formation of reactive oxygen free radicals (Halliwell & Gutteridge, 1984). As oxygen 
free radicals are capable of reacting with virtually all biological molecules in cells, their 
formation can then promote various cyto- and geno-toxic damage. Van Rensburg et al., 
(1995) suggested that the association between Tf C2 and Alzheimer's disease was due 
to defective binding of iron and aluminium by Tf C2. They proposed that the defective 
binding results in endosomal release of A13+ and Fe3+ during receptor-mediated 
endocytosis, with the released Fe3+ catalysing the production of hydroxyl free radicals, 
whilst A13+ binds to phosphate groups of the charged headgroups of endocytic 
membrane phospholipids. Repulsion of A13+ ions bound to adjacent phosphate groups 
cause gaps in the endocytic membrane, exposing fatty acids on the inside of the bilayer, 
which can then be attacked by the hydroxyl radicals causing lipid peroxidation (Fig. 
4.8. ). 
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Figure 4.8. Involvement of Fe 3+ and A13+ in membrane lipid peroxidation. 
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The damaged endocytic vesicles may then interact with lysosomes as the vesicles are 
recycled to the cell membrane. The interaction is believed to result in similar damage to 
lysosomal membranes, which may account for the presence of damaged lysosomal 
membranes in the etiology of Alzheimer's disease. The results from this study for Tf C2 
and Tf C3 plasma concentrations, and the findings of Kita et al., (1994) support the view 
that the disadvantageous selective mechanism for the two alleles involve increased iron 
transport and uptake. Low plasma transferrin concentrations are known to be associated 
with lower TIBC, increased serum iron levels and increased transferrin saturation 
(Sikstrom et at., 1993b). The results from this study are therefore supported by the 
findings of Cleve et al., (1988) that the TIBC of the Tf C1 subtype is significantly higher 
than that of the Tf C2-1 or Tf C2 subtypes. Although the lower TIBC means that fully- 
saturated Tf C2 and Tf C3 would be carrying less iron than fully-saturated Tf Cl, 
transferrin under normal conditions is only about 30% saturated (Liebman & Aisen, 
1979). Therefore the increased serum iron levels and increased transferrin saturation of 
I 
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the two transferrins are of greater significance as they would lead to greater cellular iron 
uptake and increased body iron stores. This may in turn then lead to increased free 
cellular iron and subsequent promotion of reactive free radicals as proposed by other 
workers (Beckman et al., 1985; Sikstrom et al., 1993a; van Rensburg et al., 1995). 
4.3. CONCLUSIONS 
The plasma transferrin concentrations of 931 unrelated individuals showing five of the 
six most common Tf C phenotypes have been determined by single radial 
immunodiffusion, and compared on the basis of transferrin phenotypes. A significant 
difference was found between transferrin phenotypes implying that plasma transferrin 
concentration is dependent on transferrin phenotype. The two Tf C alleles, Tf C2 and Tf 
C3, were found to be associated with low plasma concentrations. It is concluded that the 
disadvantageous selective mechanisms associated with the two alleles are related to the 
low plasma concentration, as the latter promotes greater iron uptake with possible 
formation of reactive oxygen free radicals. 
v 
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CHAPTER FIVE 
5. IDENTIFICATION OF BASE 1086 IN EXON 8 OF THE HUMAN 
TRANSFERKIN GENE 
5.1. INTRODUCTION 
The nucleotide sequence for the coding regions of the cloned human transferrin gene 
(Hershberger et al., 1991) differs at nine positions from the compiled nucleotide 
sequence (Park et al., 1985; and Schaeffer et al., 1987). Of the nine discrepancies, only 
one nucleotide difference at base 1086 in exon 8 (amino acid 310; MacGillivray et al., 
(1983) numbering) is nondegenerate, changing the asparagine (Asn) codon (AAT) in the 
compiled sequence to an aspartic acid (Asp) codon (GAT) in the Hershberger et al., 
sequence. Unlike the compiled sequence, the translated mRNA sequence (Yang et al., 
1984) agrees with the Hershberger et al., sequence at amino acid 310. Analysis of PCR 
amplified regions of exon 8 in 14 individuals also confirmed the presence of guanine 
(G) rather than adenine (A) at base 1086 (Hershberger et al., 1991). The five abnormal 
transferrins, Tf DI (Wang & Sutton, 1965), Tf Doh; (Wang & Sutton, 1967), Tf DEvans 
(1982), Tf B2 (Wang et al., 1966), Tf Bshaw (Welch & Langmead, 1990) and the wild- 
type Tf C (Yang et al., 1984) appear to contain aG at base 1086. It was therefore 
suggested by Hershberger et al., (1991) that Asp may be the predominant residue at 
position 310, and that a transferrin allele of undetermined electrophoretic class with Asn 
at position 310 (designated as Tf Xpazk) may exist within the population. An Asn residue 
at position 310 would be expected to result in a transferrin with an electrophoretic 
mobility relatively less anodal than transferrin with Asp at position 310, due to 
differences in the net charge of the transferrin molecule. As Tf C appears to contain the 
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latter, Tf Xpazk would be expected to have an electrophoretic mobility characteristic of 
the slower moving transferrin bands associated with Tf DVARIAWS or with the various Tf 
C subtypes. In the study by Hershberger et al., (1991) the 14 samples analysed for the 
identity of the amino acid at position 310, were not analysed for their transferrin 
phenotypes. Subsequently transferrin alleles studied are not known. This study was 
therefore carried out to determine whether the observation by Hershberger et al., that 
Asp predominated at position 310 was consistent in a larger sample population of 
known transferrin phenotypes, comprising the three most common Tf C alleles, Tf Cl, 
TfC2andTfC3. 
5.2. RESULTS AND DISCUSSION 
5.2.1. POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION OF THE 
NUCLEOTIDE SEQUENCE CORRESPONDING TO EXON 8 OF THE HUMAN 
PLASMA TRANSFERRIN GENE 
5.2.1.1. OLIGONUCLEOTIDE PRIMER SELECTION 
The 180bp nucleotide sequence of exon 8 of the human plasma transferrin gene was 
amplified using two primers corresponding to the flanking 5' sense and antisense 
sequences. The primers were chosen following a manual examination of the exon 
sequence. The examination was initially carried out to locate a sequence that could be 
slightly modified to give a primer with an internal restriction enzyme recognition site 
that terminated in the base of interest (i. e. G or A at base 1086, (Hershberger et al., 
(1991) numbering). The presence or absence of the base of interest would then be 
simply determined by restriction site analysis. During the course of the manual 
r 
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examination, it became apparent that there was a natural recognition site 
(5' GGATG(N)9/) for the restriction endonuclease (RE) Fok I, that included the G at 
base 1086 (Fig. 5.1. ). Furthermore, substitution of G for A at the same position also 
gave a natural recognition site (5' GAATGCN/ ) for a different restriction 
endonuclease, Bsm I (Fig. 5.1. ). As there was no longer a requirement to design 
modified primers, the entire 180bp nucleotide sequence of exon 8 was amplified using 
two primers that flanked the region (Fig. 5.1. ). The primer sequences were checked to 
ensure that there was minimal base complementarity between the two. Primers (28mer 
for the sense strand and 25mer for the antisense strand) were commercially synthesised 
and stored as 100µl aliquots. 
Figure 5.1. The nucleotide sequence (sense strand) of exon 8 of the human transferrin 
gene. 
5' GAA CAT TTT GGC AAA GAC AAA TCA AAA GAA TTC CAA CTA TTC AGC 
PCR Primer I> 
TCT CCT CAT GGG AAG GAC CTG CTG TTT AAG GAC TCT GCC CAC GGG 
Bsm I site # 
A 
TTT TTA AAA GTC CCC CCC AGG ATG GAT GCC AAG ATG TAC CTG GGC 
Fok I site # 
TAT GAG TAT GTC ACT GCC ATC CGG AAT CTA CGG GAA GGC ACA TGC 3' 
3'G TAG GCC TTA GAT GCC CTT CCG TGT ACG 5' 
< PCR Primer 2 
The above sequence is taken from Hershberger et al., (1991). The major line contains the nucleotide sequence of the 
sense strand. Nucleotide differences are denoted as bold and underlined letters. # indicates the position at which the 
sense strand is cut by the respective restriction endonuclease. 
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5.2.1.2. ESTABLISHMENT OF PCR PROTOCOL , 
Initial attempts at amplifying exon 8 used a modified version of the protocol described 
by Innis et al., (1984). A reaction concentration of 1.5mM MgCl,, 0.8µM primers and 
200µM deoxynucleotide triphosphate (dNTP) was obtained by mixing: 5µI lOx 
ammonium reaction buffer (160mM (NH, )ZSO, / 670mM Tris-HC1(pH 8.8)/ 0.1% (v/v) 
Tween-20); MAI MgCI2 (50mM); 2. t1 of each primer (20µM); 5µl dNTPs (solution 
containing all four dNTPs at 2mM each); and 14.5µl sterile double-distilled deionised 
water. To reduce the possibility of reagent cross-contamination with DNA template, 
stock reaction solutions were irradiated with ultraviolet light for 1 min in a Stratalinker. 
Solutions were made to a final volume of 50µl in 0.25m1 thin-walled PCR Eppendorf 
tubes by the addition of 20µl of sterile double-distilled deionised water or Instagene 
DNA ((250ng) (sec. 2.2.12.2. ). Samples for phenol-extracted DNA (sec. 2.2.12.1. ) from 
the same individual as the Instagene DNA sample were made up to 50µ1 by the addition 
of 5µl DNA (- lµg) and 15µl sterile double-distilled deionised water. Samples were 
briefly vortexed (-' 10sec) and incubated for 3min at 92°C in a Hybaid PCR 
thermocycler. 2.5pl Taq polymerase (5U/µl) was added, samples briefly vortexed and 
centrifuged at 2500rpm for 10sec. Tubes were returned to the thermocycler and 2Oµ1 
inert mineral oil added to each tube to minimise evaporation during amplification. 
Samples were amplified for 40 cycles of I min at 74°C, I min at 92°C and I min at 50°C. 
The cycle was ended with a final extension period of 3min at 74°C. Amplification 
products were analysed on 3% (w/v) agarose gels (sec. 2.2.14. ) (Fig. 5.2. ). Product sizes 
were determined from a calibration curve of log10 MW DNA markers against migration 
distance (Fig. 5.3. ). 
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Figure 5.2. Preliminary restriction digest analysis of amplified exon 8. 
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I=1 kb DNA markers (a = 506bp; b= 396bp; c= 344bp; d= 298bp; e= 220bp; f= 201 bp; g= 154bp; h 
= 134bp; I= 72bp); 2= Instagene DNA; 3= Instagene DNA & Fok I; 4= Phenol DNA; 5= Phenol DNA 
& Fok I; 
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Figure 5.3. Calibration curve for the determination of the sizes of amplified product. 
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The gels showed that an amplified product of estimated size 174bp was obtained with 
samples containing phenol-extracted DNA (Fig. 5.2. ). Two other bands corresponding 
to estimated sizes of 95bp and 50bp were also obtained in smaller amounts. In contrast, 
both the control and Instagene samples only had the 50bp band present. A second 
experiment was then carried out to establish whether the nonspecific amplification 
products (i. e. the 95bp and 50bp products) could be eliminated by increasing the 
stringency of amplification process. The temperature profile was changed to a 
modification of the profile described by Bangham (1991) for the amplification of 
sequences of less than 200bp. The extension step used in the previous experiment was 
omitted, and phenol-extracted DNA samples amplified for 35 cycles of I min at 69°C 
232 
(5°C below the lowest primer melting temperature (Tm)) and lmin at 92°C, followed by 
a final extension period of 3min at 74°C. In addition, samples were amplified with 
varying concentrations of primers and/or dNTPs (Table 5.1. ). 
Table 5.1. Reaction factors varied during PCR amplification of phenol-extracted DNA. 
Sample Variable factor Reaction concentration 
1 As first amplification 
3 dNTP 100 
5 primer 0.4 
7 dNTP & primer 100 & 0.4 
9 dNTP 50 
11 primer 0.2 
13 dNTP & primer 50 & 0.2 
15 dNTP & primer 100 & 0.2 
17 dNTP & primer 50 & 0.4 
Note: Control samples were amplified for each test sample 
Amplified products analysed on 3% (w/v) agarose gels showed that with the exception 
of sample 7, all other samples had the exon 8 product band and the 50bp band present 
(Fig. 5.4. ). None of the samples had the 95bp band seen in the previous amplification. 
Similarly, the only product band seen in all control samples was the 50bp band (Fig. 
5.4. ). 
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Figure 5.4.3% (w/v) agarose electrophoresis of phenol-extracted DNA under varying 
primer and dNTP concentrations. 
(Origin) 
(Anode) 
a=1 kb DNA markers; b= sample 1; c= control sample 1; d= sample 3; e= control sample 3; f= sample 
5; g= control sample 5; h= sample 7; i= control sample 7; j= sample 9; k= control sample 9; 1= sample 
11; m= control sample 11; n= sample 13; o= control sample 13; p= sample 15; q= control sample 15; r 
= sample 17; s= control sample 17. 
The results therefore suggested that the change in temperature profile had a greater 
effect on the stringency of the amplification process, since varying the concentrations of 
primer or dNTP appeared to have no significant effect on the production of exon 8 
product. A further study was conducted to determine whether the 50bp product present 
i; )n mI kjihgfedcba 
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in previous amplifications was due to reagent contamination or to nonspecific 
amplifications. Two separate experiments were performed using the same reagent 
solutions. Reagent concentrations were kept as in the first amplification experiment. The 
temperature profile was the two step cycle used in the previous amplification. In the first 
experiment, control samples were amplified with one or more of the reagent constituents 
omitted. In the second experiment, samples were amplified using varying amounts of 
phenol-extracted DNA, and bacterial DNA. Amplified products were analysed on 3% 
(w/v) agarose gels. The control results showed that the 50bp band was only present 
when all the reagent constituents were present (Fig. 5.5. ). This strongly suggested that 
the 50bp product was a template-independent artefact. As primer-dimer artefacts form 
products with a size slightly less than the combined sizes of the two primers (53bp in 
this study), the 50bp product was concluded to be a primer-dimer product. The sample 
results showed that the amount of amplified exon 8 product obtained varied 
proportionately with the amount of starting DNA material. Figure 5.6 showed that the 
primer-dimer artefact was only present in samples with less than 1 µg starting DNA 
material. Since primer-dimers can compete with the template for primers, dNTPs and 
enzyme, the results suggested that the low amplified quantities of exon 8 product at low 
DNA concentrations was probably due to interference by the primer-dimer artefact. The 
lack of amplification with the bacterial DNA sample (Fig. 5.6. ) did however indicate 
that the primers were specific for the exon 8 sequence. 
t 
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Figure 5.5.3% (w/v) agarose gel analysis of amplification products of reagent controls. 
! Origin V 
,e ,f 
Nh 
(Anode) 
1=l kb DNA markers (a = 506bp; b= 396bp; c= 344bp; d= 298bp; e= 220bp; f= 201bp; g= 154bp; It 
= 134bp; i= 72bp); 2= all reagent constituents; 3= no primer 1; 4= no primer 2; 5= no dNTPs; 6= no 
Taq polymerase; 7= no primer 1 or 2; 8= no primer 1 or dNTPs; 9= no primer I or Taq polymerase; 10 
= no primer 2 or dNTPs; 11 = no primer 2 or Taq polymerase; 12 = no dNTPs or Taq polymerase. 
Figure 5.6.3% (w/v) agarose analysis of amplification products using varying amounts 
of human genomic DNA, and bacterial DNA. 
(Origin) 
10 987654321 
(Anode) 
I& 10 = amplified exon 8 product; 2&3= primer 2; 4= control; 5= 1µg human genomic DNA; 6= 
0.1µg human genomic DNA; 7=0.02µg human genomic DNA; 8=0.01µg human genomic DNA; 9= 
I µg bacterial DNA 
12 1110 987654321 
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5.2.1.3. OPTIMISATION OF PCR PROTOCOL 
Initial PCR amplifications (sec. 5.2.1.2. ) showed that amplification of the exon 8 
sequence was associated with the presence of the template-independent primer-dimer 
artefact. As the latter can interfere with the amplification process by competing with the 
template for primers, dNTPs and enzyme, a series of optimisation experiments were 
carried out to attempt to minimise the presence of the artefact. The same phenol- 
extracted genomic DNA sample was used for the following studies. 
5.2.1.3.1. EFFECT OF MgC12 CONCENTRATION 
The stringency of the PCR gmplification process was first investigated using varying 
concentrations of MgCl2- Samples containing reaction concentrations of 1.5/ 3.0/ 4.5/ 
6.0/ and 7.5 mM MgC12 were amplified using the two step temperature profile of 30 
cycles of 1min at 69°C and 1min at 92°C, followed by a 3min extension period at 74°C 
(sec. 5.2.1.2. ). The amplified control sample had a MgC12 concentration of 7.5mM. 
Products analysed on a 3% (w/v) agarose gel (Fig. 5.7. ) showed that a concentration of 
1.5mM MgC12 failed to produce the expected exon 8 band, despite allowing 
amplification in previous experiments. MgCl2 concentrations of 3.0 - 7.5mM allowed 
amplification of the required exon 8 product. However concentrations of 4.5 - 7.5 also 
allowed amplification of two other nonspecific products (i. e. the 95bp and 50bp 
products obtained in the first amplification attempt (sec. 5.2.1.2. ). The only nonspecific 
product in the 3.0mM MgCl2 sample was the 50bp primer-dimer artefact. The results 
therefore suggested that the stringency of the amplification process could be increased 
by using a low reaction concentration of MgC12. 
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Figure 5.7.3% (w/v) agarose gel electrophoresis of amplified products obtained using 
different reaction concentrations of MgC12. 
(Origin) 
MgCI2 concentration (mM) 
(Anode) 
M= amplified exon 8 product; C =control; P= 25mer primer 
5.2.1.3.2. OPTIMISATION OF MgC12 AND TAQ POLYMERASE 
CONCENTRATIONS 
The previous study (sec. 5.2.1.3.1. ) suggested that a MgCI2 concentration between 
1.5mM and 3.0mM was optimal for PCR amplification of the exon 8 sequence. In all of 
the previous studies, samples were amplified with 2.5U of Taq polymerase. Although 
low enzyme concentrations can hinder the amplification of required product, high 
concentrations can also result in the accumulation of nonspecific products. Therefore as 
part of the optimisation process, a study was conducted to optimise both the MgCI2 and 
Taq polymerase concentrations. Samples containing either 2.0/ 2.5 or 3.0mM MgCI2 
were therefore amplified using either 2.5/ 1.5/ 1.0 or 0.5U of Taq polymerase. Reagent 
controls were amplified using 3.0mM MgC12 and the four different enzyme 
P 7.5 4.5 1.5 Al 
6.0 3.0 C 
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concentrations. Products analysed on 3% (w/v) agarose gels showed that the only MgCl2 
concentration that consistently allowed amplification of exon 8 product was 3.0mM 
(Fig. 5.8b). All four enzyme concentrations allowed amplification of the required 
product. However, the only concentration that prevented the generation of the primer- 
dimer artefact in all three MgCl, samples was 0.5U (Fig. 5.8a). The reaction controls all 
showed the presence of primer-dimers, although the amount of the artefact in the 0.5U 
sample appeared to be relatively less compared with the other three enzyme 
concentrations (Fig. 5.8a). The results therefore suggested that a MgC12 concentration of 
3.0mM and a Taq polymerase concentration of 0.5U were optimal for amplification of 
exon 8 product. 
Figure 5.8.3% (w/v) agarose gel electrophoresis of amplified products showing the 
effect of varying MgC12 and Taq polymerase concentrations. 
(Origin) 
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M= Amplified exon 8 product; P= 25-mer primer 
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5.2.1.3.3. OPTIMISATION OF PRIMER CONCENTRATION 
Since high primer concentrations can also interfere with the accumulation of required 
product by promoting mispriming and hence accumulation of nonspecific products and 
primer-dimer artefacts, the last reaction factor optimised was that of primer 
concentration. Samples containing 0.8/ 0.4/ 0.2 or 0.1µM were amplified using the 
optimal MgC12 and Taq polymerase concentrations of 3.0mM and 0.5U respectively. 
Reagent controls were amplified using the four primer concentrations. Amplified 
products analysed on a 3% (w/v) agarose gel showed that the only primer concentration 
that allowed amplification of exon 8 product was 0.8µM (Fig. 5.9-). Although the 
primer-dimer artefact was also present in the sample, the amount was considerably less 
than that of the exon 8 product. The only reagent control in which the primer-dimer 
artefact was observed was the sample containing a 0.8µM primer concentration (Fig. 
5.9 ). This suggested that nonspecific amplification could be reduced using low primer 
concentrations. However, the lack of amplification of exon 8 product in samples 
containing less than 0.8µM primer precludes the use of lower concentrations. A primer 
concentration of 0.8µM was therefore chosen as the optimal concentration. 
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Figure 5.9.3% (w/v) agarose gel electrophoresis of amplified products at different 
primer concentrations. 
(Origin) 
4321 
Primer concentration (NM) 
(Anode) 
M= Amplified exon 8 product; P= 25-mer primer 
5.2.1.3.4. OPTIMISATION OF PCR PROTOCOL FOR USE WITH 
INSTAGENE MATRIX GENOMIC DNA PREPARATIONS 
Because of the comparative ease and safety of genomic DNA sample preparation using 
the Instagene matrix system, further attempts were made to find appropriate conditions 
that would allow amplification of exon 8. Samples containing Instagene matrix 
preparations, were amplified using optimal primer (sec. 5.2.1.3.3. ), and MgCl, and Taq 
P 0.1 0.2 0.4 0.8 M 
241 
polymerase (sec. 5.2.1.3.2. ) concentrations. The amount of DNA present in the 
Instagene matrix samples used in the initial amplification studies (sec. 5.2.1.2. ) were 
typically about %a of that present in the phenol-extracted DNA samples. Previous studies 
(sec. 5.2.1.2. ) showed that the primer-dimer artefacts were more evident in samples 
containing less than 1 µg of starting DNA template (Fig. 5.6. ). This suggested that the 
lack of amplification of exon 8 product with the Instagene matrix samples may have 
been the result of the primer-dimers competing successfully with the low concentration 
of DNA template. Therefore for the ensuing amplification trials, the volume of 
Instagene matrix preparation was increased from 2Oµ1 to 33µl (i. e. an increase from 
about 250ng to about 400ng of DNA). The reaction volume was maintained at S0µ1 and 
samples amplified using modified versions of the two step temperature profile (followed 
by a final extension period of 3min at 74°C) used in previous optimisation studies. In 
each trial, the number of cycles and the two temperatures were maintained as before, 
whilst the time allocated to each temperature step was varied (Table 5.2. ). Temperature 
profile 8 of 30 cycles at l5sec at 92°C and 1min at 69°C followed by an extension 
period of 3min at 74°C was found to be the profile most conducive for amplification of 
exon 8 product. Repeated trials with the profile showed consistent amplification for both 
phenol-extracted DNA and Instagene matrix DNA samples. Although some of the latter 
samples sometimes had the additional primer-dimer artefact present in approximately 
equal quantities, the lack of other nonspecific products in the samples was paramount. 
The profile was therefore chosen as the standard temperature profile to be used for the 
ensuing PCR study. 
- 
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Table 5.2. Optimisation of temperature profile used for amplification of Instagene 
matrix DNA samples. 
Profile Temperature (°C) Time 
1 69 1 min 
92 1 min 
2 69 1 min 
92 30 sec 
3 69 30 sec 
92 1 min 
4 69 30 sec 
92 30 sec 
5 69 30 sec 
92 15 sec 
6 69 15 sec 
92 30sec 
7 69 15 sec 
92 15 sec 
8 69 1 min 
92 15 sec 
9 69 15 sec 
92 I min 
5.2.1.4. CONFIRMATION OF PCR AMPLIFIED REGION AS EXON 8 OF THE 
HUMAN TRANSFERRIN GENE 
Confirmation that the PCR amplified 174bp product was that of exon 8 of the human 
transferrin gene was obtained by restriction digest of the amplified product using the 
three RE, Fok I, Eco RI and Hae III (sec. 2.2.18. ). The three RE were chosen following 
restriction digest analysis of the human transferrin cDNA sequence using the PC-GENE 
computer-analysis program. Fok I was found to give a total of 12 RE cut sites within the 
cDNA sequence including one in exon 8. Hae III had 13 RE cut sites, none of which 
were in exon 8, whilst Eco RI had only one RE cut site which was present in exon 8. 
Amplified product corresponding to exon 8 would therefore be expected to give two 
r 
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restriction fragments when digested with either Fok I or Eco RI, and a single undigested 
174bp band when treated with Hae 111. Pre-experiment trials were carried out to 
determine the time period required to achieve complete digestion of amplified products. 
Samples were digested at 37°C with IU Fok I. and aliquots (5µl) removed at 30min/ 
Ihr/ 2hr/ 4hr/ 8hr and 24hr. 5p1 stop buffer (sec. 2.2.15. ) was immediately added to each 
aliquot after removal, mixed and left at room temperature for 5min. Samples were then 
frozen at -20°C until required. Analysis on 3% (w/v) agarose gels showed that a time 
period of l hr at 37°C was sufficient for complete digestion of amplified products. The 
analytical agarose gel for amplified product digested with Fok I, Eco RI and Hae III is 
shown in Figure 5.10. Restriction fragment sizes were determined from a calibration 
curve of 1og, o M, y of DNA markers versus migration distance (Fig. 5.11. ). 
Figure 5.10.3% (w/v) agarose gel for the restriction digest of PCR amplified exon 8 
product. 
(Origin) 
,e \ f9 
h 
(Anode) 
The above numbers and letters denote the following: I& 10 =1 kb DNA markers (a = 506bp; b= 396bp; 
c= 344bp; d= 298bp; e= 220bp; f= 201 bp; g= 154bp; h= 134bp; I= 72bp); 2&9= 25mer 
oligonucleotide primer; 3&8= undigested amplified exon 8; 4= Fok I digested sample; 5= Eco RI 
digested sample; 6= Fok I and Eco RI digested sample; 7= Hae III digested sample 
10 9876543 21 
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Figure 5.11. Calibration curve for the determination of restriction fragment sizes 
following restriction digest of PCR amplified exon 8. 
3.00 
2.50 
3 
0 2.00 
C) 
0 
J 
1.50 
32 42 52 62 
Migration distance (mm) 
Table 5.3. Restriction fragment sizes obtained from restriction digest of PCR amplified 
exon 8 product. 
Restriction 
endonuclease 
Estimated fragment sizes 
(bp) 
Expected fragment sizes 
(bp) 
Fok I 120 & 45 127 & 53 
Eco RI 145 & 35 152 & 28 
Fok I& Eco RI 89 & 45 & 35 99 & 53 & 28 
Hae 111 178 180 
Table 5.3. shows the results obtained from the calibration curve. Although the PC- 
GENE restriction digest analysis was performed on the transferrin cDNA sequence and 
so did not include possible RE cut sites for Fok I, Eco RI and Hae III in the intron 
sequences of the transferrin gene, the similarity of the estimated and expected fragment 
sizes (Table 5.3. ) strongly suggested that the amplified 178bp product was that of exon 
8. 
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5.2.2. RESTRICTION DIGEST SURVEY OF TRANSFERRIN ALLELES 
As indicated in the introduction, the study of exon 8 was conducted to determine the 
nature of amino acid 310 in a sample of known transferrin phenotypes. Plasma from 220 
individuals were therefore analysed by PAIEF (sec. 2.2.5. ) to determine their transferrin 
phenotypes. Five of the six individuals found to show abnormal transferrin phenotypes 
during the course of this theses (i. e. Blundell, Burke, Singh, Khalili and Medd) were 
also included in the study giving a total of 225 individuals studied. Of the 220 
individuals, 126 were found to have the Tf Cl phenotype, 10 the Tf C2 phenotype, 61 
the Tf C2-1 phenotype, 17 the Tf C3-1 phenotype and 6 the Tf C3-2 phenotype. This 
meant that including the 3 Tf Cl alleles present in Blundell, Burke and Singh, and the 
two Tf C2 alleles present in Khalili and Medd, a total of 333 Tf Cl alleles, 89 Tf C2 
alleles, 23 Tf C3 alleles, 3 Tf D alleles and 2 Tf B alleles were studied for the presence 
or absence of G or A at base 1086 of the nucleotide gene sequence. Genomic DNA 
samples prepared using the Instagene matrix protocol were amplified under optimal 
conditions (sec. 5.2.1.3.4. ). Amplified DNA samples were individually digested with 
Fok I and Bsm I (sec. 2.2.15. ). Figures 5.12. and 5.13. give a diagrammatic 
representation of the digestion patterns expected for the two RE. 
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Figure 5.12. Diagrammatic representation of the restriction digest pattern expected for 
digestion of amplified exon 8 product by Fok I. 
(Origin) 
Asp Asn Asp & Asn 
- 180bp 
127bp 
53bp 
(a) (b) 
(Anode) 
The letters above denote the following: a= individual with G at base 1086 of both transferrin alleles: b= 
individual with A at base 1086 of both alleles; c= individual with G or A at base 1086 of either allele 
Figure 5.13. Diagrammatic representation of the restriction digest pattern expected for 
digestion of amplified exon 8 product by Bsm I. 
(Origin) 
Asp Asn Asp & Asn 
180bp 
120bp 
60bp 
(a) (b) m 
(Anode) 
The letters above denote the following: a= individual with G at base 1086 of both transferrin alleles: b 
individual with A at base 1086 of both alleles; c= individual with G or A at base 1086 of either allele 
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The Fok I and Bsm I digested samples from the 225 individuals were subsequently 
analysed on 3% (w/v) agarose gels. Figures 5.14. and 5.15. show the analytical gels for a 
number of individuals showing different Tf C phenotypes. Figure 5.14. shows that the 
two restriction fragments expected as a result of digestion by Fok I (Fig. 5.12. ) were 
present in all samples, indicating the presence of G at base 1086 of both transferrin 
alleles. None of the samples had the 180bp fragment, or the three restriction fragments 
corresponding to the presence of A at base 1086 (Fig. 5.12. ). Conversely, Figure 5.15. 
shows that the undigested 180bp band was present in all the samples treated with Bsm I, 
confirming the observations made from gels similar to that in Figure 5.14. This pattern 
of digestion by Fok I but not by Bsm I was found for all 220 individuals studied. The 
same result was also observed for the five individuals showing abnormal transferrin 
phenotypes (Figs. 5.16. & 5.17. ) indicating that the five abnormal transferrin alleles (i. e. 
Tf DBLUNDELL, Tf DBB, Tf DsINGH, Tf B 
,u and 
Tf BNmDD) also had aG present at 
base 1086. 
r 
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Figure 5.14. Analytical agarose gel showing the effect of Fok I digestion on amplified 
exon 8 product from individuals showing different Tf C phenotypes. 
((ln_1n 
(Anodc 
The above numbers denote the following: I= undigested exon 8 product; 2&3= Tf C 1; 4&5= Tf C2; 6 
&7= Tf C2-1; 8&9= Tf C3-1; 10& 11 = Tf C3-2 
ii 10 987654321 
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Figure 5.15. Analytical agarose gel showing the effect of Bsm I digestion on amplified 
exon 8 product from individuals showing different Tf C phenotypes. 
(Uriirin) 
(Anode) 
The above numbers denote the following: I= undigested exon 8 product; 2&3= Tf C 1; 4&5= Tf C2; 6 
&7= Tf C2-1; 8&9= Tf C3-1; 10& 11 = Tf C3-2 
IU 9876543 
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Figure 5.16.3% (w/v) agarose gel for Fok I digestion of amplified exon 8 product from 
five individuals showing abnormal transferrin phenotypes. 
-> Ongin 
,, 
b 
_ý ý 
c ý1 1i 
K _-'ý n 
i ti 7 t, - -1 3 
(Anode) 
The above numbers denote the following: I&9=1 kb DNA markers (a = 506bp; b= 396bp; c= 344bp; d 
= 298bp; e= 220bp; f= 201bp; g= 154bp; h= 134bp); 2&8= undigested exon 8 product; 3= Tf 
D©lundru; 4= Tf DBirke; 5= Tf Ds1n1; 6= Tf BKhaJ ,,; 7= Tf BMedd 
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Figure 5.17.3% (w/v) agarose gel for Bsm I digestion of amplified exon 8 product from 
five individuals showing abnormal transferrin phenotypes. 
> Ongin 
ab 
ý. 
cý 
ýý 
F -ý 
h 
x7h>t_ 
(Anode) 
The above numbers denote the following: I&9= 1kb DNA markers (a = 506bp; b= 396bp; c= 344bp; d 
= 298bp; e= 220bp; f= 201bp; g= 154bp; h= 134bp); 2&8= undigested exon 8 product; 3= Tf 
DRlundell; 4= Tf Dtiurke; 5= Tf Ds1n8; 6= Tf BKha; i;; 7= Tf BMedd 
All 225 individuals studied therefore have the G nucleotide at base 1086, and 
subsequently a predicted Asp residue at position 3 10 of the amino acid sequence. The 
results agree with that found in the 14 individuals studied by Hershberger et at., (1991), 
and therefore support the premise by Hershberger et al., that Asp310 predominates in 
the population. However, the failure to find the proposed Tf Xpark allele with an A 
nucleotide at base 1086 in this study, does not negate the possibility that Tf X1 a1k may 
exist within the population. The amino acid sequence reported by MacGillivray at al., 
(1982) shows an Asn at position 310. Although the second revised sequence also reports 
Asn3 10 (MacGillivray et al., 1983), the cyanogen-bromide fragment containing the 
proposed Asn310 was not among the regions re-examined by automatic sequenator 
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analysis. The amino acid is therefore predicted by the first sequence. The latter was 
determined from sequence analysis of cyanogen-bromide fragmentation of commercial 
human transferrin obtained from pooled human sera. Although both studies report the 
sequence as that of the predominant Tf C form, it is not clear whether the 
electrophoretic Tf phenotype was determined. Likewise, the electrophoretic nature of 
the translated transferrin predicted by the complied nucleotide sequence of the human 
gene (Schaeffer et al., 1987) is not known. The genomic sequence was determined from 
the characterisation of four overlapping human transferrin genomic clones isolated from 
human genomic DNA libraries. Two of the genomic clones were detected using the 
same cDNA clone (Tf23) isolated by Park et al., (1985) from a human liver cDNA 
library. The Tf23 cDNA clone was found to encode human transferrin from amino acid 
98 onward. Both studies by Park et al., (1985) and Schaeffer et al., (1987) would 
therefore be expected to report the same nucleotide sequence, and hence A at base 1086. 
The sequence for exon 8 was not published by Schaeffer et al., (1987), on the basis that 
it had previously been published by Park et al., (1985). One can therefore only assume 
that the same sequence was found by Schaeffer et al., (1987). The possibility therefore 
exists that the three reports by MacGillivray et al., (1983), Park et al., (1985) and 
Schaeffer et al., (1987) were for the sequence of the Tf Xpý, k allele. It is however 
noticeable that other Asn/Asp differences have been reported in the established cDNA 
and genomic transferrin sequences. Uzan et al., (1984) reported the nucleotide sequence 
for a human Tf cDNA clone isolated from a human cDNA library. The clone was found 
to encode human transferrin from amino acid 403 onward. The translated amino acid 
sequence differed from the established amino acid sequence (MacGillivray et al., 1983) 
at position 417, predicting Asn instead of Asp. Similarly, the cDNA sequence reported 
by Yang et al., (1984) differed at positions 310 (Asp for Asn) and 417 (Asn for Asp). 
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Furthermore, although the cDNA clone containing the entire -coding sequence for 
transferrin was isolated using an oligonucleotide probe corresponding to residues 309- 
314 of the MacGillivray et al., (1983) sequence, the cDNA sequence found an Asp 
residue instead of the Asn of the probe. Such differences in Asn or Asp assignment 
suggest that the disparity at position 310 most probably reflects normal ambiguities that 
occur during determination of amino acid sequences as Asn can be hydrolysed to Asp. 
5.3. CONCLUSION 
The nucleotide sequence of exon 8 of the human transferrin gene has been amplified 
from 220 individuals showing five of the six most common transferrin phenotypes (i. e. 
Tf Cl, Tf C2, Tf C2-1, Tf C3-1 and Tf C3-2) and from five individuals showing 
abnormal transferrin phenotypes (i. e. Tf DBLUNDELL, Tf DBB, Tf DS1, GH, Tf B IU and Tf 
BND). The identity of the nucleotide at base 1086 in exon 8 of all individuals supports 
the proposition by Hershberger et al., (1991) that Asp3lO predominates in the 
population. Analysis of the established amino acid (MacGillivray et al., 1983), cDNA 
(Yang et al., 1984) and genomic (Uzan et al., 1984; Park et al., 1985; and Schaeffer et 
al., 1987) sequences reveal that Asn/Asp disparities are common among the various 
sequences. It is therefore concluded that the proposed Tf Xp&k allele with Asn3 10 is in 
fact that of the wild-type Tf C allele. 
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CHAPTER SIX 
6. FINAL CONCLUSIONS 
After forty years of research on genetically controlled transferrin variants in human sera, 
the majority of work published describes the incidence and distribution of variant 
transferrins detected by electrophoresis on nondenaturing polyacrylamide gels 
(Kornhuber & Kuhl, 1986; Kamboh & Ferrell, 1987; Farhud et al., 1988). Very few 
studies have been carried out to determine the change in primary structure (Wang & 
Sutton, 1965; Wang et al., 1966,1967; Evans et al., 1988b; Welch & Langmead, 1990), 
or to study the ability of variant transferrins to bind and retain iron (Evans et al., 1982, 
1984,1988b, 1994; Welch & Langmead, 1990). A handful of studies have examined the 
iron-binding properties of the polymorphic Tf Cl, Tf C2 and Tf C3 variants in terms of 
their iron-binding capacity, serum iron level, percentage saturation and/or plasma 
concentration (Eckfeldt, et al., 1985; Wong & Saha, 1986; Cleve et al., 1988; Sikstrom 
et al., 1993b; Kita et al., 1994). Other studies have concentrated on the association of 
particular transferrin forms (e. g. CDT, Tf C2 and Tf C3) with physiological conditions 
such as alcoholism (van Eijk et al., 1983; Poupon et al., 1985), spontaneous abortions 
(Beckman et al., 1980; Weitkamp & Schacter, 1985) and Alzheimer's disease (van 
Rensburg et al., 1993,1995). These studies have been carried out for a number of 
reasons. Characterisation of the amino acid change may provide an explanation for 
observed differences in electrophoretic mobility, as well as providing material for site- 
directed mutagenesis studies on the structural significance of amino acids in transferrin. 
Characterisation may also provide explanations for observed transferrin characteristics 
as in the case of Tf DEVis where the abnormal C-lobe properties were attributed to 
altered domain closure (Evans et al., 1994). Studies on iron-binding properties either as 
t 
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the ability to bind and retain iron, or in terms of body iron stores (e. g. serum iron level, 
iron-binding capacity and plasma concentration), together with receptor-binding studies, 
not only indicate differences between transferrins but may also suggest potential 
functional advantages or disadvantages. The common aim of all these studies is an 
attempt to determine the physiological mechanism(s) that may be influencing the 
distribution of the various transferrin variants. 
This thesis has approached this question in two different ways. In the first study, 
transferrin variants have been characterised in terms of their metal-binding properties 
and conformational stabilities in denaturing conditions. These studies have been 
undertaken to determine whether any or all of the detected variants show characteristics 
that may suggest functional advantage or disadvantage. As transferrin is believed to 
have a number of other functions such as antimicrobial (Ellison et al., 1988,1990), anti- 
inflammatory (Sakamoto et al., 1997) and growth factor activities (Amouric et at., 1984; 
Oguchi et at., 1995) in addition to its iron transport functions, alterations in the normal 
functions of transferrin may have several indirect effects. The study however proved 
inconclusive in this sense as all variants were found to exhibit similar characteristics to 
the wild-type Tf Cl. Such studies however rely on the assumption that the substitutional 
changes generally believed to be responsible for the differences in electrophoretic 
mobility (Yang et al., 1984) interfere with iron binding or release. The effect of amino 
acids at the iron-binding sites, and of second shell residues beyond the immediate 
coordination spheres of both iron and the carbonate anion, on protein conformation and 
iron binding and release, have been shown by a number of site-directed mutagenesis 
studies (Woodworth et al., 1991; Grossman et al., 1993; Lindley et al., 1993; Dewan et 
al., 1993; Zak et al., 1995; Faber et al., 1996; Baker et al., 1996; Nicholson et al., 1996). 
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These studies have generally shown that substitutions in or around these regions affect 
iron binding and release as a result of charge or steric effects. As iron occupancy of the 
C-lobe is associated with receptor-binding and therefore cellular iron-uptake by RME 
(Young et al., 1984b; Bali & Aisen, 1991; Egan et al., 1993; Qian & Tang, 1995; 
Pakdaman & el Hage Chahine, 1996), altercations of C-lobe iron binding or release 
properties, or conformation, as a result of a substitutional change would also be 
expected to affect receptor-binding as in the case of Tf DEV, u., s (Evans et al., 1984) where 
Arg394 interacts with the neighbouring Asp392 iron ligand, thereby hindering iron- 
binding and domain closure (Evans et al., 1994). It has been proposed in this thesis that 
the three Tf By s, Tf BFOXTROT, Tf Bam. and Tf B,,, D represent the polymorphic Tf 
B2 variant, whilst the two Tf DAR, k,, rs, Tf DBu, and Tf DSINGH, represent the 
polymorphic Tf D, and Tf Dc1 variants respectively. The study found that iron release 
from variant transferrins titrated at pH 7.5 were slightly faster than from Tf Cl. 
Although the differences did not appear to be significant, if the above assumptions 
relating to the identities of the variants are correct, then the iron release properties may 
be related to the established substitutional changes of G1u300 for Tf B2 (Wang et al., 
1966), G1y277 for Tf D1 (Wang & Sutton, 1965) and Arg300 for Tf DcM (Wang et al., 
1967). As both G1u300 and Arg300 are next to Lys301 which is involved in opening of 
the N-lobe binding cleft (Dewan et al., 1993), interactions between the three may result 
in earlier opening and hence iron release from the N-lobes of the three Tf BvS, and 
Tf Dswcx" G1y277 on the other hand may hinder iron-binding by interacting with the 
iron ligand His249 (Anderson et al., 1989; Sarra et al., 1990) such that the iron at the N. 
lobe of Tf DBB is not bound as tightly as in Tf Cl. These assumptions would 
however not be expected to affect the normal transport functions of the variant 
transferrins as they would still be able to bind and ferry iron. They would also not be 
r 
257 
expected to affect receptor-binding as the characteristics of their C-lobe would be 
normal. It may however be the case that the respective substitutions are selectively 
neutral due to conservative non-synonymous substitutions that do not affect either iron 
binding or release as concluded in Chapter three. 
Studies on the Tf B and Tf D variants may be complemented by additional studies on 
the incidence of these variants in disease states, as in the case of the two Tf C variants, 
Tf C2 and Tf C3. These two have been generally found to have a selective 
disadvantageous role in humans and have been associated with spontaneous abortions 
(Beckman et al., 1980; Auconi et al., 1982; Weitkamp & Schacter, 1985; Saha et al., 
1990) and other disorders such as Alzheimer's disease (van Rensburg et al., 1993, 
1995). Studies on the metal-binding ability and conformational stability of Tf C2 in the 
first part of this thesis indicated that the protein exhibited normal transferrin 
characteristics, implying normal transport and cellular uptake. However, results from the 
second study have shown that Tf C2 and Tf C3 are associated with low plasma 
concentrations. As low plasma concentrations are associated with increased serum iron 
levels and iron saturation (Sikstrom et al., 1993b), the results support the general 
consensus that the selective mechanism associated with the two transferrin variants 
involve increased iron transport (Beckman et al., 1985; Sikstrom et al., 1993b; van 
Rensburg et al., 1995). Transcription of the transferrin gene occurs at high levels in liver 
hepatocytes and is controlled by the binding of specific nuclear factors such as HNF-4 
and COUP-TF to 5' regulatory regions of the transferrin gene (Alfred et al., 1987; 
Schaeffer et al., 1989; Mendelzon et al., 1990). Whether the respective substitutional 
changes in Tf C2 and Tf C3 are directly or indirectly involved in the physiological 
mechanism(s) that appear to affect transcription of the two alleles remains to be 
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determined. Likewise, the nature of the mechanism(s) that result in the observed 
decrease in plasma concentrations needs to be examined. It is possible that the latter 
may involve alterations in the 5' regulatory DNA sequence distinct to the single 
substitutional change associated with transferrin variants, as mutations in the PRI and 
PRU regions of the regulatory region have been shown to decrease transcription 
(Schaeffer et al., 1993). This will again need to be examined further as such alterations 
are normally avoided by natural selection pressure. 
As indicated earlier, transferrin variants detected to date have generally been detected by 
their different electrophoretic mobilities on nondenaturing polyacrylamide or 
polyacrylamide isoelectric focusing gels. However, a nondegenerate nucleotide 
difference at base 1086 in exon 8 of the cloned human transferrin gene sequence, 
prompted Hershberger et al., (1991) to suggest the presence of a transferrin variant, Tf 
Xp&k, with A at base 1086 (i. e. Asn310) rather than the proposed wild-type G (Asp310). 
The third study however failed to indicate the presence of A at base 1086, therefore 
supporting the proposal by Hershberger et al., (1991) that Asp310 predominates within 
the population. As Asn/Asp disparities are common among transferrin sequences 
derived by different workers, and transitional substitutions more common than 
transversions, it is concluded that the proposed Tf Xp k variant is that of the wild-type 
protein, Tf Cl. The study was unusual in that the electrophoretic mobility of the 
transferrin variant was not known, but rather assumed to be similar to that of the Tf C 
and Tf D variants on the basis of a decrease in net negative charge. Detection of 
transferrin variants on the basis of differences in overall -protein charge have one 
drawback in that they fail to detect synonymous codon substitutions where the same 
amino acids are specified, or substitutions where amino acids are replaced by residues 
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with a like charge. Whether these variants would show anything other than normal 
transferrin properties remain a matter of conjecture until studies are carried out to 
determine otherwise. 
6.1. FUTURE RESEARCH PROSPECTS 
The transferrin variants detected in this study were extensively studied in terms of their 
metal-binding properties and conformational stabilities to urea and thermal denaturation. 
However insufficient material after these studies prevented amino acid sequencing or 
receptor-binding studies to be carried out. The respective amino acid substitutions of the 
six variants would not only help to confirm their proposed identities, but may also 
contribute to future site-directed mutagenesis studies on the role of amino acids in 
transferrin. Receptor-binding studies would also confirm whether the variant transferrins 
continue to show normal transferrin properties. Receptor-binding is thought to be 
facilitated by binding of iron at the C-site (Bali & Aisen, 1991; Egan et al., 1993; Zak et 
al., 1994; Pakdaman & el Hage Chahine, 1996). It is therefore highly probable that 
unlike Tf DEVANS which shows reduced receptor-binding as a result of its C-site lability 
(Evans et al., 1984; Young et al., 1984a), all variant transferrins studied in this thesis 
will show normal receptor-binding properties as the conformation and metal-binding 
abilities of their C-sites appear to be normal. 
The study on the three most common Tf C variants indicated that the disadvantageous 
selective role of Tf C2 and Tf C3 types were related to their low plasma concentrations. 
Future studies may therefore be carried out to determine whether patients suffering from 
the various disorders associated with the two alleles show lower plasma transferrin 
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concentrations than normal. This may then direct further studies on the selective 
mechanisms associated with the two alleles. 
Finally, although results from this study support the view that Asp3 10 predominates 
among individuals showing Tf C 1, Tf C2 or Tf C3 types, a number of other Tf C and 
Tf D variants need to be examined before the situation is finally resolved. Alternatively, 
site-directed mutagenesis experiments may be used to produce a recombinant transferrin 
with Asn3 10, and the electrophoretic mobility subsequently determined. 
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